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ABSTRACT OF THE DISSERTATION 
CORRELATES OF VITAMIN D STATUS IN HEALTHY OLDER ADULTS LIVING 
IN MIAMI-DADE AND ITS ASSOCIATION WITH NONSKELETAL OUTCOMES: A 
CROSS-SECTIONAL STUDY 
 by 
Johanna Lopez 
Florida International University, 2015 
Miami, Florida 
Professor Adriana Campa, Major Professor 
Examining factors that affect vitamin D status in the fast-growing elderly 
population of Miami-Dade, Florida, is needed. Vitamin D deficiency in older adults has 
been linked to correlates of disability, including falls and fractures, and cardiovascular 
disease. The purpose of this study was to determine the proportion of vitamin D 
insufficient individuals and their relationship with vitamin D insufficiency in older adults 
(n=97) living in Miami-Dade. We evaluated the association between vitamin D status and 
1) dual task physical performance to understand the link between vitamin D and 
cognition in the context of mobility; and 2) cardiometabolic risk, measured by galvanic 
skin response, pulse oximetry, and blood pressure to create a composite score based on 
autonomic nervous system and endothelial function. Participants completed baseline 
assessments that included serum levels of vitamin D, anthropometrics, body composition, 
dual task physical performance and cardiometabolic risk. Surveys to evaluate vitamin D 
intake, sun exposure, physical activity, and depressive symptoms were completed. 
Spearman’s correlations, independent t-tests, paired t-tests, repeated measures ANOVAs, 
vii 
and multiple logistic and linear regressions were used to examine the relationship of 
vitamin D insufficiency (25(OH)D <30 ng/ml) and sufficiency (25(OH)D ≥30 ng/ml) 
with determinants of vitamin D status, dual task physical performance variables and 
cardiometabolic risk scores. Although the proportion of vitamin D insufficient 
individuals was lower when compared to the prevalance of the general United States 
elderly population, it was still common in healthy community-dwelling older adults 
living in Miami-Dade County, especially among Hispanics. Factors that affected skin 
synthesis (ethnicity, and sun exposure), and bioavailability/metabolism (obesity) were 
significant predictors of vitamin D status. Vitamin D insufficiency was not significantly 
correlated with worse dual task physical performance; however, cognitive performance 
was worse in the vitamin D insufficient group. Our results suggest a relationship of 
vitamin D insufficiency with executive dysfunction, and support an association with 
cardiometabolic risk using an innovative electro-sensor complex, possibly by modulating 
autonomic nervous system activity and vascular function, thus affecting cardiac 
performance. 
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CHAPTER I: INTRODUCTION 
 
Statement of Problem 
Approximately one billion people in the world have deficient or insufficient levels 
of vitamin D.1 The National Health and Nutrition Examination Survey (NHANES) 2005-
2006 revealed that 41.6% of United States adults (18 years or older) had deficient vitamin 
D levels, defined as <20 ng/ml of 25-hydroxyvitamin D (25(OH)D).2,3 Elderly are at 
higher risk of vitamin D deficiency. NHANES 1988-1994 data indicated that serum 
vitamin D levels among adults 65 years and older were lower when compared to middle 
aged (40-59 years of age) and younger adults (18-29 years of age). Of these older adults, 
23% and 62.5% had vitamin D deficient (<20 ng/ml) and insufficient (<30 ng/ml) levels, 
respectively.4,5 The main sources of vitamin D are skin synthesis and dietary intake. 
Vitamin D deficiency may be more prevalent in theelderly population due to a complex 
interplay between several factors affecting dietary intake, skin synthesis and 
bioavailability. These include age-related decreased appetite, impaired intestinal 
absorption, decreased capacity of the skin to synthesize vitamin D, and less sun exposure, 
which may be related to physical inactivity and decreased outdoor activities.6,7 
Furthermore, elderly are at higher risk of vitamin D deficiency due to age-related 
increased adiposity, which may be secondary to decreased metabolic rate, use of 
medications and the presence of comorbidities that affect vitamin D metabolism.8,9 
In the United States, very few foods contain significant amounts of vitamin D; 
therefore, vitamin D intake through food may be minimal as shown in NHANES 1988-
1994.10,11 Although supplement use may compensate for the lack of vitamin D intake 
 2 
from foods; however, low vitamin D intakes from food and supplements have been 
reported in the elderly populations and associated with low serum vitamin D.6,7,12 Thus, 
for those who are not meeting the vitamin D requirements through diet, sunlight is often 
the main source of vitamin D.13,14 The skin’s ability to synthesize vitamin D depends on 
the amount of solar radiation reaching the biosphere that is influenced by latitude, season 
and time of day.8,15 Based on the impact of sunlight exposure on vitamin D status, it has 
been assumed that vitamin D deficiency is less prevalent in populations living at lower 
latitudes and/or where seasonal variations are not as pronounced, like in South Florida, 
where the weather is sunny and warm year-round.9 However, other investigators have 
reported that the prevalence of hypovitaminosis D (25(OH)D <20 ng/ml) is 38-40% in 
adult men and women (>18 years of age) living in South Florida.9  
Vitamin D deficiency in older adults has been linked to non-skeletal outcomes 
that go beyond bone health. In 2010, of the 30 leading causes of disability and death in 
the United States, 19 were associated with deficient vitamin D levels, including cancer, 
diabetes, falls and fractures, and cardiovascular disease.16-25 Vitamin D deficiency has 
received much attention as a risk factor for falls because of its effect on musculoskeletal 
health thus affecting gait.26-33 The mechanism by which vitamin D affects mobility and 
fall risk, however, may go beyond its role in musculoskeletal health. Since mobility 
depends on the musculoskeletal and nervous systems, it could be possible that the role of 
vitamin D in fall risk is not only through its effects on musculoskeletal health but also 
through its role in brain function and cognition.34 Several investigators have reported the 
association of vitamin D deficiency with higher risk of cognitive impairment and/or 
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lower scores on cognitive performance tests.5,17,35-54 Little is known, however, about the 
role of this nutrient in cognitive function in the context of mobility.  
Another potential role of vitamin D in the brain is on the regulation of cardiac 
autonomic nervous system (ANS) function, affecting cardiovascular health. Vitamin D 
deficiency and cardiovascular disease (CVD) are prevalent worldwide.1,55 Furthermore, 
the prevalence of vitamin D deficiency is high among those with CVD.56,57 Several 
observational studies and meta-analyses have demonstrated associations between vitamin 
D deficiency and outcomes related to CVD and CVD-related deaths.58-72 Furthermore, 
dysfunction of cardiac autonomic function, more specifically of the cardioprotective 
parasympathetic tone, results in an imbalance between sympathetic (SNS) and 
parasympathetic (PNS) nervous systems. This imbalance has been well-established as a 
risk factor for adverse cardiovascular events, such as sudden cardiac death (SCD) or 
congestive heart failure.73-78 Besides affecting heart rate, the ANS also influences cardiac 
performance by controlling vascular dynamics and blood pressure, which in part is also 
affected by endothelial health. Low vitamin D status has been independently associated 
with ANS and endothelial dysfunction; thus affecting cardiovascular health.55,57,79,80 The 
observations that vitamin D deficiency, cardiac ANS, and endothelial dysfunction are 
independently linked to each other and CVD-related outcomes suggest a potential 
mechanism by which vitamin D affects CVD risk. The mechanisms that explains the 
relationship between vitamin D deficiency and CVD-related outcomes and mortality is 
unclear and therefore, a growing area of research.55  
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Significance of the Proposed Study  
Currently, vitamin D status and factors associated with vitamin D serum levels in 
the elderly population in Miami-Dade have not been well studied. This is important 
because according to the Florida Department of Elder Affairs, the top county for elders in 
2010 and 2012 was Miami-Dade, with 14.9% of the Miami-Dade population being over 
the age of 65 in 2010.81 Also, Miami is the fourth city in the national ranking that is 
graying the fastest.81-85 Between 2007 and 2009, falls were the leading cause of injury of 
residents in Miami-Dade aged over 65 years and responsible for 79% of injury 
hospitalizations. One-third of hospitalizations related to falls resulted in a hip fracture and 
11% involved traumatic brain injury.86  
Vitamin D deficiency, which is still common among elderly living in warm South 
Florida, despite year-round sunshine, is associated with the risk of falls.28,87-94 The role of 
vitamin D deficiency in increasing the risk of falls may be dual; through its function in 
both the musculoskeletal and nervous systems. Vitamin D is involved in brain 
physiology. Lower vitamin D status has been associated with impaired neuronal function 
in the caudal primary motor cortex of older adults, which may contribute to the 
pathophysiology of gait disorders in older adults with vitamin D deficiency.95 
Furthermore, several studies have demonstrated an association of vitamin D deficiency, 
with gait impairment (slower gait speed), global cognitive impairment and impaired 
executive function.5,17,35-54 Studies that investigated vitamin D status’ relationship to gait 
and cognition, however, have looked at these factors independently. Until now, no cross-
sectional study has evaluated how vitamin D status is related to cognitive processing 
during motor activity.  
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To date very few studies have investigated the role of vitamin D deficiency in the 
development of cardiac ANS and vascular dysfunctions, which are risk factors for poor 
cardiovascular related health.58,71,96 In addition, no studies have correlated vitamin D 
insufficiency with cardiometabolic risk, as assessed by cardiovascular risk indicators 
such as ANS dysfunctions, endothelial dysfunction and anthropometric characteristics. 
Objectives of this study were: 
1. To determine the proportion of vitamin insufficient individuals and correlates 
of vitamin D status in a healthy older adult (>55 years of age) sample living in 
Miami-Dade County. 
2. To investigate the association of vitamin D status with cognitive processing 
during movement, as measured using the dual task physical performance tests.  
3. To investigate the association between vitamin D status and cardiometabolic 
risk , measured by a combination of body composition, ANS activity, and 
endothelial function markers.  
 
Specific Aims and Hypotheses 
Specific Aim 1: To determine the proportion of vitamin D insufficient individuals 
and correlates of vitamin D status in a healthy older adult (>55 years old) 
population living in Miami-Dade County.  
Hypothesis 1a: The proportion of vitamin D insufficient individuals (25(OH)D <30 
ng/ml) in a healthy older adult (>55 years old) sample living in Miami-Dade will be 
lower than the prevalence reported for the general United States population. 
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Hypothesis 1b: Vitamin D dietary intake will not be a determinant of vitamin D status in 
an older adult sample living in Miami-Dade. Thus vitamin D intake will not predict 
vitamin D status and will not be significantly different between vitamin D insufficient 
(25(OH)D <30 ng/ml) and vitamin D sufficient (25(OH)D ≥30 ng/ml) individuals. 
Hypothesis 1c: Sun exposure will be a significant positive correlate of vitamin D status in 
older adults living in Miami-Dade County. Those who are vitamin D insufficient 
(25(OH)D <30 ng/ml) will have significantly lower sun exposure scores than those who 
are vitamin D sufficient (25(OH)D ≥30 ng/ml). 
 
Specific Aim 2: To investigate the association of vitamin D status with cognitive 
processing during movement as measured using the dual task physical performance 
tests. 
Hypothesis 2:  Vitamin D status of healthy older adults (>55 years old) will be 
significantly associated with worse performance in dual tasking compared to single 
tasking. 
Hypothesis 2a: Participants who are vitamin D insufficient (25(OH)D <30 ng/ml) will 
have significantly slower dual task velocities as well as a larger dual to single task gait 
velocity difference than those who are vitamin D sufficient (25(OH)D ≥30 ng/ml) 
Hypothesis 2b:  Participants who are vitamin D insufficient (25(OH)D <30 ng/ml) will 
have significantly slower dual task counting rates and a larger dual to single task counting 
rate difference than those who are vitamin D sufficient (25(OH)D ≥30 ng/ml).  
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Specific Aim 3: To investigate the association between vitamin D status and 
cardiometabolic risk (CMR), measured by integrating markers of body 
composition, ANS activity function, and endothelial function markers.  
Hypothesis 3:  Vitamin D status of healthy older adults (>55 years old) will be 
significantly and inversely associated with cardiometabolic risk (as calculated from the 
assessment of body composition, ANS activity and endothelial function). 
Hypothesis 3a:  Participants who are vitamin D insufficient (25(OH)D <30 ng/ml) will 
have significantly higher cardiometabolic risk scores than those who are vitamin D 
sufficient (25(OH)D ≥30 ng/ml). 
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Table 1: Summary of Hypotheses and Statistical Methods 
Hypotheses Independent 
Variable and 
Assessment 
Dependent 
Variable and 
Assessment  
Statistics 
1a 
 
Prevalence of vitamin D status 
 Vitamin D status  
 
Serum 25(OH)D  
 
Categorical  
(insufficient <30 
ng/ml, sufficient ≥ 
30 ng/ml) 
Vitamin D status was described using 
frequencies, percentages, ranges, means and 
standard deviations. Spearman’s correlations 
were used to estimate associations between 
vitamin D status and correlates. Independent t-
tests and chi-squares were used to compare 
potential correlates of vitamin D status between 
vitamin D insufficient (25(OH)D <30 ng/ml) and 
sufficient (25(OH)D ≥30 ng/ml) participants. 
Multiple linear and logistic regressions were 
used to examine the relationship between 
vitamin D status and explanatory variables.   
1b 
 
Vitamin D status and dietary intake  
Vitamin D intake  
 
Vitamin D and 
calcium short food 
frequency 
questionnaire 
  
Continuous 
 
Vitamin D status  
 
Serum 25(OH)D 
 
 
 
 
Categorical 
(insufficient <30 
ng/ml, sufficient ≥ 
30 ng/ml) 
Vitamin D intake was described using 
frequencies, percentages, ranges, means and 
standard deviations. Spearman correlations were 
performed to evaluate the relationship between 
vitamin D status and vitamin D intake. 
Independent t-tests were used to compare 
vitamin D insufficient (25(OH)D <30 ng/ml) and 
sufficient (25(OH)D ≥30 ng/ml) participants in 
vitamin D dietary intake. Multiple linear and 
logistic regressions were used to examine the 
relationship between vitamin D status and 
vitamin D intake.   
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Table 1 continued 
Hypotheses Independent Variable 
and Assessment 
Dependent Variable 
and Assessment 
Statistics 
1c 
 
Vitamin D status and sun 
exposure and related factors 
Sun exposure  
 
Sun exposure 
questionnaire 
  
Continuous 
 
 
Vitamin D status  
 
Serum 25(OH)D 
  
 
Categorical 
(insufficient <30 ng/ml, 
sufficient ≥ 30 ng/ml) 
 
Sun exposure was described using frequencies, 
percentages, ranges, means and standard 
deviations. Spearman correlations were performed 
to evaluate the relationship between vitamin D 
status and sun exposure. Independent t-tests and 
chi-squares were used to compare vitamin D 
insufficient (25(OH)D <30 ng/ml) and sufficient 
(25(OH)D ≥30 ng/ml) participants in sun 
exposure. Multiple linear and logistic regressions 
were used to examine the relationship between 
vitamin D status and sun exposure.   
2a 
 
Vitamin D status, dual task 
velocity and dual to single task 
gait velocity difference.  
Dual task gait speed 
 
GAITRite system will 
record gait speed when 
walking while counting 
backward by from 50 
by 1.   
 
Continuous 
 
Vitamin D status  
 
Serum 25(OH)D 
 
 
 
 
 
Categorical 
(insufficient <30 ng/ml, 
sufficient ≥ 30 ng/ml) 
Gait speed variables were described using 
frequencies, percentages, ranges, means and 
standard deviations. Spearman correlations were 
performed to evaluate the relationship between 
vitamin D status and single task, dual task and the 
dual to single task difference in gait speed. Paired 
t-tests were used to compare dual and single task 
gait velocities. Independent t-tests were performed 
to compare mean single and dual task gait 
velocities between vitamin D insufficient 
(25(OH)D <30 ng/ml) and sufficient (25(OH)D 
≥30 ng/ml) participants. One-way repeated 
measures ANOVAs were used to compare the 
dual to single task difference in gait velocity 
between vitamin D status categories. Multiple 
logistic regressions were used to examine the 
relationship between vitamin D insufficiency and 
the dual to single task difference in gait speed. 
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Table 1 continued 
Hypotheses Independent 
Variable and 
Assessment 
Dependent 
Variable and 
Assessment 
Statistics 
2b 
 
Vitamin D status, dual task 
counting rate and dual to single task 
counting rate difference. 
Dual task counting 
rate 
 
Voice recorder to 
count number of 
enumerate figures 
when walking while 
counting backwards 
from 50 by 1.  
 
Continuous 
 
Vitamin D 
status  
 
 
Serum 
25(OH)D 
  
 
 
 
 
 
Categorical 
(insufficient 
<30 ng/ml, 
sufficient ≥30 
ng/ml) 
Counting rate variables were described using 
frequencies, percentages, ranges, means and standard 
deviations. Spearman correlations were performed to 
evaluate the relationship between vitamin D status and 
single task, dual task and the dual to single task 
difference in counting rate.  Paired t-tests were used to 
compare dual vs. single task counting rates. 
Independent t-tests were performed to compare mean  
single and dual task counting rates between vitamin D 
insufficient (25(OH)D <30 ng/ml) and sufficient 
(25(OH)D ≥30 ng/ml) participants. One-way repeated 
measures ANOVAs were used to compare the dual to 
single task difference in counting rates between vitamin 
D status categories. Multiple logistic regressions were 
used to examine the relationship between vitamin D 
insufficiency, and the dual to single task difference in 
counting rate. 
3a 
 
Vitamin D status and 
cardiometabolic risk scores 
(CMRS) 
Vitamin D status  
 
 
Serum 25(OH)D 
 
 
 
Categorical 
(insufficient <30 
ng/ml, sufficient ≥ 
30 ng/ml) 
Cardiometabolic 
Risk Score 
(CMRS)  
 
Device that 
integrates body 
composition, 
ANS activity, 
and endothelial 
function  
 
Continuous 
CMRS was analyzed using frequencies, percentages, 
ranges, means and standard deviations. Spearman 
correlations were performed to evaluate the relationship 
between vitamin D status and CMRS. Independent t-
tests or chi-square were used to compare CMRS and 
covariates between vitamin D insufficient (25(OH)D 
<30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) 
participants. Multiple linear regressions were used to 
examine the relationship between CMRS and vitamin D 
levels after adjusting for potential confounders. 
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CHAPTER II: LITERATURE REVIEW 
 
Vitamin D Deficiency in the Elderly 
Approximately one billion people in the world have deficient or insufficient levels 
of vitamin D.1 The National Health and Nutrition Examination Survey 2005-2006 
revealed that 41.6% of United States adults (18 years or older) had deficient vitamin D 
levels, defined as 25(OH)D <20 ng/ml.2,3 The elderly are at a higher risk of vitamin D 
deficiency as indicated in the National Health and Nutrition Examination Survey 
(NHANES) 1988-1994 data that serum vitamin D levels were lower among adults 65 
years and older compared to middle aged (40-59 years of age) and  younger adults (18-29 
years of age). Of these older adults, 23% and 62.5% had vitamin D deficient (<20 ng/ml) 
and insufficient (<30 ng/ml) levels, respectively.4,5 The main sources of vitamin D are 
skin synthesis and dietary intake. Vitamin D deficiency may be more prevalent in the 
elderly population due to a complex interplay between several age-related factors 
affecting these sources like decreased dietary intake, bioavailability and skin synthesis, as 
discussed below.6,7  
 
Defining Vitamin D Deficiency Based on its Main Function  
Vitamin D deficiency in the elderly has received much attention as a risk factor 
for falls because of its effect on musculoskeletal health, thus affecting gait.8-15 The most 
studied physiological role of vitamin D is in calcium homeostasis and maintenance of 
bone health through its endocrine function in the intestine, bone, parathyroid glands, and 
kidneys.1 Vitamin D2 (ergocalciferol from plant sources) and D3 (cholecalciferol from 
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animal sources) are transported to the liver bound to Vitamin D Binding Protein (VDBP), 
where it is hydroxylated by microsomal 25-alpha hydroxylase (CYP2R1) to 25-
hydroxyvitamin D (25(OH)D or calcidiol).16 25(OH)D binds to VDBP and is transported 
to the kidney or extra-renal tissues, where it is hydroxylated again by mitochondrial 1-
alpha hydroxylase (CYP27B1) to the most biologically active form, 1,25 
dihydroxyvitamin D (1,25(OH)2D or calcitriol).16,17 This active form binds to nuclear 
vitamin D receptors (VDRs) with high affinity (Kd 10-10 M compared to 25(OH)D Kd 10-
8M), causing VDR heterodimerization with other transcription factors like retinol X 
receptors (RXR) to induce or repress genomic signaling of more than 200 target genes.16 
1,25(OH)2D is catabolized in the kidney and extra-renal tissue by mitochondrial 24-
hydroxylase (CYP24A1), producing a series of 24-hydroxylated inactive metabolites.16  
Serum 25(OH)D, and not 1,25(OH)2D (the active form), is widely accepted as the 
best clinical indicator of vitamin D status. Compared to 1,25(OH)2D, 25(OH)D is the 
major circulating form of vitamin D (500-1000 times more abundant), and it has a half-
life of 2-3 weeks, compared to 4-6 hours for 1,25(OH)2D. Also, it reflects both dietary 
and sun exposure sources from the previous 4-6 weeks, while 1,25(OH)2D reflects 
immediate physiological needs due to the tight regulation of 25(OH)D hydroxylation and 
1,25(OH)2D catabolism.18,19  
Through the regulation of genes involved in bone remodeling, intestinal calcium 
absorption, and calcium and phosphate renal reabsorption, vitamin D maintains blood 
levels of calcium and phosphorus for the mineralization of bones to preserve bone 
mineral density.16 It is well known that vitamin D deficiency leads to a reduction in 
calcium absorption and eventually in the release of calcium from bones to maintain blood 
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circulating levels of calcium. In adults, the most common manifestation of severe vitamin 
D deficiency is osteomalacia, in which the newly formed bone matrix does not mineralize 
and is characterized by symptoms of muscle weakness and discomfort, and throbbing 
aching bone pain.20 However, studies in the last two decades have provided evidence on 
roles of vitamin D that go beyond calcium homeostasis and bone health.21  
Vitamin D “non-bone” effects may be achieved through its modulation of gene 
expression by binding VDRs in other tissues. Recent data have shown that VDRs are 
found in other tissues such as macrophages, liver, pancreas, colon, lung, breast, skin, 
adipose tissue, muscle, and brain.17,22 
Table 1: Vitamin D Status in Relation to Bone Health22,23 
Category ng/ml nmol/L Clinical symptoms 
Very Deficient <25 <10 Rickets, osteomalacia, myopathy 
Severe hyperparathyroidism 
Calcium malabsorption 
Deficient 25-50 10-20 Mild hyperparathyroidism 
Decreased calcium absorption 
Decreased bone mineral density (osteoporosis) 
May have subclinical myopathy 
Insufficient 50-75 20-30 Parathyroid hormone may be high 
Sufficient 75-375 30 -150 No vitamin D dependent function disturbances  
Toxicity >375 >150 Hypercalemcia 
Soft tissue calcification 
 
Recommended Vitamin D Intake, Vitamin D Sources, and the Older Adult 
Vitamin D is considered a steroid hormone obtained naturally from dietary 
sources and synthesized by the body from sunlight. Vitamin D is not stored in the muscle 
and fat tissue until serum concentrations are higher than 20 ng/ml. Only then is the body 
able to use vitamin D reserves independently of sun exposure and dietary intakes.2,23,24 
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For older adults, however, reaching this vitamin D threshold is difficult due to complex 
interactions between factors that affect dietary intake, bioavailability and skin synthesis.  
The body of an older adult tends to draw more vitamin D reserves than a younger 
person.2,23,24  Several explanations have been proposed to explain why reaching optimal 
serum vitamin D levels is harder for the elderly compared to younger adults. First of all, 
vitamin D intake is below recommendations for older adults. The 2010 report of the 
Institute of Medicine (IOM) committee established Dietary Reference Intakes (DRIs) for 
vitamin D of 600 International Units (IU) per day for adults below the age of 70, and 800 
IU per day for adults over the age of 70, with a tolerable upper limit of 4,000 IU per day, 
to maintain serum 25(OH)D above 20 ng/ml, which was deemed necessary to preserve 
bone health.20,25-27 The Endocrine Society, however, recommended that adults over the 
age of 18 should take between 1500 and 2000 IU/day, with an upper limit of 10,000 
IU/day, to maintain 25(OH)D between 40-60 ng/ml and preserve physiological functions 
that go beyond bone health, based on 100 IU of vitamin D3 increasing 25(OH)D by 1 
ng/ml in serum.28  
In the United States, very few foods contain significant amounts of vitamin D; 
thus, dietary intake may minimally affect 25(OH)D status.29-31 Dietary sources include 
fatty fish like salmon, tuna, sardines, and fish oil, egg yolks, organ meats, mushrooms, 
and fortified foods like milk and dairy products, breakfast cereals, bread, margarine, 
spreads, and vegetable oils.29,30 Supplement use may compensate for the lack of vitamin 
D intake from foods. Use of vitamin D supplement has increased over time in adults, as 
25% reporting use of vitamin D supplements in NHANES 1999-2002 and 37% in  
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NHANES 2003-2006.32 Low vitamin D intakes from food and supplements, however, 
have been reported in older adults, and it has been associated with low serum vitamin 
D.6,7,33 
Recommended dietary intake of vitamin D is higher for the elderly; however, 
dietary intake usually decreases with age.34 This may be due to physiological and 
psychological factors, such as depression, age-related lactose intolerance that limits the 
intake of fortified milk products, and hormonal factors regulating satiety.3,34-39 Age is an 
important and complex risk factor for vitamin D deficiency because it affects 
bioavailability due to impaired gut absorption of vitamin D.3,34 Bioavailability is also 
decreased due to the age-related decrease in metabolic rate with hormonal changes that 
occur during aging that often result in weight gain, as seen in the growing prevalence of 
obesity among the elderly in the United States.40,41 Obesity has been correlated with low 
vitamin D status in the elderly, probably due to the sequestration of vitamin D by 
increased body fat.3,7,34 Besides obesity, the presence of other comorbidities and 
behavioral factors, such as liver, kidney, and gastrointestinal diseases, and the use of 
medication, tobacco and alcohol, may directly affect vitamin D metabolism and 
bioavailability.34  
For those who are not taking adequate amounts of vitamin D through diet, 
sunlight would often be their main source of vitamin D.17,42 Vitamin D is mostly 
synthesized in the skin from 7-dehydrocholesterol after solar exposure, where ultraviolet 
B (UVB, 290–315 nm) light from the sun causes a photochemical rearrangement of 7-
dehydrocholesterol to pre-vitamin D3, which then undergoes thermal isomerization into 
vitamin D3.17,30,43,44  It is believed that sunlight exposure of arms and legs for 5-15 
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minutes at midday during the summer months could produce about 3,000 IU of vitamin 
D.23 The effectiveness of vitamin D synthesis in the skin, however, is determined by skin 
pigmentation, amount of skin exposed and sunscreen use, and amount of solar radiation, 
which depends on the latitude, season, time of day, and time in the sun.  
Darker pigmentation decreases the skin’s capacity to use sunlight for making 
vitamin D because melanin absorbs UVB radiation effectively.6, 47 Ethnicity and race are 
often used as a proxy for skin pigmentation, and a substantial amount of evidence that 
indicates a significant difference in vitamin D deficiency between different ethnic 
groups.44 For example, NHANES 2005-2006 revealed that the prevalence of vitamin D 
deficiency (<20 ng/ml) was higher in blacks (82.1%), followed by Hispanics (69.2%) and 
whites (30.9%).3 A more recent study evaluated vitamin D status in a community-
dwelling elderly population (>60 years old) in South Florida and found a higher 
prevalence of vitamin D insufficiency (<25 ng/ml) among Afro-Caribbeans (30.8%) and 
African Americans (30.4%) compared to Hispanics (13%) and European Americans 
(13%).45 Those with darker skin pigmentation need four to10 times more sun exposure 
than lighter skin individuals.28 
Unfortunately, most people avoid sunshine in order to stay cool, prevent skin 
aging, and reduce the risk of skin cancer by covering the skin with clothes and using 
sunscreen, all of which interfere with UVB transmission to the skin.34 A study in Europe 
in 1995 showed that wearing short sleeves instead of long, and thus bearing arms as well 
as the face, is associated with better vitamin D status in older people living in sunnier 
climates.46 Likewise, sufficient exposure to sunlight is unusual with modern lifestyles, 
since most people live and work indoors. 34 Outdoor activity is associated with vitamin D 
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status as shown by an analysis of NHANES 1988-1994 data that revealed that those who 
were 60 years or older and participated in daily outdoor activities had optimal vitamin D 
levels (>30 ng/ml) similar to young adults.47 Furthermore, physical activity, which is 
often used as a surrogate for outdoor activity, has been positively associated with serum 
vitamin D levels, such that lower levels of serum vitamin D have been correlated with 
physical inactivity in middle-aged and older adults.7,48  
Also, the skin’s ability to synthesize vitamin D depends on the amount of solar 
radiation reaching the biosphere, which depends on latitude, season and time of day.30,43 
Based on the impact of sunlight exposure on vitamin D status, it has been assumed that 
vitamin D deficiency is less prevalent in populations living in lower latitudes and/or 
where seasonal variations are not as pronounced as in South Florida, where the weather is 
sunny and warm year-round.31 In contrast, other investigators reported a prevalence of 
38-40% of hypovitaminosis D (25(OH)D < 20 ng/ml) in adult men and women (>18 
years old) living in South Florida.31 A more recent study evaluated vitamin D status in a 
community-dwelling elderly population (>60 years old) in South Florida and found a 
prevalence of vitamin D insufficiency (<25 ng/ml) of 15.6%.45  
In summary, vitamin D deficiency and insufficiency in the elderly may be a result 
of the complex interplay between age-related factors that affect dietary intake, 
bioavailability, and skin biosynthesis. Since 90-95% of vitamin D comes from skin 
synthesis, it would be expected that vitamin D deficiency is not a public health concern in 
populations where sunlight for synthesis is available year round.6,7 This is not the case for 
older adults living in Miami-Dade, however, and understanding the factors that affect 
vitamin D status in this population is deemed necessary.  
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Vitamin D, Fall Risk, and Mobility as Measured by Gait Speed in the Elderly 
Besides vitamin D deficiency, falls is another common public health concern 
among older adults living in Miami-Dade. Vitamin D deficiency in older adults has been 
linked to important correlates of disability, including falls and fractures.49-57 The major 
cause of physical disability in the elderly is mobility limitations, which eventually may 
lead to falls.58 According to the World Health Organization (WHO), a fall is defined as 
an event that results in the person unintentionally coming to rest on the ground or other 
lower level that is not due to a major intrinsic event, like seizure, stroke, loss of 
consciousness, epilepsy, or excess alcohol, or an environmental hazard like sustaining a 
blow.59 It is estimated that approximately 30% of community-dwelling adults and 50% of 
institutionalized adults more than 65 years of age experience one fall each year.60, 61  
In the United States, the elderly population (>65 years of age) is expected to 
increase by 20%-50% by the year 2030.62 Miami is the fourth city in the United States 
that is graying the fastest, and Florida Department of Elder Affairs reported that the top 
county for elders >60 years of age in 2010 and 2012 was Miami-Dade, with 14.9% of the 
population in this age range.63 Furthermore, the Miami-Dade County Department of 
Health in 2003 observed that falls were among the three leading causes of 
hospitalizations due to injury (36.7% of all injury hospitalizations). Of these, 67.3% were 
attributed to residents over the age of 65.64 In later years, between 2007 and 2009, falls 
were the leading cause of injury of residents of Miami-Dade aged over 65 years and 
responsible for 79% of injury hospitalizations. One-third of hospitalizations related to 
falls resulted in hip fracture and 11% involved traumatic brain injury.65  
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Falls can result in increased morbidity and mortality and decreased quality of life, 
all of which translate to greater burden for the individual and healthcare system.60 Hence, 
understanding the risk factors and mechanisms behind falls is important for the 
development of effective interventions that protect the elderly from disability.   
 An extensive amount of research supports the relationship between the risks of 
falls and vitamin D deficiency and the reduction of this risk by vitamin D 
supplementation in the elderly.10,25,60,66-71 For instance, a recent meta-analysis found that 
fallers have lower 25(OH)D concentrations (25(OH)D <20 ng/ml), more often than non-
fallers.72 The mechanism by which vitamin D is related to fall risk is still unclear but it 
may be through its relationship with gait and cognition.   
Gait impairments are one of the main risk factors for falls in the elderly.73 Older 
adults, compared to their younger counterparts, have significantly reduced gait speed73-75 
and those over the age of 70 years have a 12-16% decline in gait speed per decade.76-79 
This decline may be due to a compensatory adaptation to the age-related neuro-motor 
changes that increase the complexity of walking to provide a safer gait. Although these 
changes in gait pattern may be compensatory to stabilize posture, sometimes they are 
dysfunctional and are correlated with increased risk of accidental falls.80 
 One of the ways vitamin D may be related to fall risk is through its role in 
mobility as measured by gait speed. A systematic search of Medline Ovid found 11 
observational and 6 interventional studies evaluating the relationship between vitamin D 
status and gait speed, or the effect of vitamin D supplementation on gait speed in 
community-dwelling older adults (Appendix  A). Six of the 11 studies found a significant 
positive association between vitamin D deficiency and slower gait speed. 81-85 In these 
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studies, gait speed was measured on its own or as part of a physical performance battery, 
and it involved different tasks such as timed walking at different distances (6 meters82,86, 
5 meters84, 8 feet83, and 30 meters and returning81), or walking on electronic walkways.85 
Of the six randomized controlled trials, only two found an improvement in gait speed 
with vitamin D supplementation.52,87 One of the studies did not adjust for potential 
confounders and included calcium supplementation and exercise training,87 while the 
other did not report initial and final vitamin D levels, walking speeds, and involved other 
interventions such as hormone treatment.52 In these two studies, gait speed was also 
measured as part of a physical performance battery, and gait tasks included timed 6-meter 
walks52 and distance walking for 12 minutes.87 These studies demonstrate that vitamin D 
may play a role in mobility as measured by gait speed; however, the exact mechanism is 
unclear since vitamin D can affect gait through its role in the musculoskeletal and/or 
nervous systems and cognition.   
 
Vitamin D Deficiency, Cognitive Impairment, and Executive Dysfunction in the 
Elderly 
Cognitive impairment is another major cause of physical disability in the 
elderly.88 Cognitive and mobility problems tend to coexist in the same individual; older 
adults with cognitive problems are twice as likely to fall, when compared with 
cognitively normal older adults.88 Since mobility depends on the musculoskeletal and 
nervous systems, it could be possible that the role of vitamin D in the risk of a fall is not 
only through its effects on the musculoskeletal system, but also through its role in the 
brain and cognition that affect mobility.  
 29 
Vitamin D receptors have been found to be expressed in neurons and glial cells, 
especially in areas that regulate behavior and motor activity such as the limbic system, 
cerebellum, hippocampus, hypothalamus, cortex, and spinal motor zones.8,89 Through 
these receptors, vitamin D is involved in the expression of proteins involved in DNA 
repair and genome stability, synaptogenesis and synaptic plasticity, calcium 
signaling/homeostasis, neurotransmission, and differentiation and survival of neurons and 
glial cells.90-95 Furthermore, vitamin D is involved in the metabolism of neurotransmitters 
such as gamma-aminobutyric acid (GABA), serotonin, dopamine, and acetylcholine, 
which implies its role in cognition, behavior, and motor activity.94,96-98 Recently, a study 
found that older adults who had the VDR receptor FF genotype had higher MMSE scores 
than the ff genotype, suggesting that single nucleotide polymorphisms may be possibly 
involved in cognitive function and supporting vitamin D’s role in cognition.99 
Additionally, lower vitamin D status has been associated with reduced neuronal function 
in the caudal primary motor cortex, which may explain the pathophysiology of gait 
disorders in older adults with lower vitamin D status.100 
The association between vitamin D and cognitive status has been explored in 
several studies. A systematic search in Medline, Ovid found 20 observational studies 
evaluating the relationship between vitamin D status and cognitive impairment or scores 
in cognitive tests in community-dwelling older adults (Appendix  A). Only one 
randomized clinical trial of 1,000mg of calcium carbonate and 400 IU of vitamin D3 per 
day or placebo reported no association between treatment assignment and incident of 
cognitive impairment.101 This trial included 4,143 women over the age of 65, who did not 
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have probable dementia at baseline, and participated in the WHI Calcium and Vitamin D 
trial and WHI Memory Study. 
Of the 20 observational studies, 16 found a significant positive correlation 
between vitamin D and cognitive impairment and/or decline5,102-109 or cognitive test 
scores.108-115 The studies that found that vitamin D status was associated with the 
incidence of cognitive impairment used different definitions based on either multi-
disciplinary meetings that evaluated standardized neuropsychological tests, physical 
examination, blood tests, and MRI imaging116; pre-established characteristics107; 
composite scores of different tests5; or cutoff scores in cognitive performance tests such 
as the Pfeiffer Short Portable Mental State Questionnaire (SPMSQ)103, Abbreviated 
Mental Test Score102, Mini Mental State Examination (MMSE)105,106,109, and Trails 
Making Test B.105 The studies that found a significant association between vitamin D and 
cognitive performance scores used one or more tests to assess global cognition like the 
MMSE112,113,117 and/or executive function/information processing (Digit Symbol 
Substitution Test109-111, Trail Making Test A110,113,115, Trail Making Test B110,113,115,118, 
Block Design 110, and Verbal Fluency).110,115 Overall, these studies support the 
association between vitamin D and cognition, especially in executive cognitive function.  
A recent meta-analysis of cross-sectional and longitudinal studies suggests that 
there is an increased risk of cognitive impairment in those with low vitamin D compared 
with normal vitamin D (OR 2.39; CI 1.91-3.00; P<0.0001).119 Another meta-analysis of 
observational and interventional studies showed that lower vitamin D concentration was 
significantly associated with executive dysfunction in processing speed, mental shifting, 
and information updating.120 Executive function refers to the cognitive processes that 
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orchestrate goal-directed behavior and decision-making, such as problem-solving, 
initiating and maintaining tasks, working memory (holding multiple pieces of transitory 
information and manipulating it), abstract reasoning, and dividing attention.121,122 
Interestingly, age-related decline in executive function is common among elderly123-125, 
and it has been associated with an increased fall risk and gait impairments, including 
slower gait speed, even with no obvious cognitive impairments.122,126-135  
With aging the ability to perform automatic tasks, such as walking, becomes 
harder and more cognitively demanding.80 According to recent evidence, age-related 
deficits in mobility might be partially compensated by effortful higher order cognitive 
strategies involving executive function that replace the automated sensorimotor 
processing.80 As people age, their cognitive capacity, however, tends to decrease as well, 
and their compensatory response becomes impaired. Hence, cognitive resources like 
attention allotted to movement in older adults are no longer accessible for other activities 
such as talking, avoiding obstacles, watching for traffic, or other gait-unrelated tasks.80 
Consequently, older adults often have more problems than younger adults to orchestrate 
tasks simultaneously, as shown by decreased gait speed and stride length and increased 
stride time variability of older adults during dual task performance.80 This may be due to 
lack of coordination of limited cognitive resources and decreased mental processing 
speed, which is especially evident in the elderly and people with cognitive problems. 
Dual task physical performance tests, in which participants are asked to perform 
an automatic task like walking while performing an executive function cognitive task like 
counting backwards, have been used to evaluate the interaction between cognition and 
mobility as an indicator of fall risk in older adults.136 Thus, dual task physical 
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performance tests can be used to assess the relationship between lower vitamin D 
concentration with executive dysfunction in the context of mobility.120  
 
Vitamin D and Other Non-Skeletal Outcomes: Cardiovascular Disease  
Besides its association with fall risk and fractures, vitamin D deficiency has also 
been associated with cardiovascular disease (CVD). Vitamin D deficiency and 
cardiovascular disease (CVD) are prevalent worldwide.1,137 Furthermore, the prevalence 
of vitamin D deficiency is high among those with CVD. Analysis of data from the 
NHANES 2001-2004, showed 68% of whites, 88% of Hispanics and 97% of blacks with 
CVD also had vitamin D levels, as measured by 25-hydroxyvitamin D (25(OH)D), of less 
than 30 ng/ml.138,139 The possible relationship between vitamin D deficiency and CVD-
related outcomes and mortality in both diseased and healthy populations is a growing 
area of research.137  
Several observational studies and meta-analyses have demonstrated associations 
between vitamin D deficiency and outcomes associated with CVD and CVD-related 
deaths.140-154 In 2008, Wang et al.141 observed that normotensive participants from the 
Framingham Offspring Study, free of CVD and with 25(OH)D of <15 ng/ml at baseline, 
had a 62% higher CVD risk (i.e., myocardial infarction) over a 5.4 year follow-up. 
Giovannucci et al.149 reported from the Health Professionals Follow-up study a graded 
independent correlation between low 25(OH)D and myocardial infarction risk in 18,225 
men aged 40-75 years, who were free of CVD at baseline. They found that those who had 
levels of 25(OH)D <15 ng/ml compared to those with ≥30 ng/ml had a relative risk of 
CVD of 2.1. Deo et al.140 in their report from the Cardiovascular Health Study showed 
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that lower 25(OH)D levels were independently associated with increased risk of sudden 
cardiac death (SCD) in healthy adults. Perna et al.142 investigated the relationship 
between serum 25(OH)D and the incidence of fatal and nonfatal cardiovascular events 
and found that low 25(OH)D levels were associated with a moderate increase in CVD 
risk, which was stronger for fatal than nonfatal events. In their dose-response analysis, 
cardiovascular risk increased at 25(OH)D <30 ng/ml. A study of 9,578 German 
participants, 50-74 years of age, followed for 5 years as part of the ESTHER study, found 
vitamin D deficiency (25(OH)D < 12 ng/ml) and insufficiency (25(OH)D 12-20 ng/ml) 
increased overall and cardiac mortalities.148 They risk increased at 25(OH)D 
concentrations of <30 ng/ml. This was supported by results from a meta-analysis in 2012 
that found a linear, inverse association of 25(OH)D levels between 8-24 ng/ml and CVD 
risk.147 
Other systematic reviews and meta-analyses have further supported a potential 
link between CVD risk and vitamin D status and the benefit of vitamin D 
supplementation on heart health. A meta-analysis found strong associations between 
25(OH)D and all-cause and cardiac mortality, which was consistent after adjusting for 
confounders.143 Another meta-analysis of 28 studies showed that higher 25(OH)D levels 
were associated with a 33% lower risk of CVD in middle-aged and elderly individuals. 
Wang et al.154 reported in their systematic review of 5 prospective studies that patients 
taking vitamin D supplements had a reduction in CVD-related mortality. A meta-analysis 
of 18 randomized controlled trials (RCTs) showed that vitamin D intake of more than 500 
IU/day improved all-cause mortality, partly by decreasing cardiovascular deaths.144,150  
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Besides cardiovascular mortality in the general healthy populations, other studies 
have investigated the relationship between vitamin D and heart-related outcomes in 
diseased populations. Gotsman et al.151 reported that vitamin D deficiency was 
significantly higher in heart failure (HF) patients compared to healthy controls, with 
vitamin D deficiency being an independent predictor of increased mortality in HF 
patients, and prescription of vitamin D supplementation independently associated with 
reduced mortality risk. In a study by Dobnig et al.153, of the 3,258 patients referred for 
coronary angiography, those within the lowest quartiles of 25(OH)D (<14 ng/ml) were at 
highest risk of sudden cardiac death (SCD). Pliz et al.152 studied another cohort of 
patients referred for coronary angiography over a period of 7.7 years and found that after 
adjusting for CVD risk factors the risk of SCD was higher in those with severe vitamin D 
deficiency (25(OH)D <10 ng/ml) compared to those with 25(OH)D <30 ng/ml. Drechsler 
et al.145 found vitamin D deficiency in diabetic patients on hemodialysis was associated 
with SCD, combined cardiovascular events, and mortality, after four years. They 
observed that vitamin D deficiency had a three-fold higher risk of SCD compared to 
those with sufficient vitamin D.  
 
Vitamin D and Cardiovascular Health: Possible Mechanism 
The mechanism by which vitamin D affects heart health is still unclear. Vitamin 
D affects multiple cellular signaling pathways via genomic and non-genomic actions that 
have the potential to affect cardiovascular health. These include vitamin D effects on 
parathyroid hormone (PTH), the renin-angiotensin-aldosterone system (RAAS), cytokine 
production, endothelial growth and function, and myocyte calcium influx.155 
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Furthermore, vitamin D has also been shown to be involved in molecular mechanisms 
like biosynthesis of neurotransmitters and inflammatory signaling in areas of the central 
nervous system (CNS) that regulate cardiovascular activity.98,156 Vitamin D has been 
shown to permeate the blood-brain barrier and bind to VDRs located in extremely high 
concentrations in the midbrain and brainstem where some autonomic nervous system 
(ANS) neurons are located.98,156 These findings, together with previous evidence of the 
effect of vitamin D in neurotransmitter biosynthesis and nervous system activity, suggest 
that vitamin D may contribute to the function of the cardiac ANS and subsequently, 
contribute to CVD-risk by orchestrating non-genomic regulatory activity at higher brain 
centers of the ANS.137 
 
The Relationship Between Vitamin D and Cardiac Autonomic Nervous System 
The ANS is a branch of the peripheral nervous system that controls involuntary 
processes throughout the body to regulate the internal environment and body functions 
like hemodynamics, blood glucose levels, sweating, and other visceral functions, 
including digestion, bladder and sexual organ function, respiration, and cardiovascular 
activity.157 The ANS controls autonomic body functions by the balanced opposition of 
the stimulatory sympathetic (SNS) and inhibitory parasympathetic (vagal) nervous 
systems (PNS). The cardiac ANS is composed of post-ganglionic sympathetic plexus of 
nerves and the parasympathetic Vagus nerve, both of which innervate the heart at the 
atrioventricular and sinoatrial nodes. Both act concomitantly to control cardiac 
performance and thus, changes in the duration of time between heartbeats can be 
attributed to changes in the balance between the SNS and PNS. Dysfunction of cardiac 
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autonomic function, more specifically of the cardioprotective vagal tone, results in an 
imbalance between SNS and PNS. This imbalance has been well-established as a risk 
factor for adverse cardiovascular events such as SCD or congestive heart failure.158-163 
Furthermore, cardiovascular autonomic neuropathy (CAN), which is a consequence of 
damage to the cardiac autonomic nerve fibers, results in abnormalities in heart rate (i.e., 
reduced heart rate variability or HRV) and irregular vascular dynamics (i.e., changes in 
blood flow, volume and pressure).164,165  
Several lines of evidence support a relationship between vitamin D and cardiac 
ANS. In animal studies, cardiac myocytes isolated from VDR knockout mice display 
accelerated contractility rates when compared to wild type.166 When stimulated to 
increase contractility, exposure to 1,25(OH)2D only attenuated the rapid contractility in 
the wild type but not the VDR knockout cardiac myocyte, suggesting a relationship 
between vitamin D and parasympathetic inhibitory activity. Another study showed that 
rats fed with a vitamin D deficient diet had increased ventricular and vascular muscle 
contraction and increased sensitivity to the sympathetic neurotransmitter 
norepinephrine.167 In arteries of spontaneously hypertensive rats, vitamin D 
supplementation normalized the relaxant and hyperpolarizing effects of the vagal 
neurotransmitter acetylcholine.168 In isolated chick myocardial cells, beta-adrenergic 
signal transduction was enhanced in the presence of activated vitamin D3.169  
To date, very few studies have investigated the role of vitamin D in modulation of 
cardiac ANS, a risk factor for poor CV-related outcomes in diseased and healthy 
humans.140,153,170 Some evidence has shown a relationship between vitamin D and ANS 
function in diseased populations. For instance, in 36 patients with non-ischemic dilated 
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cardiomyopathy (NIDCM) 25(OH)D was positively correlated with HRV parameters, 
with vitamin D insufficiency having deleterious effects on cardiac ANS function.171 
Krause et al.172 showed that chronic kidney disease (CKD) patients, who have impaired 
vitamin D synthesis, when exposed to short-term artificial sunlight heliotherapy had a 
significant increase in 25(OH)D levels and in measurements of vagal activity that were 
severely depressed at baseline. The magnitude of 25(OH)D increase was directly 
correlated with the level of elevated cardioprotective parasympathetic activity, implying 
that vitamin D levels may constitute an important role in the development of CVD-
related outcomes by affecting the ANS. Also, Chan et al.173 reported that patients with 
CKD demonstrated poor cardiac ANS activity, which was characterized by decreased 
activity of the inhibitory PNS.  Furthermore, in the end-stage kidney disease (ESKD) 
population, in which the prevalence of vitamin D deficiency is high, depressed HRV is 
extremely common and usually presents as suppressed PNS activity with increased SNS 
input to the sino-atrial node.173,174 For the doctoral dissertation by Mann, a crossover 
study was conducted in which 56 participants with ESKD on hemodialysis were 
randomized to either conventional (0.25 mg alfacalcidol 3 times per week plus placebo 3 
times per week for 6 weeks) or intensive (0.25 mg alfacalcidol 3 times per week plus 
50,000 IU ergocalciferol once a week plus placebo 2 days per week for 6 weeks) vitamin 
D therapy followed by a 12-week washout period and another 6 weeks of vitamin D 
therapy.174 They did not observe significant changes in measures of cardiac autonomic 
tone, mineral metabolism, or RAAS activity. However, an exploratory subgroup analysis 
found that after treatment participants who remained vitamin D deficient (25(OH)D <20 
ng/ml), compared to those who achieved sufficiency, had significant ANS imbalance.  In 
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the ESKD population, the association between low vitamin D levels and SCD may be 
mediated by ANS dysfunction.173,175-180  
The association of vitamin D and cardiac ANS function has also been observed in 
healthy adult populations. A study in 2014 observed that 25(OH)D was positively 
associated with decreased HRV in a healthy Korean population over the age of 20 
years.181 They observed that vitamin D deficient individuals (25(OH)D <15 ng/ml) were 
3.1 times more likely to have low HRV.  In 2013, Mann et al.181  used power spectral 
analysis of electrocardiogram recordings to measure HRV and thus assess cardiac ANS 
activity at baseline and during a graded angiotensin II challenge in 34 healthy humans. 
They found a significant suppression of ANS balance in vitamin D deficient (25(OH)D 
<20 ng/ml) participants at baseline, but no difference was observed during the challenge. 
In an intervention study, the same group demonstrated that healthy adults supplemented 
with 10,000 IU of vitamin D for four weeks had a significant improvement in cardiac 
ANS balance, more specifically in enhancing the cardio-protective PNS activity.182  
Studies that evaluated the relationship between vitamin D and ANS activity have 
measured HRV only at baseline. Since the early 1970’s, valid cardiovascular reflex tests 
have been used to assess cardiac ANS function and diagnose CAN by measuring the 
variations in heart rate and blood pressure in response to the Valsalva maneuver, deep 
breathing, and postural change (i.e., standing up).183 HRV parameters measured during 
cardiac autonomic function tests have been proven to detect ANS dysfunction and CAN 
in asymptomatic patients (i.e., patients without any symptoms of cardiovascular disease 
or CVD).165,184 To date, only one study has evaluated the relationship between vitamin D 
status and CAN in type 2 diabetics using cardiac autonomic reflex tests.185 In this study, 
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several HRV parameters during ANS tests were assessed and scored as normal, 
borderline, and abnormal to calculate a CAN risk score. They found that vitamin D 
deficiency (25(OH)D <10 ng/ml) was significantly correlated with decreased HRV in the 
supine and upright position, and those with vitamin D levels <10 ng/ml had significantly 
increased CAN risk compared to those with 25(OH)D between 10-20 ng/ml.185 
  
Vitamin D and Its Relationship to Other Cardiovascular Risk Correlates  
Besides modulating heart rate, the ANS influences vascular dynamics and blood 
pressure, which is also affected by endothelial function. Endothelial function is related to 
the blood vessel's ability to dilate when necessary; therefore, dysfunction is characterized 
by decreased ability to balance vasodilation and vasoconstriction, usually due to an 
imbalance of nitric oxide bioavailability.139,186-189  Endothelial dysfunction is also related 
to prothrombotic and proinflammatory states that increase arterial stiffness. Human 
endothelial cells express VDRs, and recent studies have suggested an association between 
endothelial function and vitamin D status.139,186-189 In healthy individuals, 25(OH)D 
levels were independently associated with several tests of endothelial function, arterial 
stiffness, and coronary flow reserve tests.187,190 Other studies have demonstrated that 
vitamin D treatment improved arterial stiffness measured by pulse wave velocity.191,192 
Thus, vitamin D has a role in vascular physiology by either directly affecting the 
endothelium or indirectly via modulation of ANS. 
The observations that vitamin D deficiency, cardiac ANS, and endothelial 
dysfunction are independently linked to each other and CVD-related outcomes suggests a 
potential mechanism by which vitamin D deficiency affects CVD risk. 
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Literature Review Summary  
Vitamin D insufficiency and deficiency are still common among older adult 
populations living in communities where with more opportunity for vitamin D skin 
synthesis through sun exposure, which is the main source of vitamin D.28,31,193 The 
elderly population in Miami-Dade is increasing rapidly, falls are a major cause of injury 
in this community-dwelling population, and vitamin D deficiency is still a major public 
health issue among them.64,65,194,195 The determinants of vitamin D status are not well 
documented among Miami-Dade older adults. Assessing the factors affecting vitamin D 
status of this older adult community is important to help improve health outcomes such as 
gait impairments and cognition related to the risk of falls.10,25,60,66-71 
 Furthermore, the role of vitamin D in the mechanism of falls needs further 
investigation. Several studies have demonstrated an association between vitamin D 
deficiency, gait impairment (slower gait speed), global cognitive impairment and 
impaired executive function. Studies that investigate vitamin D status’ relationship to gait 
and cognition have looked at these factors independently. A systematic search in Medline 
Ovid found eight observational studies evaluating the relationship between vitamin D 
status, gait and cognitive impairment, independently, in community-dwelling adults 
(Appendix A). Of these, two studies found gait speed only21,196, one study found 
cognitive performance only197, and five studies found that both gait speed and cognitive 
performance were associated with vitamin D status.57,198-201 Among the latter four studies, 
gait speed was measured as part of a physical performance battery including timed 
walking at different distances (20 meters199,200, 6 meters198, and 4 meters57) or electronic 
walkway201, and cognition was measured by global cognitive performance tests 
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(MMSE)57,198-201 or tests of executive function (Trail Making Test B).198 Even though 
evidence indicates that vitamin D levels are associated with cognition and gait, 
independently, until now no cross-sectional study has evaluated how vitamin D status is 
related to cognitive processing during motor activity. 
In addition, vitamin D can affect other non-skeletal outcomes, like cardiovascular 
health. Since CVD and vitamin D deficiency are prevalent worldwide, the relationship 
between these two health problems has become a growing area of translational 
research.140,153,170 Vitamin D deficiency, cardiac ANS and endothelial dysfunctions are 
independently linked to each other and CVD-related outcomes, suggesting a potential 
relationship between vitamin D deficiency and CVD risk. To date, very few studies have 
investigated the role of vitamin D in modulation of cardiac ANS and endothelial 
function.140,153,170 Furthermore, until today no study has evaluated the relationship 
between low vitamin D levels and cardiometabolic risk, using a non-invasive rapid test 
that integrates the assessment of other cardiovascular risk factors like body composition, 
ANS activity function markers, and endothelial function markers. 
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CHAPTER III: METHODS 
 
Design 
This was an observational study. Its purpose was to determine the proportion of 
vitamin D insufficient individuals and investigate the correlates of vitamin D status (i.e., 
vitamin D intake, sun exposure, etc.) in community-dwelling adults over the age of 55. In 
addition, it evaluated the possible relationships between vitamin D status with dual task 
physical performance and cardiovascular disease (CVD) risk factors. The study used the 
baseline assessment data from the parent study, which was a randomized placebo 
controlled trial (RCT) that examined the effects of vitamin D supplementation on vitamin 
D status, musculoskeletal health markers and physical performance, conducted by John 
E. Lewis, Ph.D., Principal Investigator at the University of Miami. This study was 
approved by the Institutional Review Board (IRB) at University of Miami (20120195) 
and Florida International University (13-0390).  
 
Selection of Participants and Eligibility Criteria 
Table 1: Inclusion and Exclusion Criteria 
Inclusion: Exclusion: 
• Age 55 or older men and women 
• English/Spanish speaking  
• Community dwelling  
• Scoring 0-2 errors in Short Portable 
Mental Status Questionnaire (SPMSQ) 
• Ability to give informed consent 
• Ability to perform motor tasks without 
aid 
• Participating in the parent study 
• Age younger than 55 years 
• Not English/Spanish speaking 
• Living in nursing home/ 
institutionalized 
• Scoring >2 errors in SPMSQ 
• Unable to consent 
• Unable to walk without aid  
• Not participating in parent study 
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Sample Size  
Using a two-tailed independent t-test with 5% significance and 80% power and 
assuming an allocation ratio of 60/40 (1.5), based on published prevalence of vitamin D 
deficiency in the general United States older adult population, and an effect size of 0.5 
for the dual task gait speed as the primary outcome variable, the total sample size 
calculated using G power statistical software was 134 (expected 54 vitamin D deficient 
and 80 vitamin D sufficient). Due to financial constraints, only 101 participants were 
enrolled in the study of which 4 were excluded from the analysis due to incomplete 
assessments and missing data.  
 
Recruitment  
Participants for this study were recruited from the parent study at the University 
of Miami. For the parent study, potential participants were identified through the 
clinicians and researchers from the Department of Medicine and Psychiatry  clinics on a 
daily basis. The clinicians determined the level of interest in participating in the study by 
briefly describing the purpose of the study without using any coercive or suggestive 
language to imply that participation in the study was expected or demanded. All study 
personnel were CITI certified for human research and were familiar with enrolling 
patients and the issues of confidentiality and respect of human subjects in research.  
Patients who expressed interest in participating in the study were instructed to call 
study staff to proceed with the formal screening and enrollment process. Study staff  was 
informed of any potential participant who had consented to be contacted. The study staff 
called the individual to set up a screening/appointment.  
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Screening 
Participants for the parent study were screened over the phone to determine if 
they met the inclusion and exclusion criteria. Each potential participant was given a brief 
introduction to the nature and purpose of the study and then asked if they would like to 
participate. Once the person agreed to participate, they were administered the Short 
Portable Mental Status Questionnaire (SPMSQ) to evaluate mental functioning and thus, 
assess participant competency, or in other words, mental capacity to understand 
information, appreciate risks/benefits of choices, make rational decisions regarding 
personal health, and communicate choice during the process of informed consent. 
Subjects were allowed up to 2 errors on the SPMSQ. Once they answered the SPMSQ 
successfully, then they were asked a series of questions related to the general inclusion 
criteria such as age, medical history, medication use and general exclusions. If responses 
to the inclusion/exclusion criteria were satisfactory, those who were still interested in 
participating were scheduled to undergo the consent process and their assessment visit. 
Potential participants who did not meet the inclusion criteria were thanked for their time 
and told they did not meet study eligibility.  
 
Informed Consents 
There were two informed consents were signed at the initial visit. The informed 
consent for University of Miami explained this study and the intervention study. The 
informed consent for Florida International University explained this study only. Both 
informed consent forms were available in English and Spanish, and the information was 
presented in a language understandable to the subject population. The consent forms 
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contained the studies’ purposes, procedures, confidentiality/privacy methods, 
risks/discomforts, benefits, and alternatives associated with the studies. They contained in 
bold an explanation of whom to contact for answers to pertinent questions about the 
studies, their subject rights, and protocols in case of any research-related injury. The 
statement also had the number and contact person at both IRBs and the office numbers of 
John E. Lewis, Ph.D. (the PI) and the student investigator, Johanna Lopez, in case of 
additional questions or if they wanted to place any complaint.  
The informed consent procedure took place in a private room in either Dr. Lewis’ 
office or the Department of Psychiatry and Behavioral Sciences interviewing rooms. All 
of the information on the consent form was verbally explained including but not limited 
to the purpose, procedures and expected duration of the study. Once the participant had 
expressed interest in taking part in the study, adequate time was given to read the IRB 
approved informed consent form before signing it to avoid the possibility of coercion. If 
the participant was unable to read or had any limitation, the consent form was read to the 
potential participant. Sufficient time was provided to allow the participant the opportunity 
to consider enrollment in the study and to receive answers to any questions. Once the 
informed consents were signed, the participant received a copy of both. Participants were 
also asked to sign a HIPAA Research Authorization Template form, which authorizes the 
researcher to use and disclose health information from medical and research records that 
were relevant to the research.  
 Following receipt of signed informed consent, participants were assigned a study 
Participant Identification (PID) number to track the participant’s responses over time. A 
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master list of the participant PIDs is being kept in the PI’s office in a locked file cabinet. 
Participant PIDs were created following a coded alphanumeric combination. 
 
Assessments 
Participants were reimbursed for time, travel and effort by the parent study 
sponsor. The reimbursement was believed to be fair and not constitute coercion, given the 
commitment required for completing the entire protocol.  Once the participant consented, 
the study staff collected the outcome measurements. To decrease observer bias, all 
researchers were trained for administering all screening and assessments battery using 
standardized procedures and uniform protocols. A research chart identified only by the 
PID was created for every participant containing a checklist of documents completed 
during screening and assessments and copies of socio-demographic and medical history 
questionnaires, laboratory test results, and the outcome assessments in questionnaires. 
Copies of the screening forms and informed consents, which contained the participant 
personal information and list of PID codes, were stored separately in the principal 
investigator’s locked file cabinet in his office. 
The assessments were performed in 2 baseline visits, one which lasted about 3 to 
3.5 hours and the second took 15 to 20 minutes. All of the participants included in this 
analysis were seen between February and June 2015, before randomization to parent 
study intervention. The following measures were assessed during the baseline assessment 
visit for the parent study, which were used for this study:  
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Vitamin D Status  
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D). 
Fasting venous blood (15 ml) was collected from every participant by a certified 
phlebotomist in the morning. The samples were sent the same day they were collected for 
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) identified 
with the date of the draw and the subject PID number.  Lab Corp used the 
immunochemiluminometric assay (ICMA) on the DiaSorin Liaison instrument to assess 
serum 25(OH)D. The dynamic range of the assay is 4.0-150 ng/ml, with a functional 
sensitivity of <4 ng/ml, a specificity of 100% and a high correlation with the DiaSorin 
25(OH)D radioimmunoassay, which has been used as the standard for clinical diagnosis 
for many years. ICMA is a competitive chemiluminescence immunoassay that uses 
magnetic particles coated with 25(OH)D antibody and 25(OH)D conjugated to the 
chemiluminescent isoluminol derivative. These beads are incubated with the sample, and 
the 25(OH)D in the sample competes with the labeled vitamin D bound to the particles. 
Then the sample is incubated with the labeled 25(OH)D tracer and the unbound material 
is washed off. The sample is reacted with substances that cause a chemiluminescent 
reaction that is measured by a photomultiplier. The signal is inversely related to the levels 
of 25(OH)D.1 This is a highly automated test that measures total 25(OH)D, and it has 
been widely used by others.  
 
Vitamin D Intake  
Vitamin D intake (continuous variable) was measured by a vitamin D and calcium 
specific short food frequency questionnaire (FFQ) developed by Blalock et al.2 based on 
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the Block-National Cancer Institute Health Habits and History Questionnaire (HHHQ), a 
tool that is widely used in epidemiological studies and has been previously validated for 
measuring vitamin D in a population of postmenopausal women by comparing it to a 3-
day food records and in university employees by comparing it to 7-day food records.2-6 It 
includes only 23 foods and beverages that were identified in the HHHQ as rich in either 
or both vitamin D and calcium. This self-administered questionnaire asks how frequently 
(never or less than once per month; 1/ month; 2-3/month; 1/week; 2/weeks; 3-4/week; 5-
6/week; 1/day; 2-3/day) and how much of each of these foods was consumed based on 
serving sizes (small, medium, large). The short FFQ is associated with a database; 
therefore, allowing the estimation of nutrient intakes for the reported portion size. 
Vitamin D and calcium values for the 23 foods were recorded from the Diet History 
Questionnaire database developed by the National Cancer Institute, according to serving 
size. The raw values were multiplied by the frequencies to calculate the amount of 
vitamin D and calcium per day using Microsoft Access.2  
The advantage of this instrument is that it is short; therefore, decreasing the 
burden on the participant, and it does not mix many different foods into one category, 
thus not affecting the respondents’ cognitive complexity.7 Furthermore, Blalock et al.2 
validated this tool showing that the vitamin D and calcium intakes estimated from this 
short FFQ were significantly correlated with estimates from the 7-day food diary (r=0.72 
and 0.66; respectively) and the original HHHQ (r=0.65 and 0.66, respectively). Positive 
predictive values of 100% for vitamin D and 91.7% for calcium were reported for the 
short instrument to identify those with low intakes as based on the 7-day food record.  
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Sun Exposure  
Sun exposure (continuous variable) was assessed using a questionnaire developed 
by Hanwell et al.8 This tool categorically measures the amount of time spent outdoors 
and amount of skin exposed for every day of the week. A scoring system is used to 
quantify sun exposure by multiplying time outdoors, (<5 minutes = 0; 5-30 minutes = 1; 
and >30 min = 2); to amount of skin exposed (hands and face = 0; hands, face, arms = 1; 
hands, face, arms, legs = 2; bathing suit = 3) for every day. The sum of the scores for 
each day was added for a total score.  
The researchers who developed this tool found that the sun exposure score was 
significantly correlated with serum vitamin D levels during the summer, which was 
mostly explained by the time in the sun than by the amount of skin exposed. The sun 
exposure score, however, did not correlate with vitamin D levels during the winter.8 
 
Dual Task Physical Performance  
Dual task physical performance tests have been used to evaluate the interaction 
between cognition and mobility as an indicator of fall risk in older adults.9  The dual task 
physical performance test was developed with the consultation of the Department of 
Physical Therapy. We conducted an extensive review of literature, overseen by Edgar 
Ramos Vieira, P.T., Ph.D., to investigate the methodological variations implicated in dual 
task analysis using mental tracking as the secondary task, and walking as the primary 
motor task. This was done by investigating the types of mental tracking task, secondary 
task outcomes, gait tasks, methods for the assessment of gait, the gait outcomes, and how 
dual tasking affects gait and secondary task and predicts falls in selected studies. 
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From this systematic review, it was evident that the gait task most commonly used 
was straight forward walking at different distances ranging from 3 to 25 meters, at self-
selected pace, using own footwear and a pressure pad system like the GAITRite. Of all 
the spatiotemporal variables measured in all of the studies, decrease in speed during dual 
tasking was consistently found to predict falls in older adults. In these studies, however, 
speed was calculated by measuring distance and dividing it by ambulation time. Experts 
suggest using pressure pads or other systems instead, because they are more reliable and 
allow for the measurement of changes in other gait parameters that may be more relevant 
for assessing fall risk besides speed.10 Some researchers, however, argue that a pressure 
pad systems like GAITRite, which has been shown to be a reliable tool for measuring 
spatiotemporal parameters in the elderly, have the limitation that they are of short length, 
hence, limiting the measurement of gait variability.11 Given this shortcoming, for this 
study participants were asked to repeat the trial three times to get at least ten steps.   
Our review of literature also indicated that the most common mental tracking 
tasks, which predicted fall outcomes, were serial subtractions by one and three. When 
measuring the secondary task, different outcomes have been described from number of 
enumerated figures to number of mistakes; therefore, for this study number of 
enumerated figures was measured, and counting rate (number of enumerated figures 
divided by time) was calculated. In most studies, task order was randomized, and 
participants were not asked to prioritize either task during the dual task. When 
participants prioritize either task, fewer changes are observed in that particular task.  
Therefore, it is important to measure both the gait and cognitive task, because dual task 
performance results from the interference that is caused by the competing demands of 
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two tasks for attention resources.12,13 Hence, in the present study, task order was 
randomized, and participants were not asked to prioritize either task, and thus 
performance in both tasks were measured.  
Despite the heterogeneity of the populations studied and the diverse sample sizes, 
the results from our systematic review indicated that changes in speed and stride 
variability while performing a simple gait task, such as walking in a straight line, and a 
simple mental tracking secondary task, such as counting backwards from 50 by 1, using 
the speed analysis method or even better, a spatiotemporal assessment system like the 
GAITRite, yield enough sensitivity and predictive value for falls. Therefore, for this 
study, a dual task test that involved walking in a straight line while counting backward 
from 50 by 1 using the GAITRite system was used to measure gait speed as the primary 
outcome variable.   
 
Description of Dual Task Test: 
After a practice walk, participants were asked to perform the following tasks in a 
random order, determined from a random order table.   
• Usual walking (single gait task) 
• Counting backward from 50 by one while standing (single cognitive task)14 
• Counting backward from 50 by one while walking (dual task) 
 
Gait Speed  
Gait speed (distance walked/time; cm/s; continuous variable) was measured using 
the GAITRite system (Appendix B). The GAITRite system includes a 6 meter-long and 
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64 centimeter-wide walkway mat that is used to measure spatiotemporal gait parameters 
through its embedded sensors that are activated and deactivated according to foot 
pressure. The participants wore comfortable, low-heeled shoes. Before each trial, 
participants’ leg length was measured using a measuring tape from the trochanter of the 
femur to the medial malleolus (bony part of the ankle). The GAITRite software was 
initiated to enter the participant ID, height, weight and leg length. Participants were given 
a demonstration of how to walk on the walkway from the start to the finish line that was 
located 2 meters before and after the walkway to account for acceleration and 
deceleration. Data collection was initiated by pressing “START.” 
Participants were given standardized instructions for practice and data collection 
trials in which they were asked to walk only or walk while dual tasking without 
prioritizing either task on the GAITRite walkway at their preferred gait speed. The 
instructions for the practice trials were: “This is the walkway that we will use for some 
walking tests. For each walk, you must start behind the line in front of you and continue 
walking until you pass the line at the other end of the walkway. To familiarize yourself 
with the walkway, start at this line and walk across the mat at the pace you prefer during 
daily activities. Do not run. Continue walking until you reach the line on the other side. 
You can start when you are ready.” The instructions for the single gait task were: 
“Starting at this line, walk across the mat at a pace you prefer during daily activities. Do 
not run. Continue walking until you reach the line on the other side. You can start 
whenever you are ready.” The instructions for the dual task were: “For the following test, 
you will walk across the mat at a pace you prefer during daily activities while you 
simultaneously count backward out from 50 by one. Do not run. If you make mistakes 
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during counting keep on going. Continue walking without prioritizing either of the tasks 
until you reach the line on the other side. You can start when you are ready.”  
Participants were required to perform three trials per data recording session. To 
ensure safety, the researcher walked beside the walkway, slightly behind the participants. 
The GAITRite software was used to process the information and gather the data. The first 
ten gait cycles were used in each gait condition to determine spatial-temporal gait 
parameters, which were normalized by individual leg length.  
 
Counting Rate in Secondary Cognitive Task  
Counting rate (continuous variable) was used to assess cognitive secondary task 
performance. It was measured by using a voice recorder while single and dual tasking. 
The number of enumerated figures was defined as the number achieved at the completion 
of the walking distance for the dual task. For the single task, the number of enumerated 
figures was defined as those spoken during the same time required for the completion of 
the dual task.15 The instructions for the single cognitive task were: “For the following 
test, you will remain standing the whole time, no walking. You will count backward out 
loud from 50 by one while you are standing. If you make mistakes during counting keep 
on going. You can start when you are ready.” They were recorded until they stopped 
walking if dual tasking or reached 30 if single tasking. The time to complete the dual task 
was used to calculate the number of figures enumerated during the single task. For 
instance, if the participant took 30 seconds to finish counting during the dual task, the 
number of enumerated figures for the single task was counted in the first 30 seconds of 
single tasking.  The average of the three trials was used.  
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Cardiometabolic Risk Score (CMRS) 
We used the FDA approved and patented Electro Sensor Complex (ESC) 
software, which combines three devices (ES-BC, TM-Oxi and SudoPath) that use 
bioelectrical impedance, galvanic skin response, spectrophotometry, and an oscillometric 
blood pressure device. It measures different parameters of body composition, endothelial 
function and autonomic nervous system (ANS) function during baseline and the 
performance of cardiac autonomic function tests.16,17 Steps of the procedure are shown in 
Appendix B. Briefly, study staff, trained by the manufacturer, asked participants to sit on 
a comfortable chair with their shoes and socks off, feet on the metal plates, right index 
finger in the pulse oximeter, and blood pressure cuff on the left arm. After inputting 
demographic, anthropometric and physical activity data, the software initiated the 
baseline assessment for 1-2 minutes while the participant was sitting relaxed. Then the 
participant was asked to perform the Valsalva maneuver by clamping their nose with 
their left hand while trying to breath out for 15 seconds with their mouth closed, building 
pressure like when popping ears. After releasing their nose, participants were asked to 
breath deeply for 30 seconds, inhaling for 5 seconds and exhaling for 5 seconds. Finally, 
participants were asked to stand up, while straightening their left arm to their side and 
keeping their index finger in the pulse oximeter. The whole assessment lasted about 5 
minutes.   
Details of the devices are discussed in previous publications and the 
manufacturer's website (http://www.ldteck.com).16,17 The Electro-Sensor Body 
Composition (ES-BC) device uses a single-frequency bioelectrical impedance analyzer in 
a tetrapolar mode to measure current, voltage, and phase angle to calculate impedance 
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resistance and reactance.16 This information is used by the software to compute percent 
body fat mass (%FM) using accepted peer-reviewed published algorithms tailored to the 
general and obese population based on gender, height, weight, age, and activity level.16,18-
21 The accuracy of ES-BC has been compared to dual-energy X-ray absorptiometry 
(DXA) and found an adequate relative and absolute agreement for %FM between both.16 
The TM-Oxi system assesses cardiac autonomic nervous system ANS function, 
including both sympathetic (SNS) and parasympathetic nervous systems (PNS), during 
baseline and validated cardiac autonomic reflex tests (i.e., Valsalva maneuver, deep 
breathing, and change from sitting to standing) (Appendix B).22  The software uses an 
automatic oscillometric blood pressure device and pulse oximeter, which uses an optical 
technique (spectrophotometry) to measure vascular dynamics and HRV.23,24 Briefly, the 
pulse oximeter directs red and infrared light into the nail bed area of the right index 
finger, which is absorbed, reflected, and scattered by blood hemoglobin. During systole, 
the arteries’ diameter increases as blood fills the capillary beds at the fingertip, increasing 
the concentration of hemoglobin in the vessels in the nail bed and thus affecting the 
absorption, reflection and scattering of light that is measured by the photosensor. The 
change in light absorption, reflection, and scattering between systole and diastole creates 
a pulsatile signal or waveform, illustrated as a plethysmograph (PTG), which varies in 
time with each heartbeat (Appendix B). From the time domain, the TM-Oxi calculates the 
standard deviation of the normal wave ( SDNN, the variation between each successive 
heart beat) and the square root of the mean  squared differences of successive normal to 
normal R-R intervals (RMS SD, indicator of parasympathetic activity) (Appendix B).25 
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The TM-Oxi applies a mathematical algorithm, the Fast Fourier Transform (FFT), 
to the PTG recording (FFTPTG) to manipulate the beat to beat RR intervals into a sine 
wave function thus converting the signal from a time domain to a frequency domain 
(Appendix B). The frequency domains are then categorized by oscillating frequency, 
which are the three frequencies of HRV: (1) very low frequency (PTGVLF) associated 
with thermoregulation and sweating that results in oscillation in vasomotor tone 
controlled by SNS; (2) low frequency (PTGLF) related to baroreflex which is under 
control of both SNS and PNS; and (3) high frequency (PTGHF) associated with R-R 
interval changes associated with breathing under PNS control. 17 From these components, 
the software calculates PTG total power (PTGTP, the sum of the areas under the curve 
covered by the 3 frequency domains) and PTG index (PTGi, the sum of the amplitudes of 
the 3 frequency domains) which are used to assess baseline ANS function (Appendix B).  
After baseline evaluation, the software measures heart rate and blood pressure 
changes during autonomic reflex tests (Appendix B). The first test to be performed is the 
Valsalva maneuver in which the participant is asked to perform a moderately forceful 
exhalation against a closed airway by pinching the nose shut, closing the mouth, and 
pressing out like popping the ears for 15 seconds and then breathing normally.16,17 This 
test involves 4 phases: (1) straining and beginning on intrathoracic pressure increase; (2) 
maintenance of increased intrathoracic pressure, resulting in decreased systemic blood 
pressure and increased heart rate; (3) release of breathing and sudden drop in 
intrathoracic pressure; and (4) transient bradycardia resulting from the baroreflex 
response to the sudden increase in aortic pressure due to increased cardiac output. Phase 
2 can be divided into 2 phases: (1) early phase in which preload and stroke volume are 
  74 
reduced causing a fall in cardiac output despite tachycardia that resulted from decreased 
vagal activity; and (2) late phase in which total peripheral resistance rises due to 
increased sympathetic discharge and plasma epinephrine concentration, stopping the fall 
in blood pressure. The vagal function is evaluated by calculating the heart rate ratio 
(Valsalva ratio) during phase four and two, which are compared to age-adjusted normal 
Valsalva ratios. Sympathetic function is evaluated by the beat to beat blood pressure 
response during phase 2 and phase 4.16,17  
The second autonomic reflex test is deep breathing, which measures PNS function 
since the vagal nerve mediates heart rate changes in response to deep breathing.16,17 
During the inspiration phase, intrathoracic pressure is reduced, decreasing venous return 
from the pulmonary circulation to the left atrium, decreasing preload, and thus causing an 
increase in heart rate to compensate and maintain cardiac output. During expiration, the 
opposite happens. Vagal function during this test is measured by the heart rate ratio 
between expiration and inspiration (E/I ratio). The final cardiac autonomic reflex test is 
changing in posture. The participant is in a seated position and asked to stand up. Heart 
rate increases during the first 15 seconds and decreases until it stabilizes at 30 seconds. 
At the same time, the blood pressure increases at the standing position, and this change 
should be greater than 10 mmHg when compared to blood pressure while sitting. PNS is 
evaluated by measuring the heart rate ratio at 15 and 30 seconds (K30/15). SNS is 
evaluated by measuring the systolic blood pressure response to standing (BPRS).16,17   
PTG also provides information about arterial stiffness and endothelial function. 
The TM-Oxi system quantizes PTG into a digital volume pulse (DVP) waveform that 
represents the pressure wave that spreads from the heart to the periphery (systolic peak) 
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and reflects back to the heart (diastolic peak) during the cardiac cycle.17,26-28 Arterial 
stiffness, which is partially a result of endothelial dysfunction, is defined as the 
opposition to the pressure wave in the arteries, resulting in abnormal systolic and 
diastolic peaks. Thus, the DVP waveform, which may be affected by perfusion and body 
temperature, is mainly regulated by myocardial and arterial characteristics and is used by 
the software to calculate indicators of vascular health and arterial status (i.e., reflection 
index, and stress index).16,17  
Finally, the SudoPath system measures sudomotor activity, which is controlled by 
post sympathetic cholinergic nerve fibers (C-fibers) that innervate sweat glands, using 2 
stainless steel electrodes on which the participant places the soles of the feet, where very 
high density of sweat glands are located.17 This system evaluates skin blood flow 
(microcirculation), C-fiber condition, and sweat gland activity using galvanic skin 
response. Briefly, the SudoPath system measures the electrical conductance of the skin 
that is dependent on the amount of sweat-induced moisture. The device generates a low 
voltage signal with weak DC current that is fed to the active electrode, passes through 
interstitial fluid, and reaches the skin in contact with the passive electrode. This current 
electrically stimulates C-fibers, which release acetylcholine, and thus, stimulate nicotinic 
muscarinic receptors (M-receptors) in the skin and sweat glands.17,29 In the skin, 
activation of M-receptors result in nitric oxide (NO) production, which causes 
vasodilation of vascular smooth muscle and increase blood flow to the skin. In the sweat 
glands, activation of M-receptors result in chloride movement across the apical 
membrane of sweat gland cells, depolarizing it and thus generating a negative potential 
that drives water and sodium into the lumen of the sweat gland cells to produce sweat.29 
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The change in blood flow and sweat production disturbs the electrical conductance of the 
skin, which is then measured by the device using the principles of electrolysis as the 
electric skin response to nitric oxide, a marker for SNS function.17  
The ESC complex software calculates the cardiometabolic risk score (CMRS) 
using the variables input into the software (age, gender, height, weight, and physical 
activity level) and those measured by the three devices (systolic and diastolic blood 
pressure, ANS function and endothelial function) during baseline and autonomic cardiac 
reflex tests. Appendix  B shows the ten markers (in gray) and the variables used to 
calculate the score for each marker. Each marker measured is scored as 0=normal, 
1=borderline or 2=abnormal and then used to calculate CMRS, which is normal if ≤4, or 
represents mild risk (5-7), moderate risk (8-10) or high risk (≥11) (Appendix B).17  
Previous studies have shown the accuracy of these three devices, compared to 
standardized assessments of body composition, ANS activity, and cardiac output, thus 
supporting the usefulness of these devices in detecting complications related to metabolic 
syndrome, diabetes and CVD.16 Recently, a study comparing diabetic and healthy 
controls showed that the CMRS calculated by this software is significantly correlated 
with glucose and insulin measured during the oral glucose tolerance tests (OGTT) and 
was significantly higher in participants with diabetes. Also, specificity (92%) and 
sensitivity (83%) were high for the CMRS in differentiating patients with diabetes and 
healthy controls.17  
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Assessment of Potential Covariates and Other Outcomes for All Specific Aims:  
 Sociodemographics were assessed by a questionnaire developed by parent study 
staff that asked about gender, marital status, race/ethnicity, socioeconomic status, and 
other.  
 Health history and medications were assessed by a questionnaire developed by 
parent study staff on current health status and medication use. It included questions about 
the participant’s current health status that was used to confirm inclusion criteria and for 
data analysis purposes. It asked whether they were currently under the care of a 
healthcare professional, had seen the health care professional in the past three months 
(specifying reason), had surgeries or hospitalization (including dates and reasons), had 
injuries like fractures, dislocations ,or sprains (including date), and had any diagnosed 
diseases or conditions. It also asked about the use of prescription and over-the-counter 
medications and vitamin/dietary supplement use. The questionnaire asked about health 
risk behaviors including coffee and alcohol consumption and smoking status. The final 
section asked about the history of falls in the past 12 months and the reason for the fall. 
 Physical activity, which may be a surrogate for outdoor activity, has been 
positively associated with serum vitamin D levels such that lower levels of serum vitamin 
D have been correlated with physical inactivity in middle-aged and older adults, and was 
measured using the International Physical Activity Questionnaire (IPAQ).30,31 The IPAQ 
provides individual domain-specific scores for walking, moderate-intensity, and vigorous 
activity within the domains of work, transportation, domestic chores and gardening, and 
leisure-time.32 The tool asks about the time spent doing a specific physical activity in the 
last seven days, defining for the participant vigorous physical activity as that which takes 
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hard physical effort and makes breathing harder than normal and moderate activaties as 
that which takes moderate physical effort and makes breathing somewhat harder than 
normal. For total scores, the duration (in minutes) and frequency for all types of activities 
in all domains are summed, while specific domain scores are calculated by the 
summation of the walking, moderate-intensity, and vigorous-intensity activities within 
the specific domain. The scores for the specific type of activity across domains are added. 
To measure the volume of activity, each type of activity is weighted by its energy 
requirement defined as the MET-min. METs are metabolic equivalents that are computed 
for each specific activity using formulas defined in the manual (see below for example) 
and then MET is multiplied by the minutes performed. These MET-minute scores are 
equal to kilocalories for a 60 kg person; therefore, kilocalories for a specific individual 
may be calculated by multiplying the MET-min by the person’s weight divided by 
60kg.32 
The IPAQ was developed to derive comparable measurements of physical activity 
in international settings; therefore, being suitable for use in different languages and 
cultural contexts like in an ethnically-diverse city as Miami.33,34 It has also been validated 
in different age groups against objective measures of physical activity, physical fitness 
and health outcomes. 35 For instance, it was validated in an adult population (mean ± SD: 
40.7 ± 10.3 years old) and found to have a strong positive relationship with an activity 
monitor and a physical activity log (rho=0.55, P<0.001).36 It has also validated and used 
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and 
valid as compared against pedometer use and the physical activity log with similar results 
reported for postmenopausal women. 37,38 Other studies have validated the IPAQ and used 
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it successfully in populations of middle-aged and older adults and adults with different 
diseases, like schizophrenia and breast cancer.34,39-42 The IPAQ correlated with 
measurements to other physical activity assessment methods, such as the 2001 Behavioral 
Risk Factor Surveillance System (BRFSS) physical activity, accelerometers, and energy 
expenditure as measured by doubly-labeled water, among others.35,43-46  
Depressive symptoms were measured as a potential covariate since it has been 
associated with vitamin D deficiency.47,48 In addition, those who are depressed tend to 
walk slower and take a longer time to respond to cognitive challenges.49 Depression was 
assessed using the Beck Depression Inventory (BDI), which measures the existence and 
severity of depressive symptoms based on the DSM-IV. It is a self-report 21-item 
instrument to assess the existence and severity of depressive symptoms based on the 
DSM-IV; thus having content validity. Each item corresponds to a symptom of 
depression and has a four-point scale ranging from 0 to 3, except for two items that have 
seven options to indicate decrease or increase in appetite and sleep. The score of all items 
is summed to give a single score. A total score of 0-13 is considered minimal, 14-19 
mild, 20-28 moderate, and 29-63 severe.47 Construct validity has been assessed on its 
ability to differentiate non-depressed and depressed patients (0.92 for outpatients and 
0.93 for college students). Test-retest reliability was found to be significant at 0.93. This 
tool has been used in populations ages 13-80 years.47,50-52 In an elderly population, BDI-II 
has good internal consistency (0.86), has been positively correlated with other measures 
of depression, measures of stress, anxiety, and negatively to well-being. Research with 
this toll has shown that there are no statistically significant effects for ethnicity, gender, 
and age on BDI-II scores.53 Because item 9 of the BDI inquires about “suicidal thoughts 
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or wishes,” we immediately notified Dr. Judi Woolger, study physician at the University 
of Miami Internal Medicine Department, if a participant responded affirmatively to this 
question, which may be indicative of suicidal ideation (SI).  
 Fear of falling was another potential parameter that may have interfered with the 
physical assessment battery; therefore, it was assessed using the Fall Efficacy Scale 
International (FES-I), which is a 16-question assessment tool that evaluates the fear of 
falling while performing everyday activities.49,54 Participants were asked to rate on a 
scale of 0 to 4 how concerned they are about the possibility of falling while performing 
these activities with 0 meaning “not at all concerned,” 1 being “a little concerned,” 2 
being “somewhat concerned,” 3 being “fairly concerned” and 4 being “very concerned. 
The scores of every item were added and used as a score out of 64. The higher the score, 
the more the concern for falling while performing these activities.54 The FES-I was 
developed by the Prevention of Falls Network Europe (ProFaNE) to measure the 
elderly’s level of concern about falling while performing physical and social activities 
inside or outside the home.55 This tool is based on the original Falls Efficacy Scale, 56 
which measures the levels of confidence in performing certain activities without falling, 
and it is correlated with measures of balance and gait. FES also predicts future incidence 
of falls and decline in physical functioning, and it is sensitive to change in fear after 
clinical interventions.57-65 The FES-I was adapted from the original FES to be used in 
different languages, including Spanish, and cultural contexts, which deems it appropriate 
for the culturally-diverse population in Miami.  
Both the internal and test-retest reliabilities of FES-I are 0.96. The inter-item 
correlation ranged from 0.29 to 0.79 with an average of 0.55.55 FES-I responses were 
  81 
significantly different between those who reported no falls, one fall, and multiple falls in 
the last year. They were also significantly higher in older participants, women, and those 
with lower occupational categories. Furthermore, those who reported a fall risk factor like 
falling in the past year, chronic diseases, polypharmacy, use of psychoactive medication, 
and dizziness also had higher total FES-I scores. These data indicate FES-I is sensitive to 
group differences related to risk factors and demographics.55 FES-I convergent validity 
has been confirmed for fall history, depression, disability, quality of life, and physical 
impairment (poor balance, slow gait, low muscle strength), and its predictive validity has 
also been confirmed, since it can discriminate between certain risk factors for falling, 
overall disability, and multiple fallers after 12 months.59,66-72 Scores above 23 may 
indicate a high concern of falling.71  
 Anthropometrics were measured to assess for obesity. Obesity, whether it is 
measured using body mass index (BMI), waist circumference (WC), or waist-to-hip ratio 
(WHR), has been linked to vitamin D deficiency.73-75 Obesity also increases the risk of 
impaired physical function.76 Therefore, obesity in this population was measured using 
BMI. Height was measured using a stadiometer with a movable headpiece. Participants 
were asked to stand with their back to the height rule with their feet together, while the 
back of the head, back, buttocks, calves, and heels touched the upright tape. The 
participant was asked to look straight ahead so that the ear canal was level with the cheek 
bone. The headpiece was lowered so that the hair was pressed flat. Weight and height 
were recorded to the nearest 0.1 kg and 0.1 cm, respectively. Participants were asked to 
remove shoes, and heavy outer garments like coats, and to stand in the center of the 
balance so that the weight is distributed evenly on both feet. Participants were asked to 
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stand with their back to the height rule with their feet together, while the back of the 
head, back, buttocks, calves, and heels were touching the upright tape. The participant 
was asked to look straight ahead so that the ear canal level with the cheek bone. The 
headpiece was then be lowered so that the hair was pressed flat. Weight and height were 
recorded to the nearest 0.1 kg and 0.1 cm, respectively. BMI was calculated using the 
formula: weight (kg)/ height (m)2 and accordingly, participants were classified into 
categories based on the National Heart, Lung and Blood Institute recommendations: 
underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 
kg/m2), and obese (>30 kg/m2).  
BMI is not a good measure of body composition and adiposity because it does not 
distinguish between lean mass and fat mass. Since one of the theories that explain the link 
between vitamin D deficiency and obesity is the sequestration of vitamin D in adipose 
tissue, %FM was also measured in this population using the ES-BC device described 
above, which utilizes bioelectrical impedance (BIA).77 Furthermore, the incidence of 
CVD is also linked to vitamin D deficiency; therefore, WC and WHR were used to 
measure body fat distribution around the abdomen and evaluate the risk of CVD.75,78,79 
WC was measured at the umbilicus and hip circumference (HC) was measured at the 
broadest circumference below the waist. Both of these measurements were done using a 
flexible but not stretchable measuring tape in three replicates to ensure reliability. The 
average of the three values were used to calculate WHR by dividing WC by HC.  
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Data Management 
The security and confidentiality of participant’s information are of greatest 
concern, and appropriate data management procedures, and security clearances were 
established. The confidential nature of the data was maintained by using unique PID 
numbers, which were used in all research forms. The list of participants with their 
assigned PIDs and the research charts were kept in a locked cabinet in the locked office 
of the PI. The questionnaires and forms were carefully reviewed for completeness and 
illogical, inappropriate, and discrepant responses. Data entry was started simultaneously 
with the receipt of completed questionnaires and assessment forms. After entry of data 
into the computer, the data were verified, checked for inconsistencies, and edited using 
PIDs. Regular checks of the data were used to identify duplicate and missing data. In 
cases of duplicate or missing data, the research coordinator was notified immediately.  
 
Statistical Analysis 
Data were analyzed using frequencies, percentages, ranges, means, and standard 
deviations. Independent t-tests or chi-square were used to compare socio-demographic 
characteristic between vitamin D status groups. Pearson (for two or more continuous 
variables) and Spearman (for two or more categorical variables) correlations were 
performed to evaluate the relationship of (1) vitamin D status categories to vitamin D 
intake and sun exposure; and (2) vitamin D status categories to dual task gait velocity and 
counting rate, and the dual to single task difference in gait velocity and counting rate; and 
(3) vitamin D status and CMRS. Independent and dependent variables were also 
correlated with potential covariates, such as gender, age, and race/ethnicity to determine 
  84 
the presence of multicollinearity. If multicollinearity existed between any independent 
variable and one of the dependent variables of interest, then multiple linear or logistic 
regressions were performed.  Independent t-tests and chi-squares were used to compare 
potential covariates between vitamin D insufficient and sufficient groups. Independent 
sample t-tests were performed to determine differences between vitamin D sufficient and 
insufficient groups in CMRS, single task and dual task gait velocity and counting rates. 
Paired t-tests were used to compare single to dual task gait velocity, and counting rates in 
the whole population and within each vitamin D status group. One-way repeated 
measures ANOVA was used to determine the dual to single task difference between 
vitamin D status categories. Multiple linear and logistic regressions were used to examine 
the relationship between vitamin D status and possible correlates. Multiple logistic 
regressions were used to examine the group effect (based on dual to single task difference 
in gait speed and counting rate) on vitamin D status. Multiple linear regressions were also 
used to examine the effect size and the change in CMRS for one unit change in vitamin D 
levels when controlling for covariates. The significance level was set at α=0.05, and 
statistical analyzes were performed using SPSS 21. The following table summarizes the 
hypotheses, and the statistical analysis used for hypothesis testing.  
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Table 2: Statistical Analyzes Methods for individual Hypotheses 
Hypothesis Statistical Analyses  
Hypothesis 
1a 
Analyses 
Vitamin D status was described using frequencies, percentages, ranges, 
means and standard deviations. Spearman’s correlations were used to 
estimate, associations between vitamin D status and correlates. 
Independent t-tests and chi-squares were used to compare potential 
correlates of vitamin D status between vitamin D insufficient (25(OH)D 
<30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants. Multiple 
linear and logistic regressions were used to examine the relationship 
between vitamin D status and explanatory variables.   
Hypothesis 
1b 
Analyses 
Vitamin D intake was described using frequencies, percentages, ranges, 
means, and standard deviations. Spearman correlations were performed 
to evaluate the relationship between vitamin D status and vitamin D 
intake. Independent t-tests were used to compare vitamin D insufficient 
(25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants 
in vitamin D dietary intake. Multiple linear and logistic regressions were 
used to examine the relationship between vitamin D status and vitamin D 
intake.   
Hypothesis 
1c 
Analyses 
Sun exposure was described using frequencies, percentages, ranges, 
means, and standard deviations. Spearman correlations were performed 
to evaluate the relationship between vitamin D status and sun exposure. 
Independent t-tests and chi-squares were used to compare vitamin D 
insufficient (25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) 
participants in sun exposure. Multiple linear and logistic regressions were 
used to examine the relationship between vitamin D status and sun 
exposure.   
Hypothesis 
2a 
Analyses 
Gait speed variables were described using frequencies, percentages, 
ranges, means, and standard deviations. Spearman correlations were 
performed to evaluate the relationship between vitamin D status and 
single task, dual task, and the dual to single task difference in gait speed. 
Independent t-tests were performed to determine the difference in mean  
single and dual task gait velocities between vitamin D insufficient 
(25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants. 
Paired t-tests were performed to compare dual and single task gait 
velocities. One-way repeated measures ANOVAs were used to compare 
the dual to single task difference in gait velocity between vitamin D 
status categories. Multiple logistic regressions were used to examine the 
relationship between vitamin D insufficiency and the dual to single task 
difference in gait speed.  
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Table 2 continued. 
Hypothesis Statistical Analyses  
Hypothesis 
2b 
Analyses 
Counting rate variables were described using frequencies, percentages, 
ranges, means, and standard deviations. Spearman correlations were 
performed to evaluate the relationship between vitamin D status and 
single task, dual task, and the dual to single task difference in counting 
rate. Independent t-tests were performed to determine the difference in 
mean  single and dual task counting rates between vitamin D insufficient 
(25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants. 
Paired t-tests were performed to compare dual and single task counting 
rates. One-way repeated measures ANOVAs were used to compare the 
dual to single task difference in counting rates between vitamin D status 
categories. Multiple logistic regressions were used to examine the 
relationship between vitamin D insufficiency and the dual to single task 
difference in counting rate. 
Hypothesis 
3a 
Analysis 
CMRS was analyzed using frequencies, percentages, ranges, means, and 
standard deviations. Spearman correlations were performed to evaluate 
the relationship between vitamin status and CMRS. Independent t-tests or 
chi-squares were used to compare CMRS and covariates between vitamin 
D insufficient (25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 
ng/ml) participants. Multiple linear regressions were used to examine the 
effect size and the change in CMRS expected from a one-unit change in 
vitamin D levels after adjusting for potential confounders. 
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CHAPTER IV: CORRELATES OF VITAMIN D DEFICIENCY IN SOUTH 
FLORIDA OLDER ADULTS 
Abstract 
Objective: The purpose of this cross-sectional analysis is to determine the proportion of 
vitamin D insufficient individuals and correlates of vitamin D status in an older adult 
population (>55 years of age) living in Miami-Dade, Florida. 
Methods: Participants (n=97) completed assessments that included vitamin D serum 
levels, surveys to evaluate vitamin D intake, sun exposure, and other variables. 
Spearman’s correlations, independent t-tests, chi-squares, and multiple linear and logistic 
regression were used to examine the relationship between vitamin D status and 
explanatory variables.   
Results: The proportion of individuals with vitamin D deficiency (25(OH)D <20 ng/ml), 
insufficiency (20-30 ng/ml) and sufficiency (≥30 ng/ml) were 10.3%, 36.1% and 53.6%, 
respectively. Vitamin D status correlated significantly with higher vitamin/mineral 
supplement use  (P=0.014), and lower % fat mass (P=0.008) in linear regression models,  
and increased sun exposure (P=0.016) in logistic regression models. However, ethnicity 
was consistently an independent predictor of vitamin D levels in both analyses (P=0.023 
and P=0.010, respectively), with Hispanics being at higher risk of insufficiency. 
Conclusions: Since vitamin D deficiency is linked to health risk factors, it is important 
that health professionals become aware of the connections of vitamin D status with 
intake, bioavailability, and skin synthesis, to identify those at risk and develop and plan 
pertinent interventions to prevent and correct deficiency.   
Keywords: vitamin D insufficiency, vitamin D intake, sun exposure, elderly 
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Introduction 
Vitamin D deficiency in the elderly has been linked to factors associated with 
disability, including cognitive impairment, poor physical performance, and increased risk 
of falls and fractures.1-7 The elderly is at higher risk of vitamin D deficiency as shown by 
National Health and Nutrition Examination Survey (NHANES) 1988-1994 data that 
indicated serum vitamin D levels were lower among adults 65 years and older, compared 
to middle aged (40-59 years of age) and younger adults (18-29 years of age).8,9 Vitamin 
D is considered a steroid hormone obtained naturally from dietary sources and skin 
synthesis and stored in muscle and fat tissue. The body can use muscle and fat reserves 
independent of sun exposure and dietary intake, only when vitamin D concentrations are 
lower than 20 ng/ml.10-12 For older adults, reaching this vitamin D threshold is difficult; 
they become more dependent on their vitamin D reserve, as they encounter more barriers 
for adequate dietary and skin sources, which place them at higher risk of deficiency and 
insufficiency. This may be a consequence of a complex interplay between age-related 
factors that affect dietary intake, bioavailability, and skin biosynthesis.10-12 
In the United States, very few foods contain significant amounts of vitamin D. For 
those who are not taking adequate amounts of vitamin D through diet or supplement use, 
sunlight would often be their main source of vitamin D.13,14 Vitamin D is mostly 
synthesized in the skin when ultraviolet B (UVB, 290–315 nm) light from the sun causes 
a photochemical rearrangement of 7-dehydrocholesterol to pre-vitamin D3, which then 
undergoes thermal isomerization into vitamin D3.13,15,16 The skin’s ability to synthesize 
vitamin D depends on the amount of solar radiation reaching the biosphere that depends 
on latitude, season, and time of day.15,16 Since 90-95% of vitamin D comes from skin 
  96 
synthesis, it would be expected that the prevalence of vitamin D deficiency and 
insufficiency to be lower in a populations where sunlight for synthesis is available year 
round.17,18 Thus, it has been assumed that vitamin D deficiency and insufficiency is less 
prevalent in populations living at lower latitudes and/or where seasonal variations are not 
as pronounced like in South Florida, one of the southernmost regions of the United States 
(latitude 25.46N) where the weather is sunny and warm all year.19 However, research has 
shown a considerable amount of vitamin D deficient and insufficient individuals. A 
previous study reported a prevalence of 38-40% of hypovitaminosis D (25(OH)D <20 
ng/ml) in adults (≥18 years old) living in South Florida.19 Lagari et al.20 found that 35% 
of participants in a study conducted in Miami-Dade were vitamin D insufficient 
(25(OH)D <30 ng/ml). Another study conducted in Boca Raton, Florida, evaluated 
vitamin D status in a community dwelling elderly population (≥60 years old) and found 
an occurrence of vitamin D insufficiency (25(OH)D <25 ng/ml) of 15.6%.21  
The determinants of vitamin D status in the elderly population in Miami–Dade 
have not been well studied. This is important because Miami occupies the fourth place 
among cities that are graying the fastest, and it is the top county for elders, with 14.9% of 
the Miami-Dade population being over the age of 65.22 Understanding the factors that 
affect vitamin D status in this growing population of older adults, who have an increased 
opportunity for skin biosynthesis via sun exposure, is critical to promote public health 
initiatives aimed to correct and prevent nutritional deficiencies. Therefore, the purpose of 
this cross-sectional analysis was to evaluate correlates of vitamin D insufficiency in older 
adults living in Miami-Dade.    
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Methods 
Study Design and Setting 
This study was approved by the IRBs of Florida International University (13-
0390) and the University of Miami (20120195).  
 
Participants 
The study enrolled 101 participants, and four were excluded due to missing data 
(n=97). Participants for this study were recruited from the parent study, a double-blinded 
randomized placebo-controlled clinical trial that examined the effects of vitamin D 
supplementation on vitamin D level, bone formation, resorption, and mineral density, 
flexibility, and balance in the elderly, which was conducted at the University of Miami. 
Briefly, each potential participant was screened over the phone by administering the 
Short Portable Mental Status Questionnaire (SPMSQ)23 to evaluate mental functioning 
(allowed up to 2 errors) and questions regarding general inclusion criteria such as age, 
and medical, pharmacological and general exclusions. Inclusion criteria for this study 
included: (1) Men and women age 55 or older; (2) English and Spanish speakers; (3) 
Community-dwelling; (4) Ability to give informed consent; (5) Ability to perform motor 
tasks without aid; and (6) Participating in the parent study. All participants in this study 
were required to sign IRB approved informed consents for both the University of Miami 
and Florida International University. 
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Biomarkers 
Vitamin D Status  
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D). 
Fasting venous blood (15 ml) was collected from every participant by a certified 
phlebotomist in the morning after fasting. The samples were sent the same day for 
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) that used 
immunochemiluminometric assays (ICMA) on the DiaSorin Liaison instrument to assess 
25(OH)D. This is a highly automated test that measures total 25(OH)D, and it has been 
widely used by others.24  
 
Surveys 
Sociodemographics, Health History, Health Risk Behaviors and Medications 
Sociodemographic and health-related data were collected using questionnaires 
developed by staff of the parent study that asked about gender, marital status, 
race/ethnicity, socioeconomic status, education, income, current medical diagnoses, 
medication/ supplement use and health risk behaviors such as coffee, alcohol, and 
tobacco use.   
 
Vitamin D Intake  
Vitamin D intake was assessed using a vitamin D and calcium specific short food 
frequency questionnaire (FFQ) developed by Blalock et al.25, which is based on the 
Block-National Cancer Institute Health Habits and History Questionnaire (HHHQ). It 
includes only 23 foods and beverages that were identified in the HHHQ as rich in either 
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vitamin D, calcium or both. The short FFQ is associated with a database; therefore, 
allowing the estimation of nutrient intakes for the reported portion size. The raw values 
were multiplied by the frequencies to calculate the amount of vitamin D and calcium per 
day using Microsoft Access.25 Blalock et al validated this tool and the vitamin D and 
calcium intakes estimated from this short FFQ were significantly correlated with 
estimates from the 7-day food diary (r=0.72 and 0.66; respectively) and the original 
HHHQ (r=0.65 and 0.66, respectively).25 Positive predictive values of 100% for vitamin 
D and 91.7% for calcium were reported for the short instrument in its ability to identify 
those with low intakes as based on the 7-day food record.  
 
Sun Exposure  
Sun exposure was assessed using a questionnaire developed by Hanwell et al.26 
This tool measures the amount of time spent outdoors and the amount of skin exposed for 
every day of the week using a scoring system. The original questionnaire by Hanwell et 
al. was developed for hospital workers in Southern Italy and designed to report the sun 
exposure within the last week by recording time outdoors (<5 min; 5-30 min; >30 min) 
and amount of skin exposed (hands and face; hands, face and arms; hands, face and legs; 
bathing suit). The amount of time spent outdoors was multiplied by the amount of skin 
exposed for every day of the week. The sum of the seven days was used as the sun 
exposure scores. These researchers found that the sun exposure score was significantly 
correlated with serum vitamin D levels during the summer, which was mostly explained 
by the time in the sun than by the amount of skin exposed. Other researchers have 
validated this tool in other populations in South Florida.27,28 
  100 
Physical Activity Levels  
Physical activity level was measured using the International Physical Activity 
Questionnaire (IPAQ), 29 which provides individual domain-specific scores for walking, 
moderate-intensity and vigorous-intensity activity within the domains of work, 
transportation, domestic chores and gardening, and leisure-time. To measure the volume 
of activity, each type of activity was weighted by its energy requirement defined as the 
MET-min. METs are metabolic equivalents that are computed for each specific activity 
using defined formulas, and then multiplied by the minutes performed to derive MET-
minute scores, which are equal to kilocalories for a 60 kg person.29 
The IPAQ was developed to derive comparable measurements of physical activity 
in international settings; therefore, being suitable for use in different languages and 
cultural contexts like in an ethnically-diverse city as Miami.30,31 It has also been validated 
in different age groups against objective measures of physical activity, physical fitness, 
and health outcomes.32 For instance, it was validated in an adult population (mean ± SD  
age: 40.7 ± 10.3 years) and found to have a strong positive relationship with an activity 
monitor and a physical activity log (rho=0.55, P<0.001).33 It was also validated and used 
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and 
valid when compared against pedometer use and the physical activity log, and had similar 
results in cohorts of postmenopausal women.34,35 Other studies have validated the IPAQ 
and used it successfully in populations of middle-aged and older adults and adults with 
different diseases, such as schizophrenia and breast cancer.31,36-39 The IPAQ correlated 
with measurements to other physical activity assessment methods such as the 2001 
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Behavioral Risk Factor Surveillance System (BRFSS) physical activity, accelerometers, 
and energy expenditure as measured by doubly-labeled water, among others.32,40-43 
 
Depressive Symptoms  
Depressive symptoms were assessed using the Beck Depression Inventory (BDI-
II), which is a widely validated and used tool that evaluates the existence and severity of 
depressive symptoms based on the DSM-IV.44 It is a self-report, 21-item instrument in 
which each item corresponds to a symptom of depression and has a four-point scale 
ranging from 0 to 3, except for two items that have seven options to indicate decrease or 
increase in appetite and sleep. The score of all items are summed to give a single score. A 
total score of 0-13 is considered minimal, 14-19 mild, 20-28 moderate, and 29-63 severe 
depressive symptoms.44 Construct validity has been assessed on its ability to differentiate 
non-depressed and depressed patients (0.92 for outpatients and 0.93 for college students). 
Test-retest reliability was found to be significant at 0.93. This tool has been used in 
populations ages 13-80 years.44-47 In an elderly population, BDI-II has good internal 
consistency (0.86), and has been positively correlated with other measures of depression, 
measures of stress, anxiety, and negatively with well-being. Research with this 
instrument has shown no statistically significant effects for ethnicity, gender, and age on 
BDI-II scores.48 In case a participant reported suicidal ideation, the investigators in this 
study contacted the study physician and/or University of Miami Mental Health 
Department, immediately. 
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Anthropometrics and Body Composition 
Weight was measured using an electronic balance. Participants were asked to 
remove shoes and heavy outer garments like coats and to stand in the center of the 
balance so that the weight was distributed evenly on both feet. Height was measured 
using a stadiometer with a movable headpiece. Participants were asked to stand with their 
back to the height rule with their feet together, while the back of the head, back, buttocks, 
calves, and heels touched the upright tape. The participant was asked to look straight 
ahead so that the ear canal was level with the cheek bone. The headpiece was lowered so 
that the hair was pressed flat. Weight and height were recorded to the nearest 0.1 kg and 
0.1 cm, respectively. Body mass index (BMI) was calculated using the formula: body 
weight (kg)/ height (m2) and accordingly, participants were classified into categories 
based on the National Heart, Lung and Blood Institute recommendations: underweight 
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 kg/m2), and obese 
(>30 kg/m2).  
Waist circumference (WC) was measured at the umbilicus and hip circumference 
(HC) was measured at the broadest circumference below the waist. Both of these 
measurements were done using a flexible but not stretchable measuring tape in three 
replicates to ensure reproducibility. The average of the three values was used to calculate 
waist-to-hip ratio (WHR) by dividing WC by HC. Body composition was measured using 
bioelectrical impedance (BIA), to determine % lean (fat-free, %FFM) and fat mass 
(%FM).  
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Statistical Analysis 
Statistical analyzes were performed on 97 participants. Data were analyzed using 
frequencies, percentages, ranges, means, and standard deviations. Variables were checked 
for non-normality and if necessary, they were transformed to achieve a normal 
distribution. Spearman correlations between two or more categorical variables were 
performed to evaluate the relationship between vitamin status, vitamin D intake, sun 
exposure, sociodemographic characteristics, health-related variables, physical activity, 
depressive symptoms, and anthropometries. Independent t-tests or chi-squares were used 
to compare vitamin D insufficient and sufficient categories in vitamin D intake, sun 
exposure, sociodemographic characteristics, health-related variables, physical activity, 
depressive symptoms, and anthropometries. Multiple linear regressions were used to 
examine the effect size and the change in vitamin D levels expected from a one-unit 
change in a set of independent explanatory variables. Multiple logistic regression were 
used to examine the relationship between vitamin D insufficiency and a set of 
explanatory variables to identify independent correlates of vitamin D status and calculate 
adjusted odds ratio. Collinearity was assessed, and variables that inter-correlated with 
other independent variables were removed from the regressions. The significance level 
was set at α=0.05, and statistical analyses were performed using SPSS 21. 
 
 Results  
A total of 97 participants aged 55 years or older were included in this analysis. 
The mean ± SD  of 25(OH)D concentration was 30.73 ± 8.73 ng/ml and ranged from 
10.00 to 59.80 ng/ml. Ten percent, 36%, and 54% of the participants were vitamin D 
  104 
deficient (25(OH)D <20 ng/ml), insufficient (20-30 ng/ml) and sufficient (≥30 ng/ml), 
respectively. Since the number of vitamin D deficient individuals was low, vitamin D 
deficient and insufficient individuals were grouped into vitamin D insufficient (<30 
ng/ml) for data analysis. The mean ± SD age was 63.06 ± 6.48 and ranged from 55-87 
years (Table 1). Participants were 63.9% and 36.10% over the age of 60 and 65 
respectively, 45% were males, and 44% were Hispanics, 35% white Caucasians, and 
15.5% African-Americans. Comparison of vitamin D status groups revealed no 
significant difference in age, gender, and the proportion of participants who were 
married,  unemployed and with less than college education and income of <$30,000 per 
year (data not shown). 
A significant difference in sun exposure (mean difference: -6.27, P=0.01) was 
observed between vitamin D categories, with those who were insufficient having lower 
sun exposure scores (Table 1). No significant difference was found in vitamin D intake 
between the categories (P=0.957). Furthermore, only 2.1% of the participants met the 
Dietary Reference Intake (DRI) of 600 IU/day (data not shown).  
A comparison between vitamin D status groups revealed several significant 
differences in potential determinants of vitamin D levels. Those who were vitamin D 
insufficient lived in the United States significantly fewer years (mean difference:-10.37, 
P=0.018). Ethnicities were also significantly different between vitamin D groups. More 
Hispanics and less white Caucasians and African Americans were in the vitamin D 
insufficient group (P=0.004) (Table 1). A one-way ANOVA comparison between ethnic 
groups on vitamin D levels showed significant differences between ethnicities (F (d.f.): 
6.27 (3), P=0.001). Hispanics had lower vitamin D levels (mean ± SD: 27.61 ± 7.75) 
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than White Caucasians (mean ± SD: 33.37 ± 7.73, P=0.015) and African-Americans 
(mean ± SD: 35.77 ± 9.60, P=0.007) (Table 2).  
Sixty-four percent of participants who were vitamin D insufficient used 
prescription medications compared to 85% of those who were sufficient (P=0.033) 
(Table 3).  Also, those in the vitamin D insufficient group were taking significantly 
fewer prescription medications than those in the vitamin D sufficient group (mean  
difference: -0.94, P=0.033). Thirty-eight percent of those who were vitamin D 
insufficient reported taking vitamin/mineral supplements compared to 54% of the 
sufficient group, but this difference was not significant (P=0.153).   
Physical activity was significantly different between groups with those who were 
vitamin D insufficient having significantly less moderate physical activity (mean 
difference: -928.61, P=0.043) (Table 3). Height was the only anthropometric variable 
that was significantly different between groups, with those who were vitamin D 
insufficient being shorter (mean difference: -6.06, P=0.004). BMI and %FM were 
higher in the vitamin D insufficient group, but the difference was not significant (mean  
difference: 0.63, P=0.559, and mean  difference: 1.29, P=0.251, respectively).  
Spearman correlations showed a significant association between vitamin D 
categories and potential correlates of vitamin D status (Table 4).  Significantly different 
variables between groups were also significantly correlated with vitamin D status. Sun 
exposure (r=0.274, P=0.007), years lived in the Unites States (r=0.272, P=0.007), 
number of participants taking prescription medications (r=0.233, P=0.022), and number 
of prescription medications (r=0.234, P=0.021) were positively correlated with vitamin 
D status, while ethnicity (r=-0.365, P=0.000) and height (r=-0.298, P=0.003) were 
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negatively correlated. Although vitamin D status did not significantly correlate with 
vitamin D intake (r=0.05, P=0.728),  it was positively correlated with vitamin/mineral 
supplement use (r=0.277, P=0.006). Lastly, vitamin D status ad a negative association 
with BMI (r=-0.220, P=0.030), and %FM (r=-0.263, P=0.010). 
To explain the effect of sun exposure and dietary intake on vitamin D levels, 
multiple linear regressions were used (Table 6). Vitamin D intake had no significant 
effect (B (SE): 0.00 (0.01), P=0.648), while sun exposure significantly predicted 4% of 
the variation in vitamin D levels (B (SE): 0.17 (0.07), P=0.017). In this model, vitamin 
D levels were expected to increase by 0.17 ng/ml for every unit increase in sun 
exposure. Adding ethnicity to the model showed that sun exposure was no longer a 
predictor of vitamin D levels (P=0.052). In this model, non-Hispanics compared to 
Hispanics would be expected to have 5.02 ng/ml higher vitamin D levels (B (SE): 5.02 
(1.70), P=0.004). Thus, sun exposure and ethnicity explained 12% of the variation in 
vitamin D levels.   
Ethnicity remained a significant predictor of vitamin D levels after adding 
variables that (1) were significantly different between vitamin D status categories, (2) 
correlated significantly with vitamin D status; and/or (3) have been shown in previous 
research to be significantly correlated with vitamin D levels (B (SE): 3.92 (1.70), 
P=0.023). In this fully adjusted model, ethnicity, %FM (B (SE): -0.25 (0.09), P=0.008), 
and vitamin/mineral supplement use (B (SE): 4.24 (1.70), P=0.014) explained 18.4% of 
the variation in vitamin D levels. For every unit increase in %FM, vitamin D levels were 
expected to decrease by 0.25 ng/ml. Furthermore, compared to those who did not use  
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supplements, those who reported taking vitamin/mineral supplements were expected to 
have 4.24 ng/ml higher vitamin D levels. 
Multiple logistic regressions showed that higher sun exposure scores predicted 
vitamin D levels with those with higher scores being 1.05 times significantly more 
likely to be vitamin D sufficient (OR: 1.05, 95% CI: 1.01; 1.09, P=0.013) (Table 6). In 
the fully adjusted model, sun exposure relationship to vitamin D levels remained about 
the same (OR: 1.05, 95% CI: 1.01; 1.10, P=0.016). In addition, this model revealed that 
Hispanics were 0.30 times less likely to be vitamin D sufficient (OR: 0.30, 95% CI: 
0.12; 0.75, P=0.010).   
 
Discussion  
The proportion of vitamin D deficient (25(OH)D <20 ng/ml) and insufficient 
(25(OH)D <30 ng/ml) individuals in this group of healthy community-dwelling older 
adults  (>55 years old) living in Miami-Dade was 10% and 36%, respectively. This was 
lower than that reported for the general United States  adult and older adult 
population.11,49 NHANES 2005-2006 revealed that 41.6% of United States adults (18 
years or older) had deficient vitamin D levels, defined as 25(OH)D < 20 ng/ml.11,49 A 
previous study conducted in South Florida showed a prevalence of 38-40% of 
hypovitaminosis D (25(OH)D < 20 ng/ml) in adults (≥18 years old).19 In older adults, 
NHANES 1988-1994 data indicated that 23% of adults 65 years and older were vitamin 
D deficient (25(OH)D <20 ng/ml), and 62.5% were vitamin D insufficient (25(OH)D <30 
ng/ml).8,9 Several reports from The Health ABC cohort study described 65-68% of adults 
over the age of 70 as vitamin D insufficient.50-52  
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Vitamin D deficiency and insufficiency in our study group was less than half of 
that previously reported for the general United States older adult population. However, 
our results are similar to that reported by Lagari et al.20 who observed vitamin D 
insufficiency in 35% of the older adult population (>65 years of age) participating in a 
study in Miami-Dade. Furthermore, in older adults (≥60 years of age) living in Boca 
Raton, Florida, Smolar et al.21 found a prevalence of 15.6% vitamin D insufficiency, 
defined as 25(OH)D <25 ng/ml. Using the same cut-off value, we found a higher 
occurrence with 27% of our study participants being vitamin D insufficient.  
Despite the lower occurrence of vitamin D insufficiency in this study compared to 
other studies and the general United States older adult population, it is still a public health 
concern and identifying risk factors is critical to developing effective interventions. As 
expected, vitamin D intake was not significantly correlated with vitamin D status in our 
study, and our findings are supported by other studies that have previously shown that 
dietary intake has minimal contribution to vitamin D status.53,54 The Institute of Medicine 
(IOM) committee reported in 2010 that in order to maintain serum 25(OH)D above 20 
ng/ml, which was deemed necessary to preserve bone health, the intake of vitamin D 
should be 600 International Units (IU) per day for adults below the age of 70 and 800 IU 
per day for adults over the age of 70, with a tolerable upper limit of 4000 IU per day.55-58 
Although these are the established Dietary Reference Intakes (DRIs) for vitamin D, the 
Endocrine Society recommends adults over the age of 18 should intake between 1,500-
2,000 IU per day, with an upper limit of 10,000 IU per day, to maintain 25(OH)D 
between 40-60 ng/ml to conserve physiological functions that go beyond bone health.59 
However, in our study only 2% of the participants met the DRI of 600 IU per day (not 
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accounting from vitamin D from supplement use) and the mean ± SD  was 170.33 ± 
168.06, with a range of 4.7–1,412.3 IU per day. Inadequate dietary intake of vitamin D is 
likely due to the limited availability of vitamin D rich foods in the daily diet of the 
elderly. Good sources of vitamin D include fatty fish such as salmon, tuna, and sardines, 
fish oil, egg yolks, organ meats, mushrooms, and fortified foods like milk and dairy 
products, breakfast cereals, bread, margarine, spreads, and vegetable oils.16,60 This may 
be aggravated in the elderly by age-related decline in food intake that results from an 
interplay between physiological and psychological factors, such as changes in taste/smell, 
chewing/swallowing problems, polypharmacy, hormonal factors regulating satiety, 
comorbidities, and age-related lactose intolerance that limits the intake of fortified milk 
products.49,61-66  
Supplement use may compensate for the lack of vitamin D intake from foods. Use 
of vitamin D supplements has increased over time in adults, with 26% of adults reporting 
using vitamin D supplement in NHANES 1988-1994, 25% in NHANES 1999-2002, and 
37% in NHANES 2003-2006.67 However, low vitamin D intakes from food and 
supplements have been reported in older adults and associated with low serum vitamin 
D.17,18,68 Although using vitamin D and calcium supplements 2 weeks before the study 
were exclusion criteria in our study, we found that 46% of participants who reported a 
history of vitamins/minerals use, 37.8% were vitamin D insufficient and 53.8% were 
sufficient, but this difference was not significant. However, we did find that using 
vitamin/mineral supplements was a significant and independent predictor of vitamin D 
levels in adjusted multiple linear regressions, with those using supplements having higher 
25(OH)D. In addition, we found significantly more vitamin D sufficient participants who 
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reported taking prescription medications and a higher number of prescription medications 
compared to the insufficient group, and these variables had a significant association with 
vitamin D status. This relationship could be due to physicians recommending more 
vitamin D supplements to their elderly patients because of the increased public health 
awareness of the consequences of vitamin D deficiency in older adults. It could also be 
possible that those who are taking prescriptions are more likely to have access to 
healthcare or be more health conscious. Nonetheless, unlike vitamin/mineral supplement 
use, receiving prescription medication and a higher number of prescription medications 
were not predictors of vitamin D levels in neither multiple linear nor logistic regressions.   
 Other risk factors for vitamin D insufficiency are those that affect bioavailability. 
The presence of other comorbidities and behavioral factors, like liver, kidney, and 
gastrointestinal diseases, and the use of certain medications, tobacco, and alcohol, may 
also affect vitamin D metabolism and bioavailability.66 However, our study excluded 
participants who had any diseases/conditions or were taking any medications that 
affected vitamin D metabolism and absorption and hence, its bioavailability. Thus, we 
could not assess their effect on vitamin D status in our sample. We found that the 
number of diseases and condition, health risk behaviors and history of 
diseases/conditions, which have been significantly associated with vitamin D deficiency 
in previous studies, were not significantly different between, associated with, or 
predictive of vitamin D status. Obesity was the only condition that we were able to 
assess its effect on vitamin D status in our sample.49,66 In the older adult, a decline in 
metabolic rate and hormonal changes that occur during aging often result in weight gain, 
as seen in the growing prevalence of obesity among elderly in the United States.69,70 
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Obesity has been correlated with low vitamin D status in the elderly probably due to 
sequestration of vitamin D by increased body fat.18,49,66 In our sample, the mean ± SD  
of BMI was 27.09 ± 5.27 with 62% of participants being overweight (BMI ≥25). Even 
though vitamin D insufficient participants had higher BMIs, the number of participants 
who had a BMI ≥25 kg/m2 was lower, and neither was significantly different compared 
with those who were vitamin D sufficient. However, BMI was significantly correlated 
with vitamin D levels, with those with lower vitamin D levels having higher BMI, but 
this association was no longer significant when adjusting for covariates in regression 
models. Abdominal fat accumulation, as measured by WC and WHR, were also not 
significantly correlated with vitamin D levels, nor different between vitamin D groups. 
However, the %FM was higher in the vitamin D insufficient group, but this difference 
was not significant. Nevertheless, it had a significant negative correlation with vitamin 
D levels, with those with lower 25(OH)D having higher %FM. Also, %FM was found to 
predict vitamin D levels in linear regression models. Thus, body fat is a risk factor for 
vitamin D deficiency in this Miami-Dade older adult population probably by affecting 
bioavailability.  
The other factor that may affect vitamin D status is skin biosynthesis. For those 
who are not taking adequate amounts of vitamin D through diet, sunlight would often be 
their main source of vitamin D.13,14 It is believed that sunlight exposure of arms and legs 
for 5-15 minutes at midday during the summer months could produce about 3,000 IU of 
vitamin D.12 However, the effectiveness of vitamin D synthesis in the skin is determined 
by skin thickness, 7-dehydrocholesterol content, skin pigmentation, amount of skin  
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exposed, sunscreen use, length of sun exposure, and amount of solar radiation (which 
depends on the latitude, season, time of day, and time in the sun).  
Decreased skin thickness and reduction of 7-dehydrocholesterol are two age-
related factors that place elderly at high risk for vitamin D deficiency.71 This is 
aggravated by decreased sun exposure, since most people avoid sunshine to stay cool, 
prevent skin aging, and reduce the risk of skin cancer by limiting the amount of time 
spent outdoors. Covering the skin with clothes and using sunscreen are common practices 
among the elderly, the latter interfering with UVB transmission to the skin.66 Thus, 
sufficient exposure to sunlight is unusual with modern lifestyles, since most people live 
and work indoors.66 A study in Europe showed that wearing short sleeves instead of long, 
and thus bearing arms as well as the face, is associated with better vitamin D status in 
older people living in sunnier climates.72 Furthermore, outdoor activity is associated with 
vitamin D status as shown by an analysis of NHANES 1988-1994 data that revealed that 
those who were 60 years or older and participated in daily outdoor activity had optimal 
vitamin D levels (≥30 ng/ml) similar to young adults.73 In our study, sun exposure was 
measured by assessing the amount of skin exposed and time spent outdoors during sunny 
hours, and we found that sun exposure was significantly higher in participants who were 
vitamin D sufficient. Our data also showed a significant positive correlation between 
vitamin D status and sun exposure scores. In addition, we found that sun exposure had an 
effect on vitamin D levels, explaining only 4% of vitamin D status variability, and this 
was no longer significant when adjusting for covariates. However, participants with 
higher sun exposure scores had higher odds of being vitamin D sufficient.   
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Furthermore, physical activity, which is often used as a surrogate for outdoor 
activity, has been positively associated with serum vitamin D levels such that lower 
levels of serum vitamin D have been correlated with physical inactivity in middle-aged 
and older adults.18,74 We only found that moderate physical activity was significantly 
different between vitamin D categories, with those insufficient having less activity than 
those who were sufficient. However, none of the physical activity variables were 
significantly correlated with or predictive of vitamin D status. Thus in our cohort, unlike 
in previous studies, physical activity was not a risk factor for vitamin D status.  
 Besides age-related factors that affect the skin and the usual decreased sun 
exposure that accompanies modern life, skin complexion places elderly at an even higher 
risk of vitamin D deficiency. Darker pigmentation decreases the skin’s capacity to use 
sunlight for making vitamin D because melanin competes for UVB radiation 
effectively.75 Ethnicity and race are often used as a proxy for skin pigmentation, and a 
substantial amount of evidence indicates a significant difference in vitamin D deficiency 
prevalence between different ethnic groups.75 For example, NHANES 2005-2006 
revealed that the prevalence of vitamin D deficiency (25(OH)D <20 ng/ml) was higher in 
blacks (82.1%), followed by Hispanics (69.2%) and whites (30.9%).49A more recent 
study evaluated vitamin D status in a community-dwelling elderly population (≥60 years 
old) in South Florida and found higher prevalence of vitamin D insufficiency (25(OH)D 
<25 ng/ml) among Afro-Caribbeans (30.8%) and African Americans (30.4%) compared 
to Hispanics (13%) and European Americans (13%).21 In our study, we did not find lower 
levels of vitamin D and thus, higher prevalence of vitamin D insufficiency in African-
Americans, as expected, and this could be due to the few African Americans/Afro-
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Caribbeans participating in our study. Only 15.5% of our sample was of African descent 
while 26% of the population studied by Smolar et al.21 was either African American or 
Afro-Caribbean. Nevertheless, we did find a significant association between vitamin D 
status and ethnicity and a significant difference between vitamin D categories in ethnic 
groups. We found more Hispanics who had vitamin D insufficiency, while more white-
Caucasians and African-Americans were vitamin D sufficient. When comparing ethnic 
groups, we found significant differences in vitamin D levels, with Hispanics having lower 
levels compared individually to white-Caucasians and African-Americans. In all of our 
regression models that included ethnicity, we found that this variable had a significant 
effect on vitamin D levels, with Hispanics expected to have lower vitamin D levels and 
higher odds of being insufficient. These results also differ from those of Smolar et al.,21 
who reported that the prevalence of 25(OH)D insufficiency was not higher in Hispanic 
participants compared with European Americans. However, their sample population had 
only 28% Hispanics compared with 43% in our cohort. Thus, ethnicity was the strongest 
risk factor for vitamin D insufficiency in this study population.  
Interestingly, we found a significant difference in height and years lived in the 
United States, with those who were vitamin D insufficient being shorter and having lived 
fewer years in the United States. These two factors are related to ethnicity. The average 
Hispanic person is shorter, and we found a significant difference in height between 
Hispanics (mean ± SD: 163.29 ± 12.21) and non-Hispanics (mean ± SD: 171.12 ± 10.30, 
P<0.001). Furthermore, Miami being one of the southernmost cities of the U.S, is the 
home of one of the largest Hispanic communities in the country, which is mostly 
composed of immigrants. We found a significant difference in years lived in the United 
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States between Hispanics and non-Hispanics, with Hispanics having lived here for fewer 
years (mean ± SD: 26.63 ± 17.4) compared with non-Hispanics (mean ± SD: 59.74 ± 
10.66, P<0.001). Immigrant Hispanics may be more likely to be vitamin D deficient and 
insufficient due to differences in sun exposure practices, public health awareness 
initiatives in their home countries and less access to healthcare services due to their 
immigration status.    
In summary, the occurrence of vitamin D deficiency and insufficiency in this 
study was lower than that of other American and European populations. This was 
expected in a population that has a greater opportunity for vitamin D skin synthesis by 
year-round sunlight availability. However, vitamin D insufficiency is still a public health 
concern even in this population. We found that lack of sun exposure, higher %FM, and 
lack of use of vitamin/mineral supplements were risk factors for vitamin D insufficiency. 
Ethnicity, however, was the most consistent and important risk factor in this study 
population, since those who were vitamin D insufficient were more likely to be Hispanic. 
Since vitamin D deficiency is linked to health risk factors, it is important that health 
professionals become aware of connections between vitamin D status, intake, 
bioavailability and skin synthesis to develop dietary and other interventions to prevent 
and correct deficiency and insufficiency effectively.   
 This study had several limitations. It was cross-sectional and descriptive in nature 
and even though this type of investigation can establish associations among factors, it 
does not prove cause and effect. Second, this study may suffer from selection bias. 
Besides the expected higher sun exposure of this population, the age criterion could be a 
possible explanation for the lower occurrence of vitamin D insufficiency observed in our 
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study. The study recruited a younger older adult population (>55 years of age) to have a 
wider age range and the opportunity to follow them into the older years.  According to 
the World Health Organization, both 60 or 65 years of age are equivalent to retirement 
age in most developed countries and hence, considered the beginning of old age. In the 
United States, the age of 65 has been traditionally considered the beginning of senior age. 
76 Some institutions like the Florida Department of Elder Affairs, however, considers 
those >60 years of age as older adults.77 Furthermore, our age criterion may be a 
limitation because most studies of vitamin D deficiency and insufficiency in the elderly 
have been done in adults either above the age of 60, 65, or 70, making our results less 
comparable. Our study participants were younger than what is considered “old age,” with 
36% and 63.8% of participants being under the age of 60 and 65, respectively, and thus, 
adding heterogeneity to our study. Nevertheless, we did not find a significant difference 
in age, number of participants over the age of 60, and number of participants over the age 
of 65, between vitamin D insufficient and sufficient groups. Moreover, age was not a risk 
factor for vitamin D deficiency in this study population.   
The participants in this study were not only younger, but mostly healthier, since 
criteria for the parent study excluded current diagnoses of numerous diseases/conditions 
that affect vitamin D metabolism and absorption, medications that disturb vitamin D 
metabolism, and current vitamin D supplement use. Thus, this sample was not randomly 
selected from the general older adult population in Miami-Dade, but instead were 
healthier older adults who volunteered to participate and met inclusion criteria. Thus, the 
results of this study cannot be extrapolated to the general Miami-Dade older adult 
population, other populations in the United States or globally.   
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Even though questionnaires have been validated and tested, are low-cost, and 
easily administered, they have some limitations. Over or under-reporting may have 
occurred due to participants’ desire to please the researchers. Understanding terms and 
recalling information may interfere with the respondents’ ability to answer questions 
accurately. Thus, self-report may not reflect true answers on questionnaires.  
Another weakness of this study is related to vitamin D assessment. First of all, 
25(OH)D measured today may not reflect a person’s level throughout the year, since it 
varies with season, having the highest levels during the summer and fall and the lowest in 
the winter and spring. Hence, it is not known whether the average concentrations during 
the year, the peak concentration throughout the year, or the difference between the lowest 
and highest peaks are the most pertinent for the pathophysiology of vitamin D-related 
diseases.78 In addition, it is known that 25(OH)D measurements do not reflect an 
individual’s long-term status. This means that the assay will not reflect peoples’ sun 
exposure and dietary intake throughout life. For example, it will not differentiate people 
who have spent a significant amount of time in regions with distinct UVB radiation or 
who have made lifestyle modifications throughout time like using sunscreen or 
supplements. Therefore, the intra-individual variation in vitamin D levels over years is 
not considered in this research.78 Besides, the levels of 25(OH)D need to be considered in 
the context of phenotype. Genetic polymorphism of vitamin D binding protein, 25-
hydroxylase, 1-alpha hydroxylase, 24-hydroxylase, and vitamin D receptor, which are 
involved in the transport, activation, and metabolism of vitamin D may determine 
peoples’ 25(OH)D levels.78 The cutoff values for vitamin D deficiency and sufficiency 
are also widely debated. Previously, the delineation of vitamin D adequacy was 
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associated with bone health and calcium absorption regarding the prediction of rickets in 
children and osteomalacia in adults.79 Increasing evidence, however, indicates that 
vitamin D is associated with other diseases beyond those related to calcium homeostasis, 
so researchers argue that the threshold values should consider the point at which more 
vitamin D in the body will no longer provide any health benefits whether these are due to 
calcemic and/or non-calcemic effects.24, 80,81 The functions of vitamin D are still not fully 
understood, so thresholds are hard to define, and optimal cutoff points are difficult to set. 
Differences in cutoff values for different conditions can change the specificity and 
sensitivity of the assay when identifying participant’s true vitamin D status. Finally, even 
though clinicians widely use vitamin D serum assays, the inconsistency and variability 
between assays and laboratories are still concerns, even when using the same assays, due 
to the lack of reference standards.79,82  
 
Conclusions  
Vitamin D insufficiency is common in healthy community-dwelling older adults 
living in Miami-Dade County, especially among Hispanics. Vitamin D intake from food 
was not a predictor of vitamin D status; however, use of a vitamins/mineral supplement 
was an independent predictor of vitamin D levels. Factors that affected skin synthesis 
(ethnicity and sun exposure) and bioavailability/metabolism (obesity) were also 
significant predictors of vitamin D status. However, ethnicity was the strongest risk factor 
for vitamin D insufficiency in this study population. Since vitamin D deficiency is linked 
to health risk factors, it is important that health professionals become aware of the 
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connections of vitamin D status with intake, bioavailability, and skin synthesis and to 
develop and plan pertinent interventions to prevent and correct deficiency.   
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Table 1: Comparison of Vitamin D Related Variables and Sociodemographic 
Characteristics Between Vitamin D Insufficient and Sufficient Participants 
 Study 
population 
(n=97) 
Vitamin D 
Insufficient 
<30 ng/ml 
(n=45) 
Vitamin D 
Sufficient 
≥30 ng/ml 
(n=52) 
MD P- value 
Vitamin D levels 
(ng/ml) 
(Mean ± SD) 
30.73 ± 8.73 23.31 ± 4.41 37.15 ± 6.02 -13.84 0.000 
Vitamin D Intake 
(IU/day) 
(Mean ± SD) 
170.3 ± 168.1 171.3 ± 209.4 169.5 ± 123.8 1.86 0.957 
Sun Exposure 
(Total Score) 
(Mean ± SD) 
19.05 ± 12.13 15.69 ± 12.60 21.96 ± 11.02 -6.27 0.010 
Age¥ (years) 
(Mean ± SD) 63.06 ± 6.48 63.22 ± 7.65 62.92 ± 5.34 0.3 0.822 
Male gender¶ 
(N (%)) 44 (45.4) 18 (40.0) 26 (50.0)  0.414 
Ethnicity¶ (N (%)) 
Hispanic 
White Caucasian 
African American 
 
43 (44.3) 
34 (35.1) 
15(15.5) 
 
27(60.0) 
9 (20.0) 
5 (11.1) 
 
16 (30.8) 
25 (48.1) 
10 (19.2) 
  
0.004 
Years lived in 
United States¥ 
(Mean ± SD) 
45.26  ± 21.61 39.74 ± 22.14 50.12 ± 20.12 -10.37 0.018 
¥ Independent T-tests, ¶ Chi-squares.  SD: Standard Deviations; N: Number; MD: Mean  Difference; 
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Table 2: One-Way ANOVA Comparison of Vitamin D Levels Between Ethnic 
Groups 
Ethnic group 
Vitamin D Levels 
(25(OH)D, ng/ml) 
(Mean ± SD) 
F (d.f.) (P-value) 
White, Caucasian (n=34) 33.37 ± 7.73 
6.27 (3) (0.001) 
African-American (n=15) 35.77 ± 9.60 
Hispanic, Latino (n=43)* 27.61 ± 7.75 
Other (n=5) 24.46 ± 8.73 
*Post Hoc Comparisons of Hispanic, Latino vs. White, Caucasian  P=0.015 and Hispanic, Latino vs. 
African-American: P=0.007 
 SD: Standard Deviation,d.f.: degrees of freedom 
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Table 3: Comparison of Vitamin D Levels, Vitamin D Intake, Sun Exposure and 
Other Potential Correlates Between Vitamin D Insufficient and Sufficient 
Participants 
 
Study 
population 
(n=97) 
Vitamin D 
Insufficient 
<30 ng/ml 
(n=45) 
Vitamin D 
Sufficient 
≥30 ng/ml 
(n=52) 
MD P-value 
Number of diseases and 
conditions reported¥ 
(Mean ± SD) 
4.70 ± 3.03) 4.20 ± 3.01 5.13 ± 3.01 -0.94 0.130 
Participants reporting 
prescription medication 
use¶ (N (%)) 
73 (75.3) 29 (64.4) 44 (84.6)  0.033 
Number of prescription 
medications used¥ 
(Mean ± SD) 
2.24 ± 2.20 1.73 ± 2.01 2.67 ± 2.29 -0.94 0.033 
Participants reporting 
vitamins/minerals 
supplement use¶ (N (%)) 
45 (46.4) 17 (37.8) 28 (53.8)  0.153 
Depressive symptoms 
(BDI Score)¥ 
(Mean ± SD) 
7.19 ± 7.56 6.22 ± 6.30 8.02 ± 8.47 -1.80 0.240 
Height (cm)¥ 
(Mean ± SD) 
167.6 ± 10.41 164.40 ± 10.65 170.46 ± 9.43 -6.06 0.004 
BMI (kg/m2)¥ 
(Mean ± SD) 
27.09 ± 5.27 27.44 ± 4.98 26.80 ± 5.53 0.63 0.559 
Overweight 
participants (BMI ≥25)¶ 
(N (%)) 
60 (61.9) 28 (62.2) 32 (61.5)  1.000 
%FM (n=95)¥ 
(Mean ± SD) 
30.92 ± 9.01 32.08 ± 9.24 29.92 ± 8.93 1.29 0.251 
Moderate physical 
activity (MET 
equivalents per week)¥ 
(Mean ± SD) 
1779 ± 2325 1281 ± 1644 2209 ± 2727 -929 0.043 
Sitting minutes per day¥ 
Mean  ±  SD 
299.04 ± 186 260.72 ± 130.5 332.20 ± 219.3 -71.5 0.050 
¥ Independent T-tests; ¶ Chi-squares;  SD: Standard Deviations N: Number; MD: Mean  Difference; BDI: 
Beck Depression Inventory; BMI: Body Mass Index; FM: Fat Mass; MET: Metabolic Equivalents. 
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Table 4: Vitamin D Status Correlation with Vitamin D Intake, Sun Exposure, and 
Other Potential Predictors 
 Spearman Correlation 
Coefficient P value 
Vitamin D intake (IU/day) at baseline 0.05 0.728 
Sun exposure 0.274 0.007 
Ethnicity -0.365 0.000 
Years lived in the United States 0.272 0.007 
Participants taking prescription medications 0.233 0.022 
Number of prescription medications 0.234 0.021 
Participants who reported vitamins/minerals 
supplement use 
0.277 0.006 
Height (cm) -0.298 0.003 
BMI (kg/m2) -0.220 0.030 
%FM -0.263 0.010 
Average sitting minutes 0.215 0.050 
Spearman Correlations between vitamin D status groups (Vitamin D insufficient = 0; Vitamin D 
sufficient = 1) and continuous/categorical variables. BMI: Body Mass Index, FM: Fat Mass. 
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Table 5: The Relationship Between Vitamin D Status and Potential Correlates in 
Multiple Linear Regressions 
 
β (S.E.) P-value 
Adjusted 
R2 
Model 
1 
Vitamin D Intake (IU/day) 
Sun Exposure 
0.00 (0.01) 
0.17 (0.07) 
0.648 
0.017 
0.048 
Model 
2 
Sun Exposure 
Ethnicity (Non-Hispanic) 
0.138 (0.07) 
5.02 (1.70) 
0.052 
0.004 
0.120 
Model 
3 
Ethnicity (Non-Hispanic) 
%FM 
Vitamin/Mineral Supplement use 
3.92 (1.70) 
-0.25 (0.09) 
4.24 (1.70) 
0.023 
0.008 
0.014 
0.184 
Stepwise Multiple Linear Regressions. Dependent variable: Vitamin D levels (ng/ml). Model 1: Vitamin D 
Intake, Sun exposure; Model 2: Model 1 + Ethnicity; Model 3: Model 2 + Years lived in the US, number of 
participants taking prescription medications, number of prescription medications, height, moderate physical 
activity, average sitting time per day, education, vitamin/mineral supplement use, BMI, %FM, age, gender, 
marital status, employment, income, number of disease, coffee use, alcohol use, smoking, weight, calcium 
intake, depressive symptoms. β: Beta Coefficient; S.E.: Standard Error; CI: Confidence Interval; FM: Fat 
Mass. 
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Table 6: The Relationship Between Vitamin D Status and Potential Correlates in 
Multiple Logistic Regression 
 β (S.E.) OR (95% CI) P-value 
Model 1 Sun Exposure 0.05 (0.02) 1.05 (1.01; 1.09) 0.013 
Model 2 
Sun exposure 
Ethnicity (Being Hispanic) 
.05 (0.02) 
-1.21 (0.47) 
1.05 (1.01; 1.10) 
0.30 (0.12; 0.75) 
0.016 
0.010 
Forward Logistic Regression. Dependent Variable: Vitamin status (0= <30 ng/ml; 1 = ≥30 ng/ml).  Model 
1: Vitamin D intake, Sun Exposure.  Model 2: Model 1 + Ethnicity, Years lived in the US, number of 
participants taking prescription medications, number of prescription medications, height, moderate physical 
activity, average sitting time per day, education, vitamin/mineral supplement use, BMI, %FM, age, gender, 
marital status, employment, income, number of disease, coffee use, alcohol use, smoking, weight, calcium 
intake, depressive symptoms. β: Beta Coefficient; SE: Standard Error; OR: Odds Ratio; CI: Confidence 
Interval. 
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CHAPTER V:  ASSOCIATION OF VITAMIN D STATUS WITH DUAL TASK 
PHYSICAL PERFORMANCE IN OLDER ADULTS 
Abstract 
Objective: The purpose of this study is to evaluate the association between vitamin D 
status with the age-related changes in mobility through higher order cognitive function 
using a dual task physical performance test.  
Methods: Participants completed assessments that included serum levels of vitamin D, 
surveys, and dual task physical performance tests. Spearman’s correlations, independent 
t-tests, repeated measures ANOVAs and multiple logistic regressions were used to 
examine the relationship between vitamin D insufficiency (25(OH)D <30 ng/ml) and 
sufficiency (≥30 ng/ml) and dual task physical performance variables. The significance 
level was set at α=0.05. 
Results: Dual and single task counting rate were significantly lower in the vitamin D 
insufficient group compared to the sufficient group (P=0.018 and P=0.028, respectively). 
Using Spearman correlations, a slower single (P=0.011) and dual counting rate 
(P=0.006) were significantly associated with vitamin D insufficiency.  
Conclusions: Cognitive performance for dual or single tasking was worse in the vitamin 
D insufficient group. Since counting backward is a mental tracking task, which is a 
component of executive function, our results support a relationship between vitamin D 
insufficiency and executive dysfunction.   
Keywords: vitamin D insufficiency, elderly, dual task, physical performance, executive 
function. 
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Introduction 
In the United States, the elderly population (>65 years of age) is expected to 
increase by 20%-50% by the year 2030.1 The major cause of physical disability in the 
elderly is mobility limitations, which eventually may lead to falls.2 According to the 
World Health Organization (WHO), a fall is defined as an event that results in the person 
unintentionally coming to rest on the ground or other lower level, with or without injury, 
that is not due to a major intrinsic event, like seizure, stroke, loss of consciousness, 
epilepsy, or excess alcohol, or an environmental hazard like sustaining a blow.3 It is 
estimated that approximately 30% of community-dwelling adults and 50% of 
institutionalized adults >65 years of age experience one fall each year.4, 5 Falls can result 
in increased morbidity and mortality and decreased quality of life, all of which translate 
to greater burden for the individual and healthcare system.5 Hence, understanding the risk 
factors and mechanisms behind falls is important for the development of effective 
interventions that protect the elderly from future disability.   
Gait impairments are one of the main risk factors for falls in the elderly.6 Elderly, 
compared to their younger counterparts, have significantly reduced gait speed6-8 with 
those over the age of 70 years experiencing a 12-16% decline in gait speed per decade.9-12 
The postural control system positions the body in space for orientation and balance 
depending on the integration of sensorimotor information in the central nervous system, 
which, in turn, depends on the information processing capacity of the brain. As people 
age, the sensorimotor system deteriorates and the information processing capacity of the 
brain areas involved in postural control and gait declines.13 With aging, the ability to 
perform automatic tasks, such as walking, becomes harder and more cognitively 
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demanding.14  According to recent evidence, these age-related deficits in mobility might 
be partially compensated by strenuous higher-order cognitive strategies involving 
executive function that replace the automated sensorimotor processing.13 Executive 
dysfunction is common among the elderly,15-17 and it has been associated with increased 
fall risk and gait impairments, including slower gait speed.18-28 Thus, falls in the older 
adults commonly occur when they engage in more than one task at a time (i.e., dual 
tasking) because cognitive resources, such as the attention usually allotted to movement, 
are no longer accessible for other activities such as talking, avoiding obstacles, watching 
for traffic, or other gait-unrelated tasks.13 Consequently, older adults often have more 
problems than younger adults in orchestrating tasks simultaneously, due to a lack of 
coordination of limited cognitive resources and decreased mental processing speed. 
Vitamin D deficiency in older adults has been linked to important determinants of 
disability, including falls and fractures.29-37 An extensive amount of research supports the 
relationship between risk of falls and vitamin D deficiency and the benefit of vitamin D 
supplementation on reducing fall risk in the elderly.5,38-45 For instance, a recent meta-
analysis found that those who fall have lower 25(OH)D concentrations, often <20 ng/ml, 
than non-fallers.46 The mechanism by which vitamin D is related to the risk of falls is still 
unclear, but potentially it may be through its relationship to both gait and cognition by 
affecting the musculoskeletal and nervous systems.41,47-53 In the general older adult 
population, vitamin D has not only been correlated with decreased muscle strength and 
dysfunctional mobility, but also with a higher risk of cognitive decline, which together 
may lead to an increased risk of falls and fractures.54 For instance, several studies have 
demonstrated an association between vitamin D deficiency and impairments of gait 
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(slower gait speed), global cognition, and executive function.37,54-74 Furthermore, vitamin 
D status has been associated with impaired neuronal function in the caudal primary motor 
cortex of older adults, which may contribute to the pathophysiology of gait disorders in 
older adults with vitamin D deficiency.75 Studies that investigated vitamin D status’ 
relationship with gait and cognition, however, have looked at these factors independently. 
There is lack of research about the role of vitamin D in cognitive function in the context 
of mobility.  
A way to evaluate the interaction between cognition and mobility as an indicator 
of risk of falls in older adults is using the dual task paradigm, which refers to performing 
an automatic primary task while executing a secondary cognitive task.19,28,76-87 During 
dual tasking the information processing capacity of an individual is divided between the 
performance of the secondary task (i.e., talking) and maintaining postural control and gait 
stability during the performance of a motor task (i.e., walking) 88 However, in the older 
adult, dual tasking becomes more challenging, as the already-limited information 
processing capacity needs to be divided between two tasks, resulting in poor performance 
of either one or both tasks.88 Studies that compared individual’s performance during dual 
tasking to their performance of each task individually (i.e., single vs. dual task) have 
shown that performing a secondary task while walking has a destabilizing effect on gait, 
placing older adults at higher risk for falling.14 Until now, no study has evaluated the age-
related changes in mobility through higher-order cognitive function in relation to vitamin 
D status using a dual task physical performance test.  The purpose of this study was to 
investigate the association of vitamin D status with cognitive processing during 
movement by using the dual task physical performance tests. It was hypothesized that 
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those who are vitamin D insufficient (25(OH)D <30 ng/ml), compared to those who are 
vitamin D sufficient (≥30 ng/ml), will have significantly worse dual task physical 
performance, as measured by a larger difference between dual and single task gait and 
cognitive functioning. 
 
Methods 
Study Design and Setting 
This study was approved by the IRBs of Florida International University (13-
0390) and the University of Miami (20120195).  
 
Participants 
The study enrolled 101 participants, and four were excluded due to missing data 
(n=97). Participants for this study were recruited from the parent study, a double-blinded 
randomized placebo-controlled clinical trial that examined the effects of vitamin D 
supplementation on vitamin D level, bone formation, resorption, and mineral density, 
flexibility, and balance in the elderly, which was conducted at the University of Miami. 
Briefly, each potential participant was screened over the phone by administering the 
Short Portable Mental Status Questionnaire (SPMSQ)89 to evaluate mental functioning 
(allowed up to 2 errors) and questions regarding general inclusion criteria such as age, 
and medical, pharmacological and general exclusions. Inclusion criteria for this study 
included: (1) Men and women age 55 or older; (2) English and Spanish speakers; (3) 
Community-dwelling; (4) Ability to give informed consent; (5) Ability to perform motor 
tasks without aid; and (6) Participating in the parent study. All participants in this study 
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were required to sign IRB approved informed consents for both the University of Miami 
and Florida International University.  
 
Biomarkers 
Vitamin D Status  
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D). 
Fasting venous blood (15 ml) was collected from every participant by a certified 
phlebotomist in the morning after fasting. The samples were sent the same day for 
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) that used 
immunochemiluminometric assays (ICMA) on the DiaSorin Liaison instrument to assess 
25(OH)D. This is a highly automated test that measures total 25(OH)D, and it has been 
widely used by others.90  
 
Surveys 
Sociodemographics, Health History, Health Risk Behaviors and Medications 
Sociodemographic and health-related data were collected using questionnaires 
developed by staff of the parent study that asked about gender, marital status, 
race/ethnicity, socioeconomic status, education, income, current medical diagnoses, 
medication/ supplement use and health risk behaviors such as coffee, alcohol, and 
tobacco use.   
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Physical Activity Levels  
Physical activity level was measured using the International Physical Activity 
Questionnaire (IPAQ),91 which provides individual domain-specific scores for walking, 
moderate-intensity and vigorous-intensity activity within the domains of work, 
transportation, domestic chores and gardening, and leisure-time. To measure the volume 
of activity, each type of activity was weighted by its energy requirement defined as the 
MET-min. METs are metabolic equivalents that are computed for each specific activity 
using defined formulas, and then multiplied by the minutes performed to derive MET-
minute scores, which are equal to kilocalories for a 60 kg person.91 
The IPAQ was developed to derive comparable measurements of physical activity 
in international settings; therefore, being suitable for use in different languages and 
cultural contexts like in an ethnically-diverse city as Miami.92,93 It has also been validated 
in different age groups against objective measures of physical activity, physical fitness, 
and health outcomes.94 For instance, it was validated in an adult population (mean ± SD: 
40.7 ± 10.3 years old) and found to have a strong positive relationship with an activity 
monitor and a physical activity log (rho=0.55, P<0.001).95 It was also validated and used 
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and 
valid when compared against pedometer use and the physical activity log, and had similar 
results in cohorts of postmenopausal women.96,97 Other studies have validated the IPAQ 
and used it successfully in populations of middle-aged and older adults and adults with 
different diseases, such as schizophrenia and breast cancer.93,98-101 The IPAQ correlated 
with measurements to other physical activity assessment methods such as the 2001 
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Behavioral Risk Factor Surveillance System (BRFSS) physical activity, accelerometers, 
and energy expenditure as measured by doubly-labeled water, among others.94,102-105 
 
Depressive Symptoms  
Depressive symptoms were assessed using the Beck Depression Inventory (BDI-
II), which is a widely validated and used tool that evaluates the existence and severity of 
depressive symptoms based on the DSM-IV.106 It is a self-report, 21-item instrument and 
each item corresponds to a symptom of depression and has a four-point scale ranging 
from 0 to 3, except for two items that have seven options to indicate decrease or increase 
in appetite and sleep. The score of all items is summed to give a single score. A total 
score of 0-13 is considered minimal, 14-19 mild, 20-28 moderate, and 29-63 severe 
depressive symptoms. 106 Construct validity has been assessed on its ability to 
differentiate non-depressed and depressed patients (0.92 for outpatients and 0.93 for 
college students). Test-retest reliability was found to be significant at 0.93. This tool has 
been used in populations ages 13-80 years.106-109 In an elderly population, BDI-II has 
good internal consistency (0.86), and has been positively correlated with other measures 
of depression, measures of stress, anxiety, and negatively with well-being. Research with 
this instrument has shown no statistically significant effects for ethnicity, gender, and age 
on BDI-II scores.110 In case a participant reported suicidal ideation, the investigators in 
this study contacted the study physician and/or University of Miami Mental Health 
Department, immediately. 
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Fear of Falling  
Fear of falling was another potential parameter that may have interfered with the 
physical assessment battery; therefore, it was assessed using the Fall Efficacy Scale 
International (FES-I), which evaluates the fear of falling while performing everyday 
activities.111,112  
 
Anthropometrics and Body Composition 
Weight was measured using an electronic balance. Participants were asked to 
remove shoes and heavy outer garments like coats and to stand in the center of the 
balance so that the weight was distributed evenly on both feet. Height was measured 
using a stadiometer with a movable headpiece. Participants were asked to stand with their 
back to the height rule with their feet together, while the back of the head, back, buttocks, 
calves, and heels touched the upright tape. The participant was asked to look straight 
ahead so that the ear canal was level with the cheek bone. The headpiece was lowered so 
that the hair was pressed flat. Weight and height were recorded to the nearest 0.1 kg and 
0.1 cm, respectively. Body mass index (BMI) was calculated using the formula: body 
weight (kg)/ height (m)2 and accordingly, participants were classified into categories 
based on the National Heart, Lung and Blood Institute recommendations: underweight 
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 kg/m2), and obese 
(>30 kg/m2).  
Waist circumference (WC) was measured at the umbilicus and hip circumference 
(HC) was measured at the broadest circumference below the waist. Both of these 
measurements were done using a flexible but not stretchable measuring tape in three 
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replicates to ensure reproducibility. The average of the three values was used to calculate 
waist-to-hip ratio (WHR) by dividing WC by HC. Body composition was measured using 
bioelectrical impedance (BIA), to determine % lean (fat-free, %FFM) and fat mass 
(%FM).  
 
Blood Pressure and Heart Rate 
 Systolic and diastolic blood pressure and heart rate were measured three times for 
each participant after sitting down on a chair for 10 minutes using OMRON Automatic 
blood pressure monitor Sem1.  
 
Dual Task Physical Performance Test 
Participants were asked to perform the following tasks in a random order, 
determined from a random order table.   
• Usual walking (single gait task) 
• Counting backward from 50 by one while standing (single cognitive task)78 
• Counting backward from 50 by one while walking (dual task) 
The spatiotemporal gait variables were measured using the GAITRite system that 
includes a 6 meter-long and 64 centimeter-wide walkway mat with embedded sensors. 
Participants were asked to wear comfortable, low-heeled shoes. Before each trial, 
participants’ leg length was measured using a measuring tape from the trochanter of the 
femur to the medial malleolus. Participants were given a demonstration on how to walk 
on the walkway from the start to the finish line that were located 2 meters before and 
after the walkway to account for acceleration and deceleration. Participants were given 
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standardized instructions for practice and data collection trials in which they were asked 
to walk only (single gait task) or walk while dual tasking without prioritizing either task 
on the GAITRite walkway at their preferred gait speed. Participants were required to 
perform three trials per data recording session. The first ten gait cycles of the three trials 
were used for each task to determine spatial-temporal gait parameters, which were 
normalized by individual leg length. The spatiotemporal variable of interest for this study 
was gait speed (distance walked divided by time to walk; cm/s).113  
For the secondary single cognitive task only and the dual task, the participants 
were asked to count backward out loud from 50 by one until reaching 30. The number of 
enumerated figures was assessed using a voice recorder while single and dual tasking, 
and defined as the number achieved at the completion of the walking time for the dual 
task. For both single and dual tasks, the numbers of figures were defined as those spoken 
during the time required for the completion of the dual task.81 For instance, if the 
participant took 30 seconds to complete the dual task, the number of figures enumerated 
for the single task was counted for the first 30 seconds. The average of the three trials 
was used for analysis. The difference in dual and single task variables was calculated by 
subtracting the single task value from the dual task value for gait velocity and counting 
rate (dual task minus single task equals the difference). 
 
Statistical Analysis 
Statistical analyses were performed on 97 participants. Data were analyzed using 
frequencies, percentages, ranges, means, and standard deviations. Variables were checked 
for non-normality, and if necessary, they were transformed to achieve a normal 
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distribution. Spearman’s correlations were used to estimate associations between vitamin 
D status (insufficient = 0 and sufficient = 1) and dual task physical performance 
variables. Paired t-tests were used to compare dual task (dual task gait speed and dual 
task counting rate) and single task variables (single task gait speed and single task 
counting rate) within the entire group, and in subgroup analysis, considering separately 
the sufficient and the insufficient groups. Independent t-tests were used to compare 
vitamin D insufficient (25(OH)D <30 ng/ml) and sufficient (≥30 ng/ml) in dual task, 
single task, and the difference in dual and single task variables. Repeated measures 
ANOVAs were used to compare the difference in dual and single task gait velocities and 
counting rates between vitamin D status categories. Logistic regressions were used to 
examine the relationship of vitamin D insufficiency with dual and single task gait speed 
and counting rate, controlling for covariates. The significance level was set at α=0.05, 
and statistical analyses were performed using SPSS 21. 
 
Results  
A total of 97 participants aged 55 years or older were included in the analysis. 
The mean ± SD  age of the study population was 63.06 ± 6.48, and 45.4% were male. In 
this population, 44.3% were Hispanic, 35.1% white Caucasian, and 15.5% African 
American (Table 1). The mean ± SD BMI was 27.09 ± 5.27 and the number of 
diseases/disorders reported were 4.70 ± 3.03. On average, 75.3% of participants reported 
using a mean ± SD of 2.24 ± 2.20 prescription medications, and 46.4% reported a history 
of vitamin/mineral supplement use, 79.4% consumed coffee, 42.3% drank alcohol, and 
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11.3% were smokers. Fifty-one participants reported a history of injuries and 14 reported 
experiencing a fall in the past 12 months.  
The mean ± SD vitamin D level was 30.73 ± 8.73 ng/ml, ranging from 10.00 to 
59.80 ng/ml.  The mean ± SD dual task and single task gait velocities were 132.59 ± 
36.61 and 154.29 ± 29.96 cm/s, respectively. The mean ± SD dual task and single task 
counting rates were 1.24 ± 0.29 and 1.21 ± 0.28 figures/s, respectively (Table 1).  
Spearman correlations were used to assess the relationship between vitamin D 
status and physical performance (Table 2). There was a significant and positive 
correlation between vitamin D insufficiency and slower single task counting rate 
(r=0.278, P=0.006) and dual task counting rate (r=0.258, P<0.011). Those who were 
vitamin D insufficient counted fewer figures per second in both tasks (Table 3). Vitamin 
D status was not significantly correlated with gait velocity during either dual or single 
task.  
Paired t-tests, however, showed a significant difference in dual and single task 
gait velocity within the entire group and by each vitamin D status group (Figure 1, Table 
3, all P<0.001). Participants had slower gait speeds when dual tasking compared to single 
tasking, indicating interference of the cognitive task on gait task when dual tasking. 
Independent t-tests showed no significant differences between vitamin D insufficient and 
sufficient groups in the dual task and single task gait velocities (P=0.896 and P=0.934, 
respectively).  Paired t-tests showed no significant difference in dual and single task 
counting rate within the entire group of participants (P=0.128) and those in the vitamin D 
insufficient (P=0.473) and vitamin D sufficient categories (P=0.151) (Figure 2, Table 3). 
Independent t-tests showed significant differences between vitamin D insufficient and 
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sufficient groups in dual task and single task counting rates (P=0.018 and P=0.028, 
respectively) (Table 3). Vitamin D insufficient participants counted significantly fewer 
figures per second when single and dual tasking as compared to vitamin D sufficient, thus 
having worse cognitive task performance.  
One-way repeated measures ANOVA were conducted with the within-subject 
factor being either gait velocity difference (defined as the difference between dual and 
single task gait velocity) or counting rate difference (defined as the difference between 
dual and single task counting rate); and the between-subject factor being vitamin D status 
categories. The results for the ANOVAs indicated that velocity and counting rates were 
not significantly different by vitamin D status (Wilk’s Lambda =0.999; F (1, 95) =.11, 
P=.740) (Wilk’s Lambda =.999, F(1,95)=.13, P=.718). 
Logistic regression models were built to examine the relationship between 
vitamin D deficiency and gait velocity and counting rate difference in dual and single 
task when controlling for covariates (Table 4). Vitamin D status was not significantly 
associated with dual task physical performance (defined as the difference in dual and 
single task) in gait velocity (OR=1.00, 95% CI: 0.98; 1.02, P=0.772) and counting rate 
(OR=1.684, 95% CI: 0.15; 19.57, P=0.677), when controlling for variables that had 
significant correlations with or have been shown in previous research to affect either the 
independent and/or dependent variables like age, gender, marital status, education, 
employment, income, falls, number of diseases, number of injuries, prescription 
medications, vitamin/mineral supplement use, coffee consumption, alcohol use, smoking, 
weight, BMI, depressive symptoms, fear of falling, physical activity, physical 
performance test. 
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Discussion 
Vitamin D deficiency in the elderly has been linked to factors associated with 
disability, including cognitive impairment, poor physical performance, and increased risk 
of falls and fractures.5,29,43,83,114-116 Older adults are at higher risk of vitamin D deficiency 
due to a complex interplay between aging and the factors that affect vitamin D status 
such as dietary intake, skin synthesis, and bioavailability.62,117 Vitamin D deficiency has 
received much attention as a risk factor for falls because of its association with gait 
impairment (slower gait speed), global cognitive deficits, and compromised executive 
function.5,43,48,114,118 Nonetheless, studies that investigate the relationship between vitamin 
D status, gait, and cognition have looked at these factors independently. In our study a 
dual task physical performance test was used to examine the relationship between vitamin 
D status and cognition in the context of mobility, by evaluating the competition for 
information processing capacity between gait stability during the primary automatic task 
(i.e., walking) and cognitive performance during the completion of the secondary 
cognitive task (i.e., counting backwards from 50 by 1).  
Dual tasking usually results in worse performance in either one or both tasks 
when compared to the performance of each task individually.88 In our study, we found a 
marked deterioration of the automatic primary motor task during dual tasking, and not the 
secondary cognitive task when compared to single tasking. Participants had a 
significantly slower gait speed when walking while counting, compared to walking only. 
However, counting rate was not significantly different between dual and single tasks. As 
shown in previous studies that compared individual’s performance during dual tasking 
with their performance of each task individually (i.e., single vs. dual task), our results 
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showed that performing a secondary cognitive task like counting backwards from 50 to 
one, while walking, had a destabilizing effect on gait as shown by decreased gait 
speed.76,77,80,83,119 This can be explained by participants prioritizing the cognitive task 
when dividing their limited information processing capacity during dual tasking, 
therefore, sacrificing gait stability by decreasing gait speed to compensate for the 
increased need for higher cognitive processing demanded by the secondary cognitive 
task. 
When examining the relationship between vitamin D status and dual task physical 
performance, we did not find a significant association. Our results supported our 
hypothesis that those who were vitamin D insufficient were more likely to have cognitive 
deficits that would limit their information processing capacity when dual tasking. Slower 
dual task gait speeds and/or counting rates were compared to single task, which resulted 
in larger differences in both variables between tasks.  Surprisingly, gait velocity and 
counting rate were not different for either single or dual task between the vitamin D 
insufficient and sufficient group. Thus, those who were vitamin D insufficient did not 
perform worse in dual or single task physical performance tests compared to those who 
were sufficient. Of importance, in subgroup analysis, when the participants in each of the 
vitamin D groups were considered independently, in each group those performing dual 
tasks seem to prioritize the cognitive over the walking task for the use of resources, since 
counting rate was not significantly different in counting rate, but a significant difference 
in gait speed compared to single tasks (Figure 1). 
Even though counting rate was not significantly different between dual task and 
single cognitive task between vitamin D groups, we did find a significant weak 
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correlation between vitamin D insufficiency and single and dual task counting rate (Table 
3). An interesting finding of our study was that single and dual task counting rates were 
significantly lower in the vitamin D insufficient group. Those who were vitamin D 
insufficient had worse cognitive performance, since they counted significantly fewer 
figures per second compared to the vitamin D sufficient group when performing either 
single or dual tasks. Counting backward is a mental tracking task, meaning it is task that 
requires holding information while performing a mental process. Thus, mental tracking 
tasks are typically used to examine information processing speed, working memory, and 
sustained attention, all of which are part of executive function.83 Executive function 
refers to the cognitive processes that orchestrate goal-directed behavior and decision-
making, like problem-solving, initiating and maintaining tasks, working memory (holding 
multiple pieces of transitory information and manipulating it), abstract reasoning, and 
dividing attention.22,120 Counting backward from 50 by 1 is a mental tracking task that 
can assess to some extent executive functioning; therefore, our results support previous 
research that found an association between vitamin D status and executive dysfunction. 
Several studies have found a significant positive correlation between vitamin D and 
scores of cognitive tests that assess executive function like the Digit Symbol Substitution 
Test 56,70,121, Trail Making Test A56,61,65, Trail Making Test B56,61,64-66,73, Block Design56, 
and Verbal Fluency. 56,65  
Executive dysfunction is common among elderly15-17, and it has been associated 
with increased fall risk and gait impairments.18-28 Several studies have found a significant 
positive association between vitamin D deficiency and slower gait speed when walking 
(i.e., single tasking).122-126 Although we found worse executive function in vitamin D 
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insufficient subjects, we did not find a significant correlation between single gait velocity 
and vitamin D levels nor a difference in single gait velocity between vitamin D 
insufficient and sufficient groups. Executive dysfunction is sometimes present even in the 
absence of global cognitive impairment, and it may be present in the older adult before 
gait impairments are evident.15,18,22 This can explain why we observed an association 
between vitamin D deficiency and worse performance on the cognitive task and not the 
gait tasks.  Thus, in this healthy older adult population executive function may not be 
diminished enough to affect gait significantly and may be more sensitive to vitamin D 
deficiencies than mobility limitations. 
This study had several limitations. First of all, cross-sectional studies are 
descriptive in nature and even though they can establish association among factors, they 
do not prove cause and effect. Second, this study may suffer from selection bias. Age 
could be a possible explanation for the lack of association between gait velocity and 
vitamin D deficiency observed in our study. We included younger older adult participants 
(>55 years of age) to have a wider age range for recruitment purposes; therefore, our 
participants were younger than what is considered “old age,” with 36% and 63.8% of our 
participants being under the age of 60 and 65, respectively. This added heterogeneity to 
our study, and since gait instability increases with age, it might be possible that our 
population was too young to exhibit mobility limitations.  Furthermore, most studies 
evaluating vitamin D deficiency and physical and cognitive performance in the elderly 
have been done in adults either above the age of 60, 65, or 70, making our results less 
comparable.  
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Moreover, the participants in this study were not only younger, but also mostly 
healthy, since the exclusion criteria for the parent study included current diagnoses of 
numerous diseases/conditions that affect vitamin D metabolism/absorption and mobility, 
medications that disturb vitamin D metabolism, and vitamin D supplement use. Thus, this 
population might not be representative of the older adult population in Miami-Dade, but 
instead were healthy older adults who volunteered to participate and met inclusion 
criteria. Thus, the results of this study are not generalizable to the general Miami-Dade 
older adult population.   
The small sample size could have also affected the results of this study. Using an 
independent t-test with 5% significance and 80% power and assuming an allocation ratio 
of 40%, based on published prevalence of vitamin D deficiency, and an effect size of 0.5 
for the change in gait speed between dual and single task, the total sample size was 134 
(expected 54 vitamin D deficient and 80 vitamin D sufficient). However, due to 
limitations of time and resources, we were only able to recruit 101 participants of which 
97 were included in the analysis, reducing the power to detect significant differences in 
this study. Using an independent t-test with 5% significance, the actual sample size for 
each group and the mean +/- SD of single and dual task gait velocity and the difference 
between dual and single task gait velocity to calculate effect size, we calculated power to 
be 5%. With the sample size in this study were did not have enough power to detect 
significant differences between vitamin D status groups. In addition, our sample had a 
significantly lower prevalence of vitamin D deficiency, with 10.3% of our population 
having 25(OH)D < 20 ng/ml and 36.1% having between (20-30 ng/ml). Previous studies 
that have evaluated the relationship between vitamin D and physical performance have 
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included participants with lower 25(OH)D levels, showing a relationship between 
vitamin D deficiency and motor capacity. This, together with the younger age group, 
might be why we did not find a significant association between vitamin D insufficiency 
and gait speed.  
An additional limitation of this study was the low adjusted R2, which assesses the 
percentage of the variation of the dependent variable that is explained by the linear 
regression model. Even though it is indicative of how well the linear model fits the 
observations, it doesn’t provide a hypothesis test for this relationship. A low adjusted R2 
means that the model is not precise. However, if the adjusted R2 is low but the predictors 
are statistically significant, conclusions can still be drawn about the relationship between 
the dependent variable and predictors. Thus, highly variable data, as indicated by low 
adjusted R2, can still have a significant trend that indicates the dependent variable is 
affected by the predictors.  
Another weakness of this study is related to dual task physical performance tests.  
Overall, many studies show the importance of dual task effects on gait performance in 
older adults and its usefulness in the prediction of falls. Even though previous meta-
analyses and systematic reviews concluded that gait control places demand on cognitive 
systems and this may increase the risk for falls in older adults, researchers recognize that 
methodological variations complicate the interpretation of data and challenge deriving 
concrete conclusions from the literature available. Therefore, the different results on dual 
task-related gait changes and their relationship with falls elicit some concern about the 
usefulness of this technique for fall prediction. The main concerns are the lack of 
methodological standardization, as different primary motor tasks and cognitive secondary 
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tasks with diverse levels of complexity and different gait parameters, are evaluated 
during dual task analysis. Furthermore, even though most studies had their participants 
perform the single task alone, not all studies evaluated the difference in performance 
between a single and dual task in one or both tasks (i.e., change in performance).76,83 
Some studies only compared dual task performance between groups. This raises the 
question of whether it is the difference in performance from single to dual tasking or the 
difference in dual task performance only, which is relevant for fall prediction.  
To better understand the dual task-related changes and gait control mechanisms, it 
is important to standardize methodologies and improve their ecological validity.80 One of 
the criticisms of the dual task methodology used in research studies is that it does not 
resemble the everyday activities of the participants like street crossing; therefore, not 
having ecological validity. It is difficult to analyze quantitatively, however, a non-
standardized cognitive task such as engaging in a conversation or street crossing, so 
having a well-defined mental tracking task improves the reliability, validity, and 
comparability of results.80 Thus from a review of literature we found that changes in 
speed while performing a simple gait task, like walking in a straight line, and a simple 
mental tracking secondary task, like counting backwards from 50 by 1, using the speed 
analysis method or even better, a spatiotemporal assessment system like the GAITRite, 
yielded enough sensitivity and predictive value for falls. 
Moreover, studies that use dual task physical performance tests found that 
decrease in speed during dual tasking was consistently found to predict falls in elderly. 
Previous studies have used dual task testing using gait velocity as the primary outcome 
variable because it is a highly reproducible and reliable measurement of mobility in older 
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adults.2,19,127 Experts suggest that changes in other gait parameters, however, may be 
more relevant for assessing fall risk besides speed. 118 For instance, stride time and stride 
length variability due to inconsistent stepping patterns and reduced postural control are 
common in many older adults whether or not they have any pathology present.128 
Therefore, these variables are considered very good markers of gait control because they 
reflect regularity of the walking rhythm129-132 and have also been identified as risk factors 
for falls in prospective studies. Hence, using a different spatiotemporal variable to assess 
gait rather than gait speed may have yielded different results in our study.  
 
Conclusions 
When dual tasking, this healthy older adult sample prioritized the secondary 
cognitive task at the expense of compromising their motor capacity. Despite of these 
findings, we did not find a significant association between vitamin D status and the 
change in performance in cognitive and gait tasks when dual vs. single tasking; thus 
vitamin D insufficient participants did not have worse dual task performance. Motor 
functioning was not significantly different between vitamin D categories, but 
performance on the cognitive task was significantly lower in the vitamin D insufficient 
group. Since counting backward is a mental tracking task, which is a component of 
executive function, our results support a relationship between vitamin D insufficiency 
and impaired executive function. Executive dysfunction has been previously associated 
with fall risks in the elderly, and it could be a possible mediator between vitamin D and 
falls. 73 Our data suggest that cognition may play a significant role in vitamin D’s 
influence on falls, while motor function may play a lesser role.72 
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 Due to the nature of this cross-sectional study, we cannot conclude that vitamin D 
deficiency is a cause of executive dysfunction that leads to decreased performance in 
mental tracking tasks. Future randomized control studies, with sufficient resources, are 
warranted to evaluate the change in dual task physical performance in vitamin D 
insufficient older adults supplemented with vitamin D and to examine the cause-effect 
relationship.   
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Table 1: Characteristics of Participants (n=97) 
Age (years) (Mean ± SD) 63.1 ± 6.5 
Age categories: (N (%)) 
55-60 years 
60-65 years 
65-70 years 
>70 years 
 
35 (36.1) 
27 (27.8) 
21 (21.6) 
14 (14.4) 
Male gender  (N (%)) 44 (45.4) 
Ethnicity: (N (%)) 
Hispanic 
White Caucasian 
African American 
Other 
 
43 (44.3) 
34 (35.1) 
15 (15.5) 
5 (5.2) 
Vitamin D levels (ng/ml) (Mean ± SD) 30.7 ± 8.7 
Dual task gait velocity (cm/s) (Mean ± SD) 132.6 ± 36.6 
Single task gait velocity (cm/s) (Mean ± SD) 154.4 ± 30.0 
Dual task counting rate (figures/sec) (Mean ± SD) 1.2 ± 0.3 
Single task counting rate (figures/sec) (Mean ± SD) 1.21 ± 0.3 
BMI (kg/m2) (Mean ± SD) 27.1 ± 5.3 
%FM (Mean ± SD) 30.9  ± 9.0 
SBP (mmHg) (Mean ± SD) 132.6 ± 22.0 
DBP  (mmHg) (Mean ± SD) 76.0  ± 14.5 
HR (bpm) (Mean ± SD) 70.4  ± 11.8 
Depressive symptoms (BDI Score) (Mean ± SD) 7.2 ± 7.6 
Fear of falling (FES-I score) (Mean ± SD) 20.0  ± 5.9 
Participants reporting injuries (N (%)) 51 (52.6) 
Participants reporting falls in last 12 months (N (%)) 14 (14.4) 
Number of diseases and conditions reported (Mean ± SD) 4.7 ± 3.0 
Participants using prescription medications (N (%)) 73 (75.3) 
Number of prescription medications used (Mean ± SD) 2.2 ± 2.2 
Participants reporting vitamins/minerals supplement use (N 
(%)) 
45 (46.4) 
Total physical activity (IPAQ score) (Mean ± SD) 4283 ± 4318 
 SD: Standard Deviation; BMI: Body Mass Index; FM: Fat Mass; SBP: Systolic Blood Pressure; DBP: Diastolic 
Blood Pressure; HR: Heart Rate; bpm: beats per minute; IPAQ: International Physical Activity Questionnaire; BDI: 
Beck Depression Inventory; FES-I: Falls Efficacy Scale International 
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Table 2: Vitamin D Status Correlation  with Dual Task Physical Performance 
Variables 
 Spearman Correlation Coefficient P- value 
Dual task gait velocity (cm/s) -0.003 0.977 
Single task gait velocity  (cm/s) -0.040 0.698 
Dual and single task difference gait velocity 
(cm/s)£ -0.051 0.623 
Dual task counting rate (figures/sec) 0.258 0.011 
Single task counting rate (figures/sec) 0.278 0.006 
Dual and single task difference counting rate 
(figures/sec)£ -0.026 0.802 
Spearman Correlations between vitamin D status groups (Vitamin D insufficient = 0; Vitamin D sufficient 
= 1) and continuous/categorical variables. £Difference in dual and single task variables is calculating by 
subtracting single task value from dual task value (dual task – single task = difference).  
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Figure 1: Comparison of Dual and Single Task Gait Velocity Within and Between 
Vitamin D Insufficient and Sufficient Participants.  
Legend: Gait velocity is significantly higher for the entire group and the vitamin D status 
subgroups for single task compared to dual tasks. 
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Figure 2: Comparison of Dual and Single Task Counting Rate Within and Between 
Vitamin D Insufficient and Sufficient Participants. 
Legend:  Counting rate is significantly lower in the vitamin D insufficient group 
compared to the sufficient group while performing dual or single task.
* 
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Table 3: Comparison of Dual Task Physical Performance Variables Between Vitamin D Insufficient And Sufficient 
Participants 
 Total 
(n=97) 
Vitamin D 
insufficient <30 
ng/ml 
(n=45) 
Vitamin D sufficient 
≥30 ng/ml 
(n=52) 
MD between 
vitamin D status 
groups 
 
P-
value£ 
Velocity 
(cm/s) 
(Mean ± SD) 
Dual task 132.6 ± 36.6 132.1 ± 36.4 133.1 ± 37.1 -0.99 0.896 
Single task 154.4 ± 30.0 154.7 ± 30.3 154.2 ± 30.0 0.51 0.934 
Dual and 
single task 
difference 
-21.8 ± 21.9 -22.6 ± 26.1 -21.1 ± 17.8 -1.5 0.740 
Pair sample 
P-value¥ 
<0.001 <0.001 <0.001   
Counting 
rate 
(figures/ sec) 
(Mean ± SD) 
Dual task 1.2 ± 0.3 1.17 ± 0.3 1.3 ± 0.27 -0.14 0.018 
Single task 1.2 ± 0.3 1.15 ± 0.31 1.27 ± 0.25 -0.06 0.028 
Dual and 
single task 
difference 
0.03 ± 0.19 0.02 ± 0.20 0.04 ± 0.18 -0.01 0.718 
Pair sample 
P-value¥ 
0.128 0.473 0.151   
¥Paired sample t-test comparing dual and single task within total group and each vitamin D category; £Independent t-test comparing vitamin D status 
categories.  SD: Standard Deviation; MD: Mean  Difference. 
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Table 4: The Relationship Between Vitamin D Status and Dual to Single Task 
Difference in Gait Velocity and Counting Rate in Multiple Logistic Regressions 
 β (S.E.) OR (95% CI) P- value 
Dual to single task difference in 
gait velocity 
0.00 (0.010) 1.003 (0.98, 1.02) 0.772 
Dual to single ask difference in 
counting rate. 
0.52 (1.25) 1.684 (0.15, 19.57) 0.677 
Dependent: Vitamin D insufficient <30 ng/ml=0; Vitamin D sufficient ≥30 = 1. Adjusted for: age, gender, 
marital status, education, employment, income, falls, number of diseases, number of injuries, prescription 
medications, vitamin/mineral supplement use, coffee consumption, alcohol use, smoking, weight, BMI, 
depressive symptoms, fear of falling, physical activity, physical performance test. β: Beta Coefficient; SE: 
Standard Error; OR: Odds Ratio; CI: Confidence Interval. 
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CHAPTER VI:  RELATIONSHIP BETWEEN VITAMIN D STATUS AND 
CARDIOMETABOLIC RISK  
Abstract 
Objective: The purpose of this study was to investigate the relationship between vitamin 
D status and a composite cardiometabolic risk score (CMRS). 
Methods: Participants completed assessments that included serum vitamin D levels, 
surveys, and measurement of CMRS using a system that integrates body composition, 
endothelial function, and autonomic nervous system (ANS) activity markers. Spearman’s 
correlations, independent t-tests and multiple linear regressions were used to examine the 
relationship of vitamin D insufficiency (25(OH)D <30 ng/ml) and sufficiency (25(OH)D 
≥30 ng/ml) with CMRS. The significance level was set at α=0.05. 
Results: The mean ± SD vitamin D (25(OH)D) level was 30.71 ± 8.78, and CMRS was 
5.17 ± 3.58. Spearman correlations showed a significant inverse correlation between 
insufficient vitamin D levels and CMRS (P=0.019). Vitamin D insufficient participants 
had a significantly higher CMRS compared with vitamin D sufficient (P=0.046). In 
adjusted multiple linear regressions, vitamin D status had a significant effect on CMRS 
(P=0.016). 
Conclusions: An inverse association between vitamin D levels and CMRS was found, 
possibly by mediating genomic and non-genomic mechanisms that influence ANS 
activity and vascular function. Thus, vitamin D insufficiency may affect cardiac 
performance. 
Keywords: vitamin D, cardiometabolic risk, autonomic nervous system, endothelial 
dysfunction 
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Introduction  
Vitamin D deficiency and cardiovascular disease (CVD) are prevalent 
worldwide.1,2 Furthermore, the prevalence of vitamin D deficiency is high among those 
with CVD. Analysis of data from the National Health and Nutrition Examination Survey 
(NHANES) 2001-2004, showed that 68% of whites, 88% of Hispanics, and 97% of 
blacks with CVD also had vitamin D levels of less than 30 ng/ml, as measured by 25-
hydroxyvitamin (25(OH)D).3,4 Several observational studies and meta-analyses have 
suggested an association of vitamin D deficiency with CVD-related outcomes and 
mortality.5-19 These studies reported a linear, inverse relationship between CVD risk and 
25(OH)D levels between 8-24 ng/ml.12 Furthermore, vitamin D supplementation 
demonstrated a reduction in CVD-related death, with vitamin D intake of more than 500 
IU per day improving all-cause mortality, partly by decreasing CVD mortality.9,15,19  
The possible relationship between vitamin D deficiency and CVD-related 
outcomes and mortality in both diseased and healthy populations is a growing area of 
research.2 The most studied role of vitamin D is in regulating calcium homeostasis and 
mineral metabolism to maintain bone health.20 Vitamin D, via genomic and non-genomic 
actions mediated by vitamin D receptors (VDRs), however, may affect multiple cellular 
signaling pathways that have the potential to affect cardiovascular health. These include 
vitamin D effects on parathyroid hormone (PTH), the renin-angiotensin-aldosterone 
system (RAAS), cytokine production, endothelial growth and function, and myocyte 
calcium influx.21 Furthermore, vitamin D has also been shown to be involved in 
molecular mechanisms like biosynthesis of neurotransmitters and inflammatory signaling 
in areas of the central nervous system (CNS) that regulate cardiovascular activity.22,23 
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Vitamin D can permeate the blood-brain barrier and bind to VDRs located in extremely 
high concentrations in the midbrain and brainstem where some autonomic nervous 
system (ANS) neurons are located.22,23  
Recent studies in healthy and diseased populations have found an association 
between vitamin D status and cardiac ANS function, with vitamin D deficiency related to 
cardiac ANS imbalance, more specifically with decreased parasympathetic nervous 
system (PNS) activity.2,24-29 The ANS is a branch of the peripheral nervous system that 
controls involuntary processes throughout the body like cardiovascular activity.30 The 
cardiac ANS is composed of the stimulatory post-ganglionic sympathetic plexus of 
nerves and the inhibitory parasympathetic Vagus nerve, which both innervate the heart 
and act concomitantly to control heart rate by responding to internal and external 
stimuli.26,30 Dysfunction of cardiac autonomic function, more specifically of the 
cardioprotective vagal tone, results in an imbalance between SNS and PNS, that has been 
well established as a risk factor for adverse cardiovascular events, such as sudden cardiac 
death (SCD) and congestive heart failure (CHF) in both healthy and diseased 
populations.31-36  
Besides its effect on heart rate, ANS activity plays a role in vascular dynamics 
and blood pressure control, which is also influenced by endothelial function. Low vitamin 
D status has also been associated with endothelial dysfunction, characterized by a 
decreased ability to balance vasodilation and vasoconstriction. It is usually due to an 
imbalance of nitric oxide bioavailability and related to prothrombotic and 
proinflammatory states that increase arterial stiffness.4,37-39 Thus, vitamin D plays a role 
in vascular health by participating in the control of vascular tone and blood pressure via 
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indirect ANS activity or directly affecting the endothelium. These findings suggest that 
vitamin D may contribute to CVD-risk by orchestrating genomic and non-genomic 
regulatory activity at the vascular level and higher brain centers of the ANS.5,18,40  
Currently, the links between vitamin D status, ANS, and endothelial function have 
been evaluated independently, and no study has investigated the relationship between 
vitamin D and cardiometabolic risk score (CMRS) as a composite measure that integrates 
various CVD risk factors such as body composition, ANS activity, and endothelial 
function. The purpose of this study was to investigate the association between vitamin D 
status and CMRS. We hypothesized that those who are vitamin D insufficient (25(OH)D 
<30 ng/ml) will have significantly lower CMRS than those who are vitamin D sufficient 
(≥30 ng/ml). 
 
Methods 
Study Design and Setting 
This study was approved by the IRBs of Florida International University (13-
0390) and the University of Miami (20120195).  
 
Participants 
The study enrolled 101 participants, and six were excluded due to missing data 
(n=95). Participants for this study were recruited from the parent study, a double-blinded 
randomized placebo-controlled clinical trial that examined the effects of vitamin D 
supplementation on vitamin D level, bone formation, resorption, and mineral density, 
flexibility, and balance in the elderly, which was conducted at the University of Miami. 
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Briefly, each potential participant was screened over the phone by administering the 
Short Portable Mental Status Questionnaire (SPMSQ) 41 to evaluate mental functioning 
(allowed up to 2 errors) and questions regarding general inclusion criteria such as age, 
and medical, pharmacological and general exclusions. Inclusion criteria for this study 
included: (1) Men and women age 55 or older; (2) English and Spanish speakers; (3) 
Community-dwelling; (4) Ability to give informed consent; (5) Ability to perform motor 
tasks without aid; and (6) Participating in the parent study. All participants in this study 
were required to sign IRB approved informed consents for both the University of Miami 
and Florida International University.  
 
Biomarkers 
Vitamin D Status  
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D). 
Fasting venous blood (15 ml) was collected from every participant by a certified 
phlebotomist in the morning after fasting. The samples were sent the same day for 
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) that used 
immunochemiluminometric assays (ICMA) on the DiaSorin Liaison instrument to assess 
25(OH)D. This is a highly automated test that measures total 25(OH)D, and it has been 
widely used by others.42  
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Surveys 
Sociodemographics, Health History, Health Risk Behaviors and Medications 
Sociodemographic and health-related data were collected using questionnaires 
developed by staff of the parent study that asked about gender, marital status, 
race/ethnicity, socioeconomic status, education, income, current medical diagnoses, 
medication/ supplement use and health risk behaviors such as coffee, alcohol, and 
tobacco use.  
 
Physical Activity Levels  
Physical activity level was measured using the International Physical Activity 
Questionnaire (IPAQ),43 which provides individual domain-specific scores for walking, 
moderate-intensity and vigorous-intensity activity within the domains of work, 
transportation, domestic chores and gardening, and leisure-time. To measure the volume 
of activity, each type of activity was weighted by its energy requirement defined as the 
MET-min. METs are metabolic equivalents that are computed for each specific activity 
using defined formulas, and then multiplied by the minutes performed to derive MET-
minute scores, which are equal to kilocalories for a 60 kg person.43 
The IPAQ was developed to derive comparable measurements of physical activity 
in international settings; therefore, being suitable for use in different languages and 
cultural contexts like in an ethnically-diverse city as Miami.44,45 It has also been validated 
in different age groups against objective measures of physical activity, physical fitness, 
and health outcomes.46 For instance, it was validated in an adult population (mean ± SD: 
40.7 ± 10.3 years old) and found to have a strong positive relationship with an activity 
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monitor and a physical activity log (rho=0.55, P<0.001).47 It was also validated and used 
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and 
valid when compared against pedometer use and the physical activity log, and had similar 
results in cohorts of postmenopausal women.48,49 Other studies have validated the IPAQ 
and used it successfully in populations of middle-aged and older adults and adults with 
different diseases, such as schizophrenia and breast cancer.45,50-53 The IPAQ correlated 
with measurements to other physical activity assessment methods such as the 2001 
Behavioral Risk Factor Surveillance System (BRFSS) physical activity, accelerometers, 
and energy expenditure as measured by doubly-labeled water, among others.46,54-57 
 
Depressive Symptoms  
Depressive symptoms were assessed using the Beck Depression Inventory (BDI-
II), which is a widely validated and used tool that evaluates the existence and severity of 
depressive symptoms based on the DSM-IV.58 It is a self-report, 21-item instrument and 
each item corresponds to a symptom of depression and has a four-point scale ranging 
from 0 to 3, except for two items that have seven options to indicate decrease or increase 
in appetite and sleep. The score of all items is summed to give a single score. A total 
score of 0-13 is considered minimal, 14-19 mild, 20-28 moderate, and 29-63 severe 
depressive symptoms.58 Construct validity has been assessed on its ability to differentiate 
non-depressed and depressed patients (0.92 for outpatients and 0.93 for college students). 
Test-retest reliability was found to be significant at 0.93. This tool has been used in 
populations ages 13-80 years.58-61 In an elderly population, BDI-II has good internal 
consistency (0.86), and has been positively correlated with other measures of depression, 
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measures of stress, anxiety, and negatively with well-being. Research with this 
instrument has shown no statistically significant effects for ethnicity, gender, and age on 
BDI-II scores.62 In case a participant reported suicidal ideation, the investigators in this 
study contacted the study physician and/or University of Miami Mental Health 
Department, immediately. 
 
Anthropometrics and Body Composition 
Weight was measured using an electronic balance. Participants were asked to 
remove shoes and heavy outer garments like coats and to stand in the center of the 
balance so that the weight was distributed evenly on both feet. Height was measured 
using a stadiometer with a movable headpiece. Participants were asked to stand with their 
back to the height rule with their feet together, while the back of the head, back, buttocks, 
calves, and heels touched the upright tape. The participant was asked to look straight 
ahead so that the ear canal was level with the cheek bone. The headpiece was lowered so 
that the hair was pressed flat. Weight and height were recorded to the nearest 0.1 kg and 
0.1 cm, respectively. Body mass index (BMI) was calculated using the formula: body 
weight (kg)/ height (m)2 and accordingly, participants were classified into categories 
based on the National Heart, Lung and Blood Institute recommendations: underweight 
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 kg/m2), and obese 
(>30 kg/m2).  
Waist circumference (WC) was measured at the umbilicus and hip circumference 
(HC) was measured at the broadest circumference below the waist. Both of these were 
done using a flexible but not stretchable measuring tape in three replicates to ensure 
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reproducibility. The average of the three values was used to calculate waist-to-hip ratio 
(WHR) by dividing WC by HC. Body composition was measured using bioelectrical 
impedance (BIA), to determine % lean (fat-free, %FFM) and fat mass (%FM).  
 
Cardiometabolic Risk Score (CMRS) 
FDA approved and patented Electro Sensor Complex (ESC) software was used to 
determine CMRS. This instrument combines three devices (ES-BC, TM-Oxi and 
SudoPath) that use bioelectrical impedance, galvanic skin response, spectrophotometry 
and an oscillometric blood pressure device. It measures different parameters of body 
composition, endothelial function (based on pulse wave velocity) and ANS activity 
(based on heart rate variability and sudomotor function) during baseline and the 
performance of cardiac autonomic function tests (i.e., Valsalva maneuver, deep 
breathing, and standing up).63,64  
Steps of the procedure are described elsewhere.63,64  Briefly, study staff, trained 
by the manufacturer, asked participants to sit on a confortable chair with their shoes and 
socks off, feet on the metal plates, right index finger in the pulse oximeter, and blood 
pressure cuff on the left arm. After inputting demographic, anthropometric and physical 
activity data, the software initiated the baseline assessment for 1-2 minutes while the 
participant was sitting down. Then the participant was asked to perform the Valsalva 
maneuver by clamping their nose with their left hand while trying to breath out for 15 
seconds with their mouth closed, building pressure like when popping ears. After 
releasing their nose, participants were asked to breath deeply for 30 seconds, inhaling for 
5 seconds and exhaling for 5 seconds. Finally, participants were asked to stand up, while 
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straightening their left arm to their side and keeping their index finger in the pulse 
oximeter, and remain standing up until the assessment was completed. The whole 
assessment lasted about 5 minutes.   
Details of the devices are discussed in previous publications and the 
manufacturer’s website (http://www.ldteck.com).63,64 The Electro-Sensor Body 
Composition (ES-BC) device uses a single-frequency bioelectrical impedance analyzer to 
compute %FM using accepted peer reviewed published algorithms tailored to the general 
and obese population based on gender, height, weight, age, and activity level.63,65-68  
The TM-Oxi system assesses cardiac ANS function, including both SNS and 
PNS, during baseline and validated cardiac autonomic reflex tests. It uses an automatic 
oscillometric blood pressure device and pulse oximeter, which uses an optical technique 
(spectrophotometry) to measure vascular dynamics and HRV, defined as the variation in 
time intervals between each heart beat (i.e., R-R interval).69,70 The assessment of HRV is 
a valid and useful method to measure cardiac ANS activity and identifies patients with 
cardiac ANS dysfunction, which places them at risk of cardiac events.69,70 Briefly, the 
pulse oximeter directs red and infrared light into the nail bed area of the right index finger 
and measures the change in light absorption, reflection, and scattering between systole 
and diastole creating a pulsatile signal or waveform, illustrated as a plethysmograph 
(PTG) that varies in time with each heartbeat. The TM-Oxi applies a mathematical 
algorithm, the Fast Fourier Transform (FFT), to the PTG recording (FFTPTG) to 
manipulate the beat to beat R-R intervals and convert the signal from a time domain to 
frequency domains. The frequency domains are then categorized by oscillating 
frequency, which are the three frequencies of HRV: (1) very low frequency (PTGVLF) 
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associated with thermoregulation and sweating that results in oscillation in vasomotor 
tone controlled by SNS; (2) low frequency (PTGLF) related to baroreflex that is under 
control of both SNS and PNS; (3) high frequency (PTGHF) associated with R-R interval 
changes due to breathing, which is under PNS control.64 The pulse oximeter and 
oscillometric blood pressure device are used to measure HRV and changes in blood 
pressure at rest and during cardiac ANS tests to assess SNS and PNS balance.  
PTG also provides information about arterial stiffness and endothelial function. 
The TM-Oxi system quantifies PTG into a digital volume pulse (DVP) waveform that 
represents the pressure wave that spreads from the heart to the periphery (systolic peak) 
and reflects back to the heart (diastolic peak) during the cardiac cycle.64,71-73 Arterial 
stiffness, which is partially a result of endothelial dysfunction, is defined as the 
opposition to the pressure wave in the arteries, resulting in abnormal systolic and 
diastolic peaks. Thus, the DVP waveform is mainly regulated by myocardial and arterial 
characteristics and is used by the software to calculate indicators of vascular health and 
arterial status.63,64  
The SudoPath system measures sudomotor activity, which is controlled by post 
sympathetic cholinergic nerve fibers (C-fibers) that innervate sweat glands, using 2 
stainless steel electrodes on which the participant places their soles of the feet, where a 
very high density of sweat glands are located.64 This system evaluates skin blood flow 
(microcirculation), C-fiber condition, and sweat gland activity using the galvanic skin 
response. The device generates a low voltage signal with weak DC current that 
electrically stimulates C-fibers, which release acetylcholine, and thus, stimulate nicotinic 
muscarinic receptors (M-receptors) in the skin and sweat glands.64,74 This causes a 
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change in blood flow and sweat production that disturbs the electrical conductance of the 
skin, which is then measured by the device using the principles of electrolysis as a marker 
for SNS function.64  
The software integrates these measurements with demographic, anthropometric 
and physical activity data to calculate a CMRS, which is categorized as normal (≤4,) mild 
(5-7), moderate (8-10), or high risk (≥11). Previous studies have shown the accuracy of 
these three devices, compared to standardized assessments of body composition, ANS 
activity, and cardiac output, and thus supporting the usefulness of these devices in 
detecting complications related to metabolic syndrome, diabetes and CVD.63 Recently, a 
study comparing diabetic and healthy controls showed that the CMRS calculated by this 
software is significantly correlated with glucose and insulin measured during an oral 
glucose tolerance tests (OGTT) and was significantly higher in participants with diabetes. 
Also, specificity (92%) and sensitivity (83%)  were high for the CMRS in differentiating 
patients with diabetes from healthy control.64  
 
Statistical Analysis 
Statistical analyzes were performed on 95 participants. Data were analyzed using 
frequencies, percentages, ranges, means, and standard deviations. Variables were checked 
for non-normality and, if necessary, they were transformed to achieve a normal 
distribution. Spearman correlations between two or more categorical variables were 
performed to evaluate the relationship of vitamin status with CMRS. Independent t-tests 
or chi-square were used to compare CMRS between vitamin D insufficient (25(OH)D 
<30 ng/ml) and sufficient (≥30 ng/ml) participants. Multiple linear regressions were used 
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to examine the effect size and the change in CMRS expected from a one-unit change in 
vitamin D levels after adjusting for potential confounders. The significance level was set 
at α=0.05, and statistical analyses were performed using SPSS 21. 
Results  
The mean ± SD 25(OH)D level was 30.71 ± 8.78, with 46.3% being insufficient 
(<30 ng/ml) and 53.7% being sufficient (≥30 ng/ml) (Table 1). Mean ± SD age of the 
participants was 63 ± 8.8 years, and 45% of participants were males, 45% Hispanic, 35% 
white Caucasian and 16% African American. Mean ± SD number of diseases reported 
were 4.73 ± 3.1.  The percent of participants who reported diagnoses of diseases/diorders 
related to the cardiovascular system are as follows:  3.2% had arrhythmia, angina or heart 
murmur; 38.9% high blood pressure; 4.2% low blood pressure; 33.7% high cholesterol; 
16.8% high triglycerides; 6.3% circulation problems; 7.4% shortness of breath; 2.1% 
chronic obstructive pulmonary disease; 4.2% chronic bronchitis; 3.2% type 1 diabetes; 
11.6% type 2 diabetes; and 2.1% hypoglycemia. Three-quarters reported taking 
prescription medications and 80% taking over the counter (OTC) medications with an 
mean ± SD number of 2.3 ± 2.2 and 1.5 ± 1.1 of prescription and OTC medications, 
respectively. In respect to health risk behaviors, 78.9%, and 11.6% reported caffeine and 
tobacco use, respectively. The mean ± SD number of alcoholic drinks consumed per 
week was 2.1 ± 3.7. 
The mean ± SD weight and BMI of the participants were 76.1 ± 17.1 kg and 
27.01 ± 5.3 kg/m2, respectively. Sixty-one percent of the participants had BMI ≥25 and 
the mean ± SD  %FM was 30.9 ± 9.1. The mean ± SD systolic and diastolic blood 
pressures were 132.6 ± 22.0 and 76.0 ± 14.5 mmHg, respectively, and the mean ± SD 
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heart rate was 70.4 ± 11.8 bpm. The mean ± SD CMRS was 5.17 ± 3.58, with 50.5% 
having normal CMRS scores while 22.1%, 17.9% and 8.4% of the participants having 
mild, moderate and high risk of CVD, respectively.  
There was a significant inverse correlation between vitamin D status and CMRS, 
with vitamin D insufficient participants having lower CMRS (r=-0.241, P=0.019). 
Participants who were vitamin D insufficient had a significantly higher CMRS compared 
with the vitamin D sufficient group (mean difference: 1.48, P=0.046) (Table 2).   
Multiple linear regressions were used to evaluate the effect of vitamin D status on 
CMRS (B (SE): -0.11 (0.05), 95% CI: -0.20; -0.02, P=0.016), after controlling for 
covariates (Table 3). In this fully adjusted model, CMRS was expected to decrease by 
0.11 points for every unit increase in vitamin D levels. Vitamin D and number of 
prescription medications predicted about 7% of the variation in CMRS.  
 
Discussion  
CVD risk and vitamin D status and the benefit of vitamin D supplementation on 
cardiovascular health is well established.5-10,12-16,18,19,75  The observations that vitamin D 
deficiency, cardiac ANS and endothelial dysfunction are independently linked to CVD-
related outcomes suggest a potential relationship between vitamin D deficiency and 
cardiovascular risk in diseased and healthy humans.5,18,40 Vitamin D affects multiple 
cellular signaling pathways via genomic and non-genomic actions that have the potential 
to affect cardiovascular health.76,77 These include vitamin D effects on PTH, RAAS, 
cytokine production, myocyte calcium influx, endothelial growth and function, and 
cardiac ANS activity.21 Our results support the findings from previous studies on the 
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association between vitamin D deficiency and CMRS, possibly by mediating genomic 
and non-genomic mechanisms that influence ANS activity and vascular function, thus 
affecting cardiac performance. This is the first study to investigate the relationship 
between vitamin D status and cardiometabolic risk, using a rapid, non-invasive method 
that integrates measures of ANS and endothelial function, anthropometrics, lifestyle 
characteristics, and body composition data. Previous studies have shown a relationship 
between vitamin D and cardiac ANS, independent of other cardiovascular risk factors 
like endothelial dysfunction and increased %FM.  
In humans, the relationship between vitamin D status and ANS function has been 
studied in diseased and healthy populations. For instance, in 36 patients with non-
ischemic dilated cardiomyopathy (NIDCM), 25(OH)D was positively correlated with 
HRV parameters, with vitamin D insufficiency having deleterious effects on cardiac ANS 
function.28 Krause et al.78 showed that patients with chronic kidney disease (CKD), who 
have impaired vitamin D synthesis, when exposed to short-term artificial sunlight 
heliotherapy had a significant increase in 25(OH)D levels and an elevation in 
measurements of vagal activity that were severely depressed at baseline. The magnitude 
of 25(OH)D increase was directly correlated with the magnitude of increased 
cardioprotective PNS activity, implying that vitamin D levels may constitute an important 
role in the development of common CVD-related outcomes in this population by 
affecting the ANS. Chan et al.79 reported that patients with CKD demonstrated poor 
cardiac ANS activity, which was characterized by decreased activity of the inhibitory 
PNS. Furthermore, in patients with end-stage kidney disease (ESKD), depressed HRV is 
extremely common and usually presents as suppressed PNS activity with increased SNS 
  189 
input to the sino-atrial node.26,79 For the dissertation by Mann,26 a cross-over study was 
conducted in which 56 participants with ESKD on hemodialysis were randomized to 
either conventional (0.25 mg alfacalcidol 3 times per week plus placebo 3 times per week 
for 6 weeks) or intensive (0.25 mg alfacalcidol 3 times per week plus 50,000 IU 
ergocalciferol once a week plus placebo 2 days per week for 6 weeks) vitamin D therapy 
followed by a 12-week washout period and another 6 weeks of vitamin D therapy. They 
did not observe significant changes in measures of cardiac autonomic tone, mineral 
metabolism or RAAS activity but an exploratory subgroup analysis found that after 
treatment, participants who remained vitamin D deficient (25(OH)D <20 ng/ml), 
compared to those who achieved sufficiency (> 30 ng/ml), had significant ANS 
imbalance.  In the ESKD population, abnormal HRV and ANS dysfunction is also 
common in this population; thus, putting them at higher risk of sudden arrhythmic 
death.79-85  
Currently, only one study has evaluated the relationship between vitamin D status 
and Cardiac Autonomic Neuropathy (CAN) in type 2 diabetics using cardiac autonomic 
reflex tests.29 In this study, several HRV parameters during ANS tests were assessed and 
scored as normal, borderline and abnormal to calculate a CAN risk score. They found that 
vitamin D deficiency (25(OH)D <10ng/ml) was significantly correlated with decreased 
HRV in the supine and upright position and those participants with vitamin D levels <10 
ng/ml had significantly increased CAN risk compared to those with 25(OH)D between 
10-20 ng/ml.29   
In a healthy Korean population over the age of 20 years, investigators observed 
that 25(OH)D was positively associated with decreased HRV.27 They observed that 
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vitamin D deficient individuals (25(OH)D <15 ng/ml) were 3.1 times more likely to have 
low HRV.  In 2013, Mann et al.24  used power spectral analysis of electrocardiogram 
recordings to measure HRV and thus assess cardiac ANS activity at baseline and during a 
graded angiotensin II challenge in 34 healthy humans. They found a significant 
suppression of ANS balance in vitamin D deficient (25(OH)D <20 ng/ml) participants at 
baseline, but no difference was observed during the challenge. In an intervention study, 
the same group demonstrated that healthy adults supplemented with 10,000 IU of vitamin 
D for four weeks had a significant improvement in cardiac ANS balance, specifically in 
enhancing the cardio-protective PNS activity.25  
Besides the link between vitamin D and ANS, 25(OH)D levels have been 
independently associated with several tests of endothelial dysfunction, arterial stiffness, 
and coronary flow reserve.86,87 In addition, studies have demonstrated that vitamin D 
treatment improves arterial stiffness as measured by pulse wave velocity.88,89 Thus, 
vitamin D may affect vascular tone and blood pressure indirectly via modulation of 
cardiac ANS activity or directly by affecting endothelial function.  
Our study, like other cross-sectional and longitudinal studies, supports a 
relationship between low vitamin D metabolites and cardiovascular risk.21 Cross-
sectional studies are descriptive in nature, and even though they can establish association 
among factors, they do not prove cause and effect. Thus, these associations may be 
confounded by reverse causality, as cardiovascular outcomes may affect vitamin D status. 
Interventional studies until today show a modest effect of vitamin D on hypertension and 
equivocal impact on arterial stiffness, endothelial function, and ANS activity.21 Despite 
observational and mechanistic data, which support vitamin D having a protective role in 
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CVD, intervention studies to date are not promising. The mechanism by which vitamin D 
affects cardiovascular health is still unclear and the need for long-term intervention 
studies using cardiovascular events as a primary outcome is clear to provide answers to 
the many remaining questions. It is essential to determine if vitamin D supplementation 
has the potential for reversing the increase in CVD risk associated with vitamin D 
deficiency. Vitamin D supplementation may be a cost-effective treatment to improve 
ANS and endothelial function in healthy and chronic disease populations and thus reduce 
CVD risk. Based on the acceptance of preliminary findings on the effect of 
supplementation on CVD, a cost-benefit analysis has estimated a reduction of as many as 
a total of 336,000 deaths per year, including 180,000 deaths from CVD, if the United 
States adult population were to raise vitamin D levels above 40 ng/ml. This also 
translates into a reduction of about $130 billion per year in direct care costs.90   
Besides its cross-sectional nature, this study has other limitations. This study may 
suffer from selection bias. First, we included younger older adult participants (>55 years 
of age) to have a wider age range for recruitment purposes. Therefore, some of our 
participants were younger than what is considered “old age,” with 36% and 63.8% of our 
participants being under the age of 60 and 65, respectively, and thus, adding 
heterogeneity to our study. Nevertheless, we did not find a significant difference in age, 
number of participants over the age of 60, and number of participants over the age of 65 
between vitamin D insufficient and sufficient groups. Moreover, age was not a risk factor 
for vitamin D insufficiency or CMRS in this study population since it was not a 
significant predictor of any of these two variables in regression models.  Second, the 
participants in this study were mostly healthy, since the criteria for the parent study 
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excluded current diagnoses of numerous diseases/conditions that affect vitamin D 
metabolism and absorption, medications that disturb vitamin D metabolism, and current 
vitamin D supplement use. Our sample was not randomly selected from the general older 
adult population in Miami-Dade, but instead were healthier older adults who volunteered 
to participate and met inclusion criteria. The results of this study cannot be extrapolated 
to the general Miami-Dade older adult population, other populationa in the United States, 
or globally.   
An additional limitation of this study was the low adjusted R2, which assesses the 
percentage of the variation of the dependent variable that is explained by the linear 
regression model. Even though it is indicative of how well the linear model fits the 
observations, it doesn’t provide a hypothesis test for this relationship. A low adjusted R2 
means that the model is not precise. However, if the adjusted R2 is low but the predictors 
are statistically significant, conclusions can still be drawn about the relationship between 
the dependent variable and predictors. Thus, highly variable data, as indicated by low 
adjusted R2, can still have a significant trend that indicates the dependent variable is 
affected by the predictors.  
Furthermore, vitamin D is part of complex mineral metabolism functions that 
involves measures known to influence cardiovascular risk, including PTH, phosphate, 
and calcium. Our study did not measure any of these potential intermediaries between 
vitamin D and cardiovascular health. PTH, possibly through alteration in calcium 
homeostasis, has been associated with cardiomyocyte hypertrophy, increased myocardial 
contractility, calcification of heart valves and myocardium, and arterial stiffness, and 
predisposition to increased blood pressure.91-93 Also, these studies did not measure 
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biomarkers that are clinically established as risk factors for CVD, such as cholesterol, 
triglycerides, glucose, hemoglobin A1C, and others. Moreover, we did not find a 
significant association between vitamin D and self-reported CVD outcomes that may 
affect CMRS, such as hypertension, dyslipidemia and diabetes. Thus, future studies need 
to consider measuring other biomarkers related to vitamin D and mineral metabolism to 
examine the possible mechanism by which this nutrient may affect cardiovascular health. 
The ESC system software may need to be updated to include cardiometabolic biomarker 
information integrated into the calculation of CMRS.  
Finally, although plethysmography and pulse wave velocity have been considered 
valid tools for measuring HRV and arterial stiffness to evaluate ANS activity and 
endothelial function, no one parameter has been established as superior in their predictive 
ability as surrogate marker for adverse cardiovascular outcomes.69,94-97 Although short-
term analysis of HRV and endothelial function at rest may provide significant prognostic 
value, it limits the comparison of HRV parameters obtained during various activities that 
can challenge the cardiac ANS like exercise and sleep. Thus, it only measured relative 
changes in ANS activity rather than the absolute intensity of SNS and PNS activity.  An 
advantage of this study, however, is the use of established tests of cardiac autonomic 
reflex that have been validated to detect CAN, by measuring changes in HRV and 
vascular dynamics during different challenges to the body.  
 
Conclusions 
Our study found a significant association of vitamin D status with CMRS, 
calculated from composite measures of body composition, ANS activity, and endothelial 
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function by using a novel system. Thus, data suggest that vitamin D may play a 
significant role in CVD, probably through modulation of cardiac performance by 
affecting ANS activity, vascular tone, and endothelial function. Due to the nature of this 
cross-sectional study, we cannot conclude that vitamin D deficiency is a cause of 
increased cardiovascular risk. Future prospective randomized control studies, with 
sufficient resources, are warranted to evaluate the change in cardiometabolic risk in 
vitamin D insufficient older adults supplemented with vitamin D and to examine the 
cause-effect relationship.   
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Table 1: Characteristics of Participants (n=95) 
Vitamin D levels (ng/ml) (Mean ± SD) 30.71 ± 8.78 
Age (years) (Mean ± SD) 62.96 ± 6.45 
Male gender (N (%)) 43 (45.3) 
Ethnicity (N (%)) 
  Hispanic  
  White Caucasian 
  African-American 
  Other 
 
43 (45.3) 
33 (34.7) 
15 (15.8) 
4 (4.2) 
Years lived in the United States (Mean ± SD) 44.98 ± 21.62 
Number of diseases or conditions (Mean ± SD) 4.73 ± 3.05 
Participants reporting prescription medication use (N (%)) 71 (74.7) 
Number of prescription medications (Mean ± SD) 2.27 ± 2.21 
Participants reporting OTC medication use (N (%)) 76 (80.0) 
Number of OTC medications (Mean ± SD) 1.47 ± 1.12 
Caffeine consumers (N (%)) 75 (78.9) 
Cups of caffeinated coffee or caffeine containing beverages per 
day (Mean ± SD) 1.64 ± 1.38 
Alcoholic drinks per week (Mean ± SD) 2.11 ± 3.70 
Smokers (N (%)) 11 (11.6) 
Weight (kg) (Mean ± SD) 76.12 ± 17.11 
BMI (kg/m2) (Mean ± SD) 27.01 ± 5.27 
%FM (Mean ± SD) 30.92 ± 9.09 
SBP (mmHg) (Mean ± SD) 132.60 ± 21.97 
DBP (mmHg) (Mean ± SD) 76.03 ± 14.48 
HR (bpm) (Mean ± SD) 70.43 ± 11.83 
Total physical activity (IPAQ MET minutes per week) 
(Mean ± SD) 
4353.75 ± 
4333.15 
Depressive symptoms (BDI score) (Mean ± SD) 7.21 ± 7.62 
 SD: Standard Deviation; N: Number; BMI: Body Mass Index; FM: Fat Mass; SBP: 
Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HR: Heart Rate; bpm: beats 
per minute; IPAQ: International Physical Activity Questionnaire; BDI: Beck 
Depression Inventory. 
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Table 2: Comparison of Cardiometabolic Risk Scores (CMRS) Between Vitamin D 
Insufficient and Sufficient Participants 
 
Study 
population 
(n=95) 
Vitamin D 
Insufficient 
<30 ng/ml 
(n=44) 
Vitamin D 
Sufficient 
≥ 30 ng/ml 
(n=51) 
MD P-Value 
CMRS 
(Mean ± SD) 5.17 ± 3.58 5.95 ± 3.29 4.48 ± 3.72 1.48 0.046 
Independent t-tests.  SD: Standard Deviation; MD: Mean  Difference.  
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Table 3: The Relationship Between Vitamin D Levels and CMRS in Multiple 
Linear Regressions 
 β (S.E.) P-Value Adjusted R2 
Model 1 Vitamin D status (ng/ml) -0.09 (0.05) 0.056 0.029 
Model 2 
Vitamin D status  (ng/ml) 
Number of prescription medications 
-0.11 (0.05) 
0.37 (0.17) 
0.016 
0.029 
0.069 
Stepwise linear regression.  Dependent variable:CMRS. Model 1: Vitamin D status; Model 2: Model 1 
+ age, gender, marital status, race, years living in United States, education, employment, income, 
surgery, injury, falls, number of diseases, presence of  diseases that can affect cardiovascular system 
(arrhythmias, high blood pressure, low blood pressure, high cholesterol, high triglycerides, circulation 
problems, stroke, COPD, bronchitis, shortness of breath, type 1 and type 2 diabetes, hypoglycemia), 
prescription medications, over the counter medications, vitamin/ mineral supplement use, coffee use, 
alcohol use, smoking, depressive symptoms, fear of falling, physical activity. β: Beta Coefficient; SE: 
Standard Error; CI: Confidence Interval. 
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 CHAPTER VII: SUMMARY AND CONCLUSIONS 
 
Our study showed that vitamin D insufficiency is common in healthy community-
dwelling older adults (>55 years old) living in Miami-Dade County, especially among 
Hispanics. The prevalence of vitamin D deficiency (25(OH)D <20 ng/ml) and 
insufficiency (25(OH)D <30 ng/ml) was 10% and 36%, respectively, which, as expected, 
was lower than that reported for the general United States  adult and older adult 
population. This was expected in a population that has a greater opportunity for vitamin 
D skin synthesis due to year-round sunlight availability. Our results, however, are similar 
to that reported in previous studies conducted in South Florida.1,2  
Despite the lower prevalence of vitamin D insufficiency in this study compared to 
the general United States older adult population, it is still a public health concern, and 
identifying risk factors is critical to develop effective interventions. As expected, vitamin 
D intake was not significantly correlated with vitamin D status in our study, and our 
findings are supported by other studies that have previously shown that dietary intake has 
minimal contribution to vitamin D status.3,4 On the other hand, we found that lack of sun 
exposure, higher percent fat mass (%FM), and lack of use of vitamin/mineral 
supplements were risk factors for vitamin D deficiency in this older group. Ethnicity, 
however, was the most consistent and important risk factor in this study population, since 
those who were vitamin D insufficient were more likely to be Hispanic, and thus 
Hispanics had significantly lower vitamin D levels than white Caucasians and African-
Americans.  The reasons why immigrant Hispanics may be more likely to be vitamin D 
deficient and insufficient are unknown, but it may be due to differences in sun exposure 
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behaviors, public health awareness initiatives in their home countries and less access to 
healthcare services due to their immigration status. Since vitamin D deficiency is linked 
to health risk factors, it is important that health professionals become aware of the 
connections of vitamin D status with intake, bioavailability, and skin synthesis, so that 
they are able to identify patients at risk and develop and plan pertinent interventions to 
prevent and correct deficiency and insufficiency, especially in vulnerable populations like 
Hispanics.    
Vitamin D deficiency in older adults has been linked to leading causes of 
disability and death in the United States including cancer, diabetes, falls, fractures, and 
cardiovascular disease (CVD).5-14 Vitamin D deficiency has received much attention as a 
risk factor for falls because of its association with gait impairment (slower gait speed), 
global cognitive deficits, and compromised executive function.15-19 Nonetheless, studies 
that investigate the relationship between vitamin D status, gait and cognition have looked 
at these factors independently. We used the dual task physical performance test to assess 
the relationship between vitamin D and cognition, especially executive function, in the 
context of mobility. We evaluated the competition for information processing capacity 
between gait stability during the primary automatic task (i.e., walking) and cognitive 
performance during the completion of the secondary cognitive task (i.e., counting 
backwards from 50 by 1). Dual tasking usually results in worse performance in either one 
or both tasks when compared to performance of each task individually.20 As 
hypothesized, in our study we found a marked deterioration of the automatic primary 
motor task during dual tasking, and not the secondary cognitive task, when compared to 
single tasking. Thus, when dual tasking, this healthy older adult population prioritized the 
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secondary cognitive task at the expense of compromising their motor capacity. Despite 
these findings, we did not find a significant assocation between vitamin D status and the 
change in peformance in cogntive and gait tasks from dual to single tasking; thus, vitamin 
D insufficient participants did not have worse dual task performance. No signficant 
differences were found between vitamin D status in motor functioning during each 
individual task. Interestingly, we found counting rates were significantly lower in the 
vitamin D insufficient group, meaning they had worse cognitive performance, since they 
counted significantly less figures per second compared to the vitamin D sufficient group 
when performing either single or dual tasks. Since counting backwards is a mental 
tracking task, which is a component of executive function, our results support a 
relationship between vitamin D insufficiency and impaired executive function. Executive 
dysfunction has been previously associated with fall risks in the elderly, and it could be a 
possible mediator between vitamin D and falls.21 Our data suggest that cognition may 
play a signifcant role in vitamin D’s influence on falls, while motor function may play a 
lesser role in healthy young older adults.22 
Furthermore, our results support previous studies that found an association 
between vitamin D deficiency and cardiometabolic risk, We found a significant 
association of vitamin D status with cardiometabolic risk score (CMRS), calculated from 
composite measures of body composition, autonomic nervous system (ANS) activity and 
endothelial function by using a novel system. Our data suggest that vitamin D may play a 
signifcant role on CVD, probably through modulation of cardic performance by 
mediating genomic and non-genomic mechanisms that affect ANS activity, vascular tone 
and endothelial function. This is the first study to investigate the relationship between 
  209 
vitamin D status and cardiometabolic risk, using a rapid, non-invasive method that 
integrates measures of ANS and endothelial function, anthropometrics, lifestyle 
characteristics, and body composition data. Previous studies have shown a relationship 
between vitamin D and cardiac ANS, independent of other cardiovascular risk factors 
like endothelial dysfunction and increased %FM.  
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CHAPTER VIII: STRENGTHS AND LIMITATIONS  
Cross-sectional studies can establish association among factors; however, they do 
not prove cause and effect. However, understanding the relationship between nutrition 
and disease is the foundation for developing interventions that seek to enhance nutritional 
status to prevent or ameliorate continued proliferation of chronic diseases during the 
process of aging. Thus, this study provides the foundation for future longitudinal 
interventional studies that investigate the cause and effect relationship between vitamin D 
status, nutritional supplementation, and non-skeletal outcomes such as cardiometabolic 
risk and falls associated with cognitive executive function during mobility.   
 Another limitation of this study was selection bias. Besides the expected higher 
sun exposure of this population, the broader age criterion could be a possible explanation 
for the lower prevalence of vitamin D insufficiency observed in our study. In addition, 
the participants in this study were healthier, since the exclusion criteria for the parent 
study included current diagnoses of numerous diseases/conditions. Thus, this was not a 
randomly selected sample from the general older adult population in Miami-Dade, but 
instead were healthier older adults who volunteered to participate and met inclusion 
criteria. Volunteer bias may be a strong limitation, as volunteers have been found to be 
more intelligent, have higher social status and the need for approval, and be less 
authoritarian and conforming than the general population.1  Furthermore, small sample 
size could have also affected the results of this study. Due to limitations of time and 
resources, we were only able to recruit 97 participants, reducing the power to detect 
significant differences in this study.  
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Other limitations include over-and under- reporting in surveys, the amount of 
error inherent to short food frequency questionnaires, and the lack of ecological validity 
of the dual task physical performance test and cardiometabolic risk assessment. Despite 
the limitations in study design and tools used, we did find significant findings in relation 
with vitamin D status and executive function and cardiovascular risk in this healthy 
young older adult population. This may indicate that healthy older adults may be at risk 
of developing health consequences from vitamin D insufficiency at a younger age and 
before any cognitive impairment and cardiometabolic risks are evident. Furthermore, the 
major strength of this study was that it used novel tests to assess non-skeletal outcomes 
that have been previously associated with vitamin D insufficiency and deficiency. These 
allowed for the evaluation of the relationship of vitamin D status with cognition in the 
context of mobility and with other risk factors for cardiovascular disease. Thus, future 
studies evaluating the relationship between this nutrient and nonskeletal health outcomes 
in the elderly should consider including younger older adults to determine the early onset 
of health consequences related to vitamin D status 
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CHAPTER IX: FUTURE RESEARCH 
Future double-blind longitudinal randomized controlled clinical trials, with 
significant resources to support a bigger sample size, are warranted to evaluate the 
determinants of vitamin D status, the long-term consequences of vitamin D 
deficiency/insufficiency, and the effect of vitamin D supplementation on non-skeletal 
outcomes in healthy middle-aged and older adults with vitamin D insufficiency and/or 
deficiency. This type of study is necessary to determine a causal relationship between 
vitamin D status and non-skeletal outcomes, such as cognition in the context of mobility 
(as measured by dual task physical performance tests) and cardiometabolic risk (as 
measured by a composite score involving several cardiovascular risk factors).  
This study provides data to support the need for further research that investigates 
the determinants of vitamin D status living in sunny South Florida.  Despite the lower 
prevalence of vitamin D insufficiency in this study compared to the general United States 
older adult population, it is still a public health concern. Identifying risk factors is critical, 
so that health professionals become aware of the connections of vitamin D status with 
intake, bioavailability, and skin synthesis. Thus, clinicians need to identify patients at risk 
of vitamin D deficiency and insufficiency and develop pertinent interventions in order to 
prevent and correct these, especially in vulnerable populations such as the immigrant 
Hispanic community. It is important to determine the barriers to sun exposure and 
vitamin D supplementation that makes this population vulnerable to vitamin D 
insufficiency and at risk of developing chronic diseases associated with this nutrient 
deficiency.  
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Findings from our study support further research that investigates the benefit of 
vitamin D supplementation in this population. Our results support a relationship between 
vitamin D deficiency and executive dysfunction, suggesting that cognition may play a 
signifcant role in vitamin D’s influence on falls, while motor function may play a lesser 
role in this healthy younger older adult population. Future interventions are warranted to 
determine if vitamin D deficiency is a cause of executive dysfunction that leads to 
decreased performance in mental tracking tasks during dual tasking. Furthermore, our 
study supports a relationship between vitamin D and cardiometabolic risk, suggesting 
vitamin D may mediate its effects on cardiovascular health through modulation of the 
autonomic nervous system (ANS) and vascular dynamics. Despite observational and 
mechanistic data, which support vitamin D having protective role in CVD, intervention 
studies to date are controversial. The mechanism by which vitamin D affects 
cardiovascular health is still unclear and the need for long-term intervention studies using 
cardiovascular events as a primary outcome is clear to provide answers to the many 
remaining questions. It is essential to determine if vitamin D supplementation has the 
potential for reversing the increase in CVD risk associated with vitamin D deficiency.  
Vitamin D supplementation may be a cost-effective treatment for improving 
and/or maintaining the health of both healthy and populations with chronic disease. This 
type of intervention may reduce the risk of developing chronic disease. A cost-benefit 
analysis has estimated a reduction of as many as a total of 336,000 deaths per year if the 
United States adult population were to raise vitamin D levels above 40 ng/ml. This also 
translates into a reduction of about $130 billion per year in direct healthcare costs.1 
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Table 1: Observational Studies Investigating the Association Between Vitamin D Status and Gait Velocity in Healthy 
Community-Dwelling Older Adults 
 Author, 
Year, Study 
Design 
Study 
Population 
Outcomes Conclusions 
1 Verreault et 
al. (2002)1 
Longitudinal 
(3 yrs.) 
628 
postmenopausal 
women (>65 
years old) from 
WHAS study in 
USA. 
25(OH)D (ng/ml) 
Gait velocity (time 
(s) to walk 4m at 
usual gait) 
No significant findings. 25(OH)D Continuous: mean  of 21.2 and 
median of 19.8. Categorical, 25(OH)D cut off groups and % 
sample:  <10: 12.4%. Baseline 25(OH)D to gait velocity: not 
significant (p value NR).  No association between low 25(OH)D 
and decline in gait velocity through time (<10ng/ml: p=0.98; 10-
21ng/ml: p=0.76). 
2 Zamboni et 
al. (2002)2 
Cross-
sectional 
269 adults (68-
75 years old) in 
Verona. Mean  
+/- SD age of 
women and men 
71.9+/-2.4 and 
71.8+/-2.1 
years. 
 
25(OH)D (ng/ml) 
Gait velocity 
(distance (cm) 
walked in 6 min. 
at normal velocity) 
No significant findings. 25(OH)D Continuous: mean +/- SD for 
women and men of 13.2+/-9.6 and 22.6+/-15.0, respectively. Men 
vs. women: p<0.001. 25(OH)D cut off categories and % sample: 
women <15: 50.8% and >15: 49.2%; men <15: 35.1% and >15: 
64.9%. Gait velocity: mean  distance +/-  SD for women and men 
of 340.9+/-64.2 and 391.2+/-69.4, respectively. Men vs., women: 
p<0.001. 25(OH)D to distance: not significant in men (r=0.04) and 
women (r= 0.13; both p>0.05). Difference in distance between 
25(OH)D <15 and  >15: not significant in men (p=0.214) and 
women (p=0.156). 
3 Bischoff-
Ferrari et al. 
(2004)3 
Cross 
sectional 
4100 adults (60-
90 years old) 
from NHANES 
1988-1994. 
Mean  +/- SD 
age: 71.4+/-7.9 
years. 
25(OH)D (ng/ml) 
 
Gait velocity (time 
(s) to walk 8ft 
(2.4m). 
Significant findings: lower 25(OH)D, slower gait velocity. 
25(OH)D continuous: mean  of 26.3. 25(OH)D quintiles and 
ranges: Q1: 3.5-17.4; Q2: 17.5-22.7; Q3: 22.7-27.8; Q4: 27.9-
34.4; Q5: 34.5-160.3. Gait velocity: mean  time +/-  SD (s) of 
3.7+/-1.6s. Difference in time between quintiles: p for trend 
<0.0001. Fully adjusted model: Q2-Q5 were significantly different 
(all p<0.05) from Q1 (p for trend <0.001). Regression plots: time 
decreased throughout range of 9.0-37.6ng/ml but most 
improvement between 9-16ng/ml 
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Table 1 continued. 
 Author, Year, 
Study Design 
Study 
Population 
Outcomes Conclusions 
4 Gerdhem et al. 
(2005)4 
Cross-sectional 
 
986 
ambulatory  
women (>75 
years old) 
from OPRA 
study in 
Sweden. 
 
25(OH)D 
(ng/ml) 
Gait velocity 
(time (s) to walk 
30m and turn 
back at fastest 
pace) 
Significant findings: lower 25(OH)D, slower gait velocity. 25(OH)D 
Continuous: mean +/- SD of 38+/-12. 25(OH)D cut off categories 
and % sample: <20: 4%; <30: 26%. Gait velocity: mean  time +/- SD 
for <20: 29+/-10; >20: 24+/-19 (difference: 19%); <30: 27+/-12; >30: 
24+/-7 (difference: 14%)). 25(OH)D to time: significant (r=0.17, 
p<0.001). Difference in time between groups: significant for both cut-
off values (p <0.001). 
5 Faulkner et al. 
(2006)5 
Cross-sectional 
389 women 
(>65 years 
old) from 
SOF in USA. 
Median age 
(IQR): 70 
years (67-75) 
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated from 
time (s) to walk 
6m at rapid or 
usual pace; m/s) 
No significant findings. 25(OH)D Continuous (ng/ml): median 
(IQR) of 25 (19.0-31.0). 25(OH)D cut off categories and % sample: 
<10: 2.6%. 25(OH)D quartiles and range: Q1: 7-22; Q2: 23-30; Q3: 
31-40; Q4: 41-220. Gait velocity: mean  +/- SD of 1.01+/-0.22. 
25(OH)D to gait velocity: not significant (p>0.05). Difference in Gait 
between quartiles: not significant (p trend= 0.784). 
6 Suzuki et al. 
(2008)6 
Cross-sectional 
2044 adults 
(>65 years 
old) in Tokyo. 
Mean  +/-  SD 
age of men 
and women: 
74.5+/-5.1 
and 75.4+/-
4.7 years, 
respectively. 
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated from 
time (s) to walk 
5m at normal 
velocity, m/s) 
Significant findings: lower 25(OH)D, slower gait velocity. 25(OH)D 
continuous: mean  +/- SD men and women of 28.5+/-5 and 24.2+/-
4.9, respectively. Men vs. women: p<0.001. 25(OH)D quartiles and 
ranges for men (Q1: <25; Q2: 25-29; Q3: 29-32; Q4: >32) and 
women (Q1: <21; Q2: 21-24; Q3: 24-28; Q4: >28). 25(OH)D cut of 
groups and % sample for men (< 20: 4.8%) and women (<20: 
17.7%). Gait velocity: mean  +/-  SD of men (1.23+/-0.26) and 
women: (1.18+/-0.29). Difference in gait between Q1 and Q4 and cut 
off groups: not significant in men, significant in women (both 
p<0.001). Adjusted model: significant in men: (p=0.012) and women 
(p<0.001) 
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Table 1 continued. 
 Author, 
Year, Study 
Design 
Study Population Outcomes Conclusions  
7 Annweiler et 
al. (2010)7 
Cross-
sectional 
739 women (>75 
years old) from 
EPIDOS study 
cohort in France. 
Mean  +/-  SD 
age: 80.2 +/-3.5 
years. 
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated 
from time (s) to 
walk 6m at 
usual and 
fastest) 
Significant findings: lower 25(OH)D, slower fast gait velocity. 
25(OH)D cut offs categories and % sample: <10: 17%; 10-20: 
55%; 20-30: 18%; >30:10%. Gait velocity: mean  +/- SD of usual 
and fastest 0.87+/-0.22 and 1.010+/-0.27, respectively. Difference 
in usual gait velocity between groups: not significant (p = 0.145). 
Difference in fast gait velocity between groups: significant (p = 
0.021, p trend 0.007). Adjusted model for fast pace: significant (β = 
0.18, p=0.033). 
8 Chan et al. 
(2012)8 
Longitudinal 
(4 yrs.) 
714 men (>65 
years old) from 
MrOS in Hong 
Kong. Mean  +/- 
SD age: 72.8 +/-
5.1 years.  
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated 
from time (s) to 
walk 6m at 
normal pace). 
No significant findings. 25(OH)D Continuous: mean  of 31.2. 
25(OH)D cut off categories and  % sample: < 20: 5.9%; 20-30: 
41.5%; > 30: 52.6%. 25(OH)D quartiles and ranges: Q1: <25; Q2: 
25.3-30.4; Q3: 30.5-36.5; Q4:>36.5. Difference in gait velocity 
between quartiles: not significant (p=0.08). Change at 4 years for 
ALL quartiles: not significant  (p=0.93).  
9 Boersma et 
al. (2012)9 
Cross-
sectional 
145 adult (>65 
years old) fallers 
in Australia. Mean  
+/-  SD age 
(range): 79.1+/-
7.8 years (73-88).  
25(OH)D 
(ng/ml) 
Gait velocity 
(measured 
using 
GAITRITE, 
m/s). 
Significant findings: lower 25(OH)D, slower gait velocity. 
25(OH)D cut off categories and % sample: < 12: 26%; 12-20:19%; 
>20:54%. Gait velocity: mean  +/-  SD of 0.55+/-0.5. Gait velocity 
difference between groups: significant (p<0.05). Adjusted model: 
significant (B=0.26, p=0.045). 
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Table 1 continued. 
 Author, 
Year, Study 
Design 
Study Population Outcomes Conclusions  
10 Kositsawat 
et al. 
(2013)10  
Cross-
sectional 
1826 adults (>50 
years old) from 
NHANES 2001-
2002. 
25(OH)D (ng/ml) 
Gait velocity 
(calculated from 
time to walk 20ft 
(6m) at usual 
velocity, m/s). 
Slow gait 
<0.8m/s  
Significant findings: lower 25(OH)D, slower gait velocity. 
25(OH)D cut off categories and % sample: <10: 30.8%; 10-19.9: 
19.7%; 20-29.9: 13.5%; >30: 10.1%. Difference in % subjects 
with slow gait velocity between all 25(OH)D groups: 
significantly higher in those with lower vitamin D (p trend 
<0.001). Difference in % subjects with slow gait velocity between 
<10 and >30:  <10 more likely than >30 to have slow gait 
velocity (<10: OR 2.77; CI 1.08-7.10: p=0.03; >30: ref). 
11 Mathei et al. 
(2013)11 
Cross-
sectional 
367 Caucasian 
adults (>80 years 
old) from BFc80+ 
study, Belgium. 
Mean  +/- SD age: 
84.7+/-3.6 
25(OH)D (ng/ml) 
Gait velocity 
(calculated from 
time  (s) to walk 
3m, turn around 
and walk back as 
quickly as 
possible; m/s). 
Converted into 
gender-adjusted 
quartiles, 
dichotomized 
into a score 
above or in the 
lowest quartile 
(<p25). 
No significant findings. 25(OH)D cut off categories and % 
sample: <10: 32.7%; 10-19: 32.9%; 20-29: 21.5%; >30: 12.8%. 
Gait velocity: 24.6% were in the lowest quartile of walking 
velocity. Difference % participants with walking velocity <p25 
between 25(OH)D groups: not significant (p=0.286). 
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Table 2: Interventional Studies Investigating the Effect of Vitamin D on Gait Velocity in Healthy Community-Dwelling 
Elderly 
 Author, 
Year, 
Study 
Design 
Study 
Population 
Intervention Outcomes Conclusions 
1 Kenny et al. 
(2003)12 
Double 
blind RCT 
65 men 
(>65 years 
old), in the 
USA. Mean  
+/-  SD age: 
76+/-4 
years. 
 
1. Placebo. 
2. 1000 
IU/day 
Vitamin D. 
All received 
500mg 
calcium. F/U 
6months. 
25(OH)D 
(ng/ml) 
Gait velocity 
(time (s) to 
walk 8ft) 
No significant findings. Baseline 25(OH)D for placebo and 
intervention: mean  +/-  SD of 23.6+/-7.5 and 26.0+/-6.7, 
respectively; Between groups: p=0.21. F/U 25(OH)D for 
placebo and intervention: mean  +/- SD of 22.6+/-6.8 and 
34.9+/-5.5, respectively. Baseline to F/U change in placebo 
and intervention: p>0.05 and p<0.001, respectively. Baseline 
gait velocity between groups: p=0.63. Difference in gait 
velocity between placebo vs. intervention at F/U: p =0.128; 
group x time p value = 0.678. 
2 Gallagher, 
J.C. 
(2004)13 
Double 
blind RCT 
48 adults 
(age 
inclusion 
not 
reported), 
including 
hysterectom
ized women 
in USA. 
Mean  age: 
72 years. 
1. Hormone 
treatment. 2. 
0.25ug 
calcitriol 
twice daily. 
3. Hormone 
treatment + 
calcitriol. 4. 
Placebo. F/U 
6 months for 
3 yrs. 
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated 
from time (s) 
to walk 5m at 
normal and fast 
velocity; m/s) 
No significant findings. Decline in timed walk at 3yrs: 
calcitriol vs. placebo: p>0.1. 
  
 223 
Table 2 continued.  
 Author, Year, 
Study Design 
Study 
Population 
Intervention Outcomes Conclusions  
3 Bunout et al. 
(2006)14 
Double blind RCT 
96 adults (>70 
years old) in 
Chile. Mean  +/- 
SD age: 76+/-4 
years.  
 
1. Control. 2. 
400IU/day 
only. 3. 
Training only. 
4. 400IU/day 
and training. 
All groups 
received 
800mg/ml 
calcium. F/U 
9 months. 
 25(OH)D 
(ng/ml) 
Gait velocity 
(Distance 
(m) walked 
at constant 
pace for 12 
min.) 
Significant findings: Increased distance 
(faster gait velocity) in vitamin D only group 
compared to control and in vitamin D 
supplemented groups (2 and 4) compared to 
non-supplemented. 25(OH)D at baseline for 
vitamin D supplemented and non-
supplemented: mean  +/- SD of 12.4+/-2.2 and 
13.1+/-2.7, respectively. 25(OH)D at F/U for 
vitamin D supplemented and non-supplemented 
groups: mean  +/-  SD of 25.8+/-6.4 and 
14.5+/-4.6, respectively; baseline vs. F/U: 
p<0.001. Gait velocity: between group 
difference at baseline: p=0.61. Difference in 
gait velocity between control vs. vitamin D only 
at F/U: significant (p<0.01). Difference in gait 
velocity in vitamin D supplemented vs. non-
supplemented at F/U: significant (p=0.02). 
4 Brunner et al. 
(2008)15 
Double blind RCT 
2301 
postmenopausal 
women (50-79 
years old) from 
WHI, USA 
 
 
1. Placebo. 
2.1000mg 
calcium 
carbonate + 
400IU vitamin 
D3 per day. 
F/U: 2 yrs. 
and 5 yrs. 
25(OH)D 
(ng/ml) 
Gait velocity 
(Time  (s) to 
walk 6m at 
usual 
velocity). 
Significant findings: Less increase in time to 
walk distance (smaller change in gait velocity) 
from baseline to F/U in the control group 
compared to intervention. Gait velocity: no 
difference between groups at baseline 
(p=0.114). Time difference between baseline 
and 5 years F/U: significant (mean  difference 
between groups: -.054 +/-26; p=0.030. 
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Table 2 continued.  
 Author, Year, 
Study Design 
Study 
Population 
Intervention Outcomes Conclusions  
5 Lips et al. 
(2010)16 
Double blind RCT 
226 adults (>70 
years) with 
25(OH)D 
between 6-20 
ng/ml. Mean  +/- 
SD age placebo 
and intervention: 
77.6+/-6.6 and 
78.5+/-6.2 years, 
respectively. 
1. Placebo. 2. 
Weekly oral 
8400 IU D3. 
F/U 16 weeks. 
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated 
from time (s) 
to walk 4m; 
cm/s) 
No significant findings. 25(OH)D at baseline for 
placebo and intervention: mean  +/- SD of 14.1+/-
5.5 and 13.7+/-4.4, respectively; mean  difference 
of 13; p>0.05. 25(OH)D at F/U for placebo and 
intervention: mean  of 14.0 and 26, respectively. 
25(OH)D difference in intervention from baseline 
to F/U: p<0.001. 25(OH)D difference between 
placebo and intervention at F/U: p<0.001. 
Difference in change in gait velocity from baseline 
to F/U between groups: not significant (p=0.717).  
6 Lagari et al. 
(2013)17 
RCT 
86 adults (65-95 
years old) in 
Miami Dade. 
Mean  +/-  SD 
age: 73.4+/-6.4 
years.  
1. 400 IU/day 
D3. 2. 2000 
IU/day D3. 
F/U 6 months 
25(OH)D 
(ng/ml) 
Gait velocity 
(calculated 
from time (s) 
to walk 4m 
at usual 
velocity). 
No significant findings. 25(OH)D at baseline for 
all: mean  +/-  SD of 33.0+/-10; not significantly 
different between groups within men and women 
(p=0.865 and p=0.832, respectively). 25(OH)D 
change at F/U: the change from baseline to follow 
up between groups was not significant for men and 
significant for women (p=0.208 and p=0.004). Gait 
velocity at baseline: not significantly different 
between groups for men (p=0.600) and women 
(p=0.628). Difference in change in gait velocity 
from baseline to F/U between groups: non-
significant for men and women (p=0.291 and 
p=0.438, respectively). 
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Table 3: Observational Studies Investigating the Association Between Vitamin D Status and Cognition in Healthy 
Community-Dwelling Older Adults 
 Author, 
Year, Study 
Design 
Study Population Outcomes Conclusions  
1 Przybelski 
et al. 
(2007)18 
Cross-
sectional 
32 adults in United 
States Mean  +/- SD 
age: 79.5+/-1.6 years. 
25(OH)D 
(ng/ml) 
Cognitive test: 
MMSE  
Significant findings: lower 25(OH)D, lower MMSE score. 
25(OH)D Continuous: Mean +/- SD of 21.6+/-1.6. 25(OH)D to 
MMSE score: significant (p=0.006). 
2 Buell et al. 
(2009)19 
Cross-
sectional 
3133 adults (65-99 years 
old) from NAME study 
in USA. Mean  +/-  SD 
age: 75.0+/-8.5 years. 
 
25(OH)D 
(ng/ml) 
Cognitive tests: 
NAART. 
WMS-III WLL, 
WMS-III LM, 
DSST, TMT-A, 
TMT-B, MA, 
WAIS-III BD, 
MR, COWA. 
Significant findings: lower 25(OH)D, worse cognitive 
performance, especially in executive function tests. 25(OH)D 
cut off categories and % sample: <10: 18%; 10- 20: 47%; >20: 
35%. 25(OH)D to cognitive tests: TMT-A ( p<0.03), TMT-B 
(p<0.02), DSST (p<0.001), MR (p<0.02), WAIS-III BD 
(p<0.04). Differences in cognitive test scores between 
25(OH)D groups: TMT-A (p<0.05), TMT-B (p<0.05). MR  
(p=0.03), DSST (p<0.01). 25(OH)D to executive function: 
significant (β =0.01, p=0.001). 25(OH)D to 
attention/processing velocity: significant (β = 0.01, p=0.03). 
3 Lee et al. 
(2009)20 
Cross-
sectional 
3369 men (40-79 years 
old) from EMAS, USA. 
Mean  +/- SD age: 60+/-
11 years.  
25(OH)D 
(ng/ml) 
Cognitive tests: 
ROCF, CTRM 
test, DSST. 
Significant findings: lower 25(OH)D, worse cognitive 
performance, especially for executive function tests. 
25(OH)D continuous: mean +/- SD of 25.2+/-12.4. 25(OH)D 
cut off categories and % sample: <10: 7.9%; 10-19.9: 32.8%; 
20-29.9: 30.5%; >30: 28.8%. Adjusted models, 25(OH)D to 
cognitive tests: only DSST significant (p<0.01). Difference in 
cognitive test scores between groups: significant for DSST 
(p<0/05). Locally weighted and spline regression: significant 
relationship between 25(OH)D and cognitive function, 
stronger at <14ng/ml.  
Table 3 continued. 
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 Author, 
Year, Study 
Design 
Study Population Outcomes Conclusions  
4 Llewellyn et 
al. (2009)21 
Cross-
sectional 
1766 community- dwelling 
and institutionalized adults 
(>65 years old) in England. 
Mean  +/-  SD age: 78.2+/-
8.6 years.  
25(OH)D 
(ng/ml) 
Cognitive tests: 
AMT Score. 
MCI defined as 
3 errors of 10.  
Significant findings: increased odds of MCI in the lower 
quartiles of 25(OH)D. 25(OH)D quartiles and ranges: Q1: 
3-12; Q2: 12-18; Q3: 18-26; Q4: 26-68. Cognitive status: 
12% MCI. Difference in odds for cognitive impairment of 
non-institutionalized participants between quartiles: 
significant (p trend =0.001). 
5 Wilkins et 
al. (2009)22  
Cross- 
sectional. 
60 adults (>55 years old) 
African and European 
Americans from ADRC study 
in United States Mean  +/- 
SD age: 74.99+/-8.2 years. 
25(OH)D 
(ng/ml) 
Cognitive tests: 
MMSE, SBT. 
 
Significant findings: lower 25OH, worse performance in 
SBT.  25(OH)D continuous: mean +/- SD of 21.59+/-7.8. 
25(OH)D cut off categories and % sample: <20: 52%; >20: 
48%. Difference in cognitive test scores between groups: 
significant for SBT only (p=0.016). 
6 Annweiler et 
al. (2010)23 
Cross-
sectional 
752 women  (>75 years old) 
from EPIDOS in France. 
Mean  +/- SD age: 80.4+/-3.6 
years. 
25(OH)D 
(ng/ml) 
Cognitive tests: 
SPMSQ score to 
define MCI 
(score <8). 
 
Significant findings: lower 25(OH)D, higher odds of MCI. 
Mean : 7.21+/-2.09. 25(OH)D cut off categories and % 
sample: <10: 17.2%; >10 82.8%. MCI: 10%. Difference in 
SPMSQ scores between groups: significant (p<0.001). 
Difference in % SPMSQ <8 (i.e.,MCI) between groups 
(p=0.006). Odds of having MCI when 25(OH)D <10: 
significant (adjusted OR=1.99, p=0.017) 
7 Llewellyn et 
al. (2010)24 
Longitudinal 
(6 yrs.) 
858 adults (>65 years old) 
from InCHIANTI study in 
Italy. Mean  +/-  SD age: 
73.8+/-6.4 years.  
25(OH)D 
(ng/ml) 
Cognitive tests: 
MMSE, TMT-
A, TMT-B. 
Significant findings: lower 25(OH)D, worse performance 
in cognitive tests, especially for executive function. 
25(OH)D cut off categories and % sample: <10: 20%; 10-
20: 42%; 20-30: 19%; >30: 18%. Cognitive score 
differences between groups: significant MMSE, TMT-A, 
TMT-B (all, p trend: p<0.001). Cognitive score differences 
between <10 vs. >20: significant MMSE  (p trend =0.02) 
and TMT-B (p trend =0.04). 
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 Author, 
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Study 
Design 
Study 
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Outcomes Conclusions  
8 Seaman
s et al. 
(2010)25 
Cross-
sectiona
l 
380 adults  
(55-87 years 
old) from 
ZENITH study 
in Europe. 
Mean  +/-  SD 
age: 68.1+/-4.1 
years. 
25(OH)D 
(ng/ml) 
Cognitive tests: 
SWM assessed 
by 4 parameters 
from CANTAB 
 
Significant findings: lower 25(OH)D, lower SWM scores. 25(OH)D 
continuous: mean +/- SD of 30.5+/-19.3. 25(OH)D cut off categories and 
% sample: <12: 12%; <20: 36%; <32: 64%. 25(OH)D tertiles and range: 
Q1: <19.1; Q2: 19.1-34.4; Q3: >34.4. 25(OH)D to 4 parameters of SWM: 
significant (all p<0.005). SWM scores of three assessments were 
significantly lower in subjects in Q3, but not Q2, compared to Q1 (p trend 
=0.084). 
9 Slinin et 
al. 
(2010)26 
Longitu
dinal 
(4.6 
yrs.) 
1376 men (>65 
years old) from 
MrOS in USA.  
 
25(OH)D 
(ng/ml) 
Cognitive tests: 
3MS <80 as 
MCI; decline 
>5 points in 
F/U. MCI as 
change in 
TMT-B at F/U. 
No significant findings. 25(OH)D cut-off categories and % sample: <30: 
75%. 25(OH)D quartiles and range:Q1: < 19.9; Q2: 20.0-25.09; Q3: 25.1 
-29.79; Q4: >29.8. Cognitive status: baseline 3.4% and F/U 22.8% MCI 
per 3MS, and baseline 9.3% and F/U 8.0% per TMT=B. Adjusted models, 
Difference in odds of MCI (3MS) between quartiles: not significant (p 
trend: p=0.97). Difference in odds of MCI (TMTB) between quartiles: not 
significant (p trend: p=0.96). Difference in odds of incident MCI (3MS) 
between quartiles: not significant (p trend = 0.10). Difference in odds of 
incident MCI (TMTB) between quartiles: not significant (p trend >0.5). 
10 Chan et 
al. 
(2011)27 
Case 
control 
939 men (>65 
years old) from 
Os Study in 
Hong Kong. 
Mean  +/-  SD 
age: 75.2+/-5.3 
years. 
25(OH)D 
(ng/ml) 
Cognitive tests: 
MCI defined by 
CSI-D < 28.4. 
 No significant findings. 25 OHD Continuous: mean +/- SD for No MCI 
of 31.2+/-8.3 and MCI of  31.6+/-7.6. 25(OH)D cut off categories and % 
sample: <20: 6%; 20-30: 42%; 30-40: 39%; >40: 14%. 25(OH)D 
quartiles and range: Q1: <25; Q2: 26-30; Q3: 31-36; Q4: >37. Cognitive 
status: 94% No MCI, 6% MCI. Difference in 25(OH)D levels in No MCI 
vs. MCI: not significant (p=0.735). Difference MCI odds per quartiles: 
not significant (p trend= 0.843). per groups: not significant (p 
trend=0.911). 
Table 3 continued. 
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Study 
Design 
11 Llewellyn 
et al. 
(2011)28 
Cross-
sectional 
3396 adults (age 
inclusion not reported) 
from NHANES 1988-
1994. Mean  +/-  SD 
age: 73.7+/-10.9 years. 
25(OH)D (ng/ml) 
Cognitive tests: Global cognitive 
function score from sum of 6 tests 
including: 
MMSE, East BMT, and WAIS. 
MCI defined as lowest 10% of the 
distribution of cognitive 
performance.   
Significant findings: higher odds of MCI 
in lower 25(OH)D groups. 25(OH)D cut 
off categories and % sample: <10: 1.8%; 
10-20: 21.8%; 20-30: 39.0%; >30: 37.5%. 
Adjusted model: Difference in odds for 
MCI between 25(OH)D group: (p 
trend=0.03). Difference in odds for MCI 
between 25(OH)D <20 vs. >20: p 
trend=0.002. Cognitive status: 90% No 
MCI and 10% MCI.  
12 Annweiler 
et al. 
(2012)29 
Cross-
sectional 
95 non demented  
Caucasian adults (age 
inclusion not reported) 
with subjective memory 
complaint from GAIT 
study in France. Mean  
+/-  SD age: 71.1+/-6.4 
years. 
 
25(OH)D (ng/ml) 
Cognitive tests: MCI diagnosed by 
multidisplinary meetings with 
geriatricians, neurologist and 
neuropsychologists based on 
standardized neuropsychological 
tests, physical examination, blood 
tests and MRI brain imaging. MCI 
diagnosed according to Winblad et 
al. criteria.  
Significant findings: higher odds of MCI 
in lower 25(OH)D quartiles. 25(OH)D 
Continuous: mean +/- SD of 25.2+/-12.1 in 
all, MCI: 21.4+/-8.7 in MCI and 28.3+/-
13.7 in healthy. 25(OH)D quartiles and 
ranges: Q1: 4-16; Q2: 16-23.6; Q3: 24.0-
31.7; Q4: 32.1-75.7. Cognitive status: 45% 
MCI. Difference in 25(OH)D levels 
between MCI and healthy: significant (p = 
0.006). Fully adjusted model: Difference in 
odds for MCI between quartiles: 
significant (p trend =0.003) and between 
each quartile compared to ref (all p<0.03). 
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13 
 
 
 
Slinin et al. 
(2012)30 
Longitudinal 
(2 and 4 yr) 
6257 Caucasian 
women (>65 
years old) from 
SOF in United 
States Mean  +/-  
SD age: 76.6+/-
4.7 years.  
25(OH)D (ng/ml) 
Cognitive tests: 
3MS to define 
MCI as score 
<21.6 and TMT-
B to define MCI 
as >250s  
 
Significant findings: higher odds of MCI at baseline and 
cognitive decline at F/U, defined by MMSE, in those with lower 
25(OH)D, not significant when MCI defined by TMT-B. 
25(OH)D cut off categories and % sample: <10: 7.3%; 10-19.9: 
32.7%; 20-29.9: 38.6%; >30: 21.4%. Cognitive status: 7.2% MCI 
with both tests. Full adjusted models, Difference in odds of MCI 
at BL (MMSE) between groups: significant (p trend = 0.029). 
Difference in odds of cognitive decline at F/U (MMSE) between 
groups: significant (p trend=0.003). Difference in odds of MCI at 
baseline (TMT-B) between groups: not significant (p trend = 
0.314). Difference in odds of cognitive decline at F/U (TMT-B) 
between groups: (p trend = 0.931) 
14 Brouwer-
Brolsma et al. 
(2013)31 
Cross-
sectional 
127 adults (>65 
years old) frail 
or prefrail from 
ProMuscle 
Study in 
Netherlands. 
Mean  +/- SD 
age:  79+/-7.6 
years.  
25(OH)D (ng/ml) 
Cognitive tests: 
MMSE, WLT, 
WDS forward 
and backward 
test, TMT-A, 
TMT-B, ST, VF, 
RT. 
Significant findings: lower 25(OH)D, worse cognitive 
performance in executive function test. 25(OH)D continuous: 
mean  of 21.6. 25(OH)D cut off categories and % sample: <12: 
17%; <20: 53%; <30: 77%. 25(OH)D tertiles and range: T1: 5.2-
15.2; T2: 15.2-26.0; T3: 26.0-65.3. Difference in cognitive test 
score between tertiles: significant for VF and RT combined 
(p=0.04) and TMT-A and B combined (p=0.05). Fully adjusted 
model: significantly better performance in executive function per 
0.4ng increase in serum 25(OH)D (B: 0.007, p=0.01). 
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15 Annweiler et al. 
(2014)32 
Cross-sectional 
100 Caucasian 
adults (>60 
years old) with 
memory 
complaint in 
France. Mean  
+/-  SD age: 
71.02+/-0.74 
years. 
25(OH)D (ng/ml) 
Cognitive tests: 
MMSE, TMT-B, N-
back test, ST, Go/No-
Go. 
Signficant findings: lower 25(OH)D, worse cognitive 
performance, especially in mental flexibility. 25(OH)D 
continuous: mean +/- SD of 24.2+/-1.6. 25(OH)D cut off 
categories and %sample: <10: 6%; 10-20: 36%; >20: 
58%. Cognitive test scores differences between group: 
not significant for MMSE, N-back test, ST, and Go/No-
Go (p>0.05 for all) and significant for TMT-B 
(p<0.001) Fully adjusted model: TMT-B significantly 
associated with 25(OH)D <10: B: 1.48; CI: 0.36-2.61; 
p=0.011. 
16 Chei et al. 
(2014)33 
Cross-sectional 
2004 adults 
(>60 years old) 
from CLHLS 
study in China. 
Mean  +/-  SD 
age: 84.9+/-
12.7 years.  
25(OH)D (ng/ml) 
Cognitive tests: 
Chinese version of 
MMSE to categorize 
MCI (score <30). 
 
Significant findings: those with MCI had lower 
25(OH)D and odd of MCI is greater in low 25(OH)D. 
25(OH)D continuous: mean +/- SD of 17.3+/-7.9 in all, 
12.8+/-6.1 in MCI and 18.2+/-7.8 in No MCI. 25(OH)D 
quartiles and ranges: Q4: 2.3-12.7; Q3: 12.7-17.2; Q2: 
21.2-22.8; Q1: 22.8-83.6.  Cognitive status: 18% MCI 
and 82% No MCI. Difference in 25(OH)D between MCI 
and No MCI: Significant (p=0.001). Difference in odds 
of MCI between quartiles: significant, (p trend =0.05). 
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17 Hooshmand et 
al. (2014)34 
Cross-sectional 
75 adults (age 
inclusion not 
reported) in 
Sweden. Mean  
+/-  SD age: 
61.6+/-9.1 
years. 
25(OH)D (ng/ml) 
Cognitive tests: 
Dementia and AD: 
DSM-IV and 
NINCDS-ADRDA. 
MCI: not demented, 
report of cognitive 
impartment but 
preserved basic ADL. 
SCI: subjective 
complaints, objective 
impairment cognitive 
tests. 
Significant findings: lower 25(OH)D in MCI groups 
and higher odds of MCI with lower 25(OH)D. 
25(OH)D Continuous: mean +/ SD of 67.3+/-26.5, 
median (IQR) for AD of 24.0 (19.0, 28.8), MCI of 
24.2 (16.5, 29.8) and SCI of 28.0 (24.0, 38.5). 
Difference in 25(OH)D between cognitive groups: 
significant difference between SCI vs. AD (p=0.014) 
and SCI vs. MCI (p=0.027) The OR for worse 
cognitive status for each increase of 0.4ng/ml in 
25(OH)D was 0.972 (CI 0.953-0.991). 
18 Schneider et al. 
(2014)35 
Cross-sectional 
and 
longitudinal (3 
and 10.6 years) 
1652 adults 
(45-65 years 
old) from 
ARIC study in 
United States 
Mean  +/-  SD 
age: 62.3+/-
4.45 years.  
 
25(OH)D (ng/ml) 
Cognitive tests: 
DWRT, DSST, VF 
No significant findings. 25(OH)D Continuous: mean 
+/- SD for whites of 25.5+/-7.9 and blacks: 17.3+/-
6.3. 25(OH)D tertiles and ranges: whites (T3: <21.8; 
T2: 21.8-28.3; T1: >28.3) and blacks (T3: > 19.3; T2: 
14.0-19.3; T1: <14.0). 25(OH)D to cognitive test 
score in whites or in blacks: not significant (all 
p>0.05). Difference in 25(OH)D levels between 
quintiles of cognitive decline on all of the cognitive 
tests in white or blacks at either 3 years or 10.6 years: 
not significant (all p>0.05). Association of 25(OH)D 
with linear change in cognitive test scores: not 
significant (all p>0.05) 
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19 Toffanello et 
al. (2014)36 
Cross-
sectional and 
Longitudinal  
(4.4 years) 
1927 Caucasian 
adults  (age 
inclusion not 
reported) from Pro 
V.A. study in Italy. 
Mean  +/-  SD age: 
73.9+/-6.7 years.  
25(OH)D (ng/ml) 
Cognitive tests: 
MMSE to define 
MCI as score <24. 
A decline of 3 or 
more points at F/U 
defined as 
substantial cognitive 
decline.  
 
Significant findings: lower 25(OH)D, worse MMSE 
scores, MCI and cognitive decline. 25(OH)D Continuous: 
mean +/- SD of 33.7+/-21.6. 25(OH)D cut off categories 
and % sample: <20: 27.9%; 20-30: 22.4%; >30: 49.7%. 
Cognitive status: 31% MCI. Difference in MMSE scores 
between groups at baseline: Significant (p<0.0001). Those 
with lower 25(OH)D were more likely to be cognitively 
impaired (p=0.0001). Difference in MMSE scores between 
groups at 4.4 year F/U: <20 more likely of cognitive decline 
than >30 (RR: 1.26; CI: 1.09-1.52,p=0.005). 
20 Wilson et al. 
(2014)37 
Cross-
sectional and 
longitudinal 
(4 years) 
2777 adults (70-79 
years old) from 
Health ABC cohort 
in United States 
Mean  +/-  SD age: 
73.6+/-2.9 years.  
25(OH)D (ng/ml) 
Cognitive tests: 
3MS, DSST 
Significant findings: lower 25(OH)D, worse cognitive 
performance but not greater cognitive decline. 25(OH)D 
cut off categories and % sample: <20: 32.9%; 20-30: 
35.5%; >30: 31.6. Baseline (adjusted model): 25(OH)D<20 
scored lower on 3MS (p=0.02) and DSST than 25(OH)D> 
30 (p=0.01). 4 year F/U (adjusted model): 25(OH)D to 
cognitive decline defined by 3MS and DSST: not 
significant. 
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Table 4: Observational Studies Investigating the Association Between Vitamin D Status, Gait Velocity and Cognition 
(Independently) in Healthy Community-Dwelling Older Adults 
 Author, 
Year, 
Study 
Design 
Study 
Population 
Outcomes Conclusions  
1 Beauchet et 
al. (2011)38 
Cross-
sectional 
411 adults 
(>65 years 
old) in 
France. 
Mean  +/- 
SD age: 
70.4 +/-1.8 
years. 
25(OH)D (ng/ml) 
Gait velocity: SMTEC system: 
footswitches to measure temporal step 
parameters. One trial at usual velocity 
calculated from the Timed Up and Go 
test (m/s). Cognitive tests: Abnormal 
episodic memory (6 memory items 
from MMSE; score < 6) and abnormal 
CDT were considered as cognitive 
impairment. 
Significant findings: lower 25(OH)D, slower 
velocity. No significant findings with cognition. 
25(OH)D cut off categories and % sample: <10: 
16.6%; 10-30: 70.3%; >30: 13.1%. % Cognitive 
impaired in each group: <10: 48.5%; 10-30: 
39.8% >30: 38.9% Difference in gait velocity 
between groups: significant (p=0.003). Difference 
in gait velocity between  <10 vs. >30: significant 
(p=0.002). Difference in % cognitive impaired 
between groups: not significant (p=0.394). 
2 Houston et 
al. (2011)39 
Cohort 
307 adults 
(70-89 years 
old) from x 
LIFE-P 
study in 
United 
States Mean  
+/-  SD age: 
76.7+/-4.3 
years.  
25(OH)D (ng/ml) 
Gait velocity: time (s) to walk 400m 
by walking 10 times 20m. 
Cognitive tests: MMSE 
Significant findings: lower 25(OH)D, slower gait 
velocity. No significant findings with cognition. 
25(OH)D continuous: mean  of 20.9. , 25(OH)D 
cut off categories and % sample: <20: 50% and 
>30 ng/ml 10%. Difference in gait velocity 
between <20 vs. >20: significant (p=0.01). 
Difference in MMSE between groups: not 
significant (p = 0.17). Change in vitamin D status 
in 12 months association with changes in gait 
velocity:  not significant for increase or decrease 
(p = 0.64 and p=0.13). 
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Table 4 continued. 
 Author, 
Year, Study 
Design 
Study 
Population 
Outcomes Conclusions  
3 Houston et al. 
(2012)40 
Longitudinal 
(2,4 6 yrs.) 
2307 adults 
(70-79 years 
old) from 
Health ABC 
study in 
United 
States Mean  
+/-  SD age: 
74.7+/-2.9 
years.  
25(OH)D (ng/ml) 
Gait velocity: calculated from time to 
walk 20m at usual velocity (m/s)  
Cognitive tests: 3MS 
Significant findings: lower 25(OH)D, slower 
gait. Lower 25(OH)D, lower MMSE scores. 
25(OH)D cut off groups and % sample: <20: 
32.3%; 20-30: 35.0%; >30: 32.7%. Difference 
in MMSE between groups at BL: Significant 
(p<0.001). Difference in gait velocity between 
groups at baseline: significant (p<0.001). 
25(OH)D threshold for gait velocity: 33.2 
(27.2-39.1) ng/ml (p<0.0001). Adjusted model: 
gait velocity difference between <20 vs. >30: 
significant (p<0.001 and p trend =0.003). 
Those who at baseline had <20 had slower gait 
velocity at 2, 4, 6 years compared to >30 
(p<0.01 for all). 
4 Peterson et al. 
(2012)41 
Cohort 
159 adults 
(>70 years 
old) from 
ISAAC 
study in 
United 
States Mean  
age: 85.5 
years.  
25(OH)D (ng/ml) 
Gait velocity: Tinetti gait velocity, 
m/s. 
Cognitive tests: CDR to define MCI as 
<0.5. DSF, DSST, TMT-A, Simple 
and Choice RT, COT, DSB, LNS, 
LM, DVR, CERAD WL, CERAD, 
VFR language, WRAT-R, EBMT, 
TMT-B, ST, VF, OMOT, PC, BD. 
Significant findings: Lower 25(OH)D in those 
with MCI.  Lower 25(OH)D, lower global 
cognition score (MMSE). No significant 
findings with gait. 25(OH)D Continuous: 
mean  of 37.7 for all. 32.9 for fallers vs. 39.3 
for non-fallers (p<0.01), and 31.0 for MCI and 
no MC 0: 38.9 (p<0.05). Adjusted models, Gait 
velocity to 25(OH)D: not significant (r=-0.08, 
p=0.33); MMSE to 25(OH)D: significant 
(r=0.24, p<0.01); MCI to 25(OH)D: significant 
(p=0.02) 
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Table 4 continued.  
 Author, Year, 
Study Design 
Study Population Outcomes Conclusions  
5 Menant et al. 
(2012)42 
Cross-
sectional 
463 adult (70-90 years 
old), independent in 
ADL and able to walk 
independently in 
Australia. Mean  +/-  SD 
age: 78.0+/-4.6 years.  
25(OH)D (ng/ml) 
Gait velocity: 
calculated from time to 
walk 6m as part of the 
Physiological Profile 
Assessment.  
Cognitive tests: 
MMSE, DSST, TMT-
A, TMT-B. 
 
Significant findings: lower 25(OH)D, slower gait. 
Lower 25(OH)D, worse cognitive performance, 
especially in executive function tests. (TMT-B). 
25(OH)D continuous: mean  +/-  SD of 24.9+/-9.9. 
25(OH)D cut off categories and % sample: all (<20: 
33.3%), men (<20: 22%), and women (<20: 44%). 
Difference in gait velocity between groups: 
significant (p<0.01). Difference in MMSE, TMT-A, 
DSST and BD between groups: not significant. 
Difference in TMT-B between groups: significant 
(p<0.05). 
6 Toffanello et 
al. (2012)43 
Cross-
sectional 
2694 older adults (age 
inclusion NR) Pro.V.A., 
Italy 
Women: 75.6 +/-7.5  
Men: 76.2 +/- 7.8. 
25(OH)D (ng/ml) 
Gait velocity: 
calculated from best 
time (s) in 2 walks at 
usual pace along a 4m. 
Cognitive tests: 
Indexed MMSE 
Significant findings: gait velocity increased 
significantly for 25(OH)D levels up to 40ng/ml, 
mostly improving at 20-30 ng/ml. Lower 25(OH)D, 
lower MMSE scores. 25(OH)D continuous: mean  
+/-  SD of 26.3+/-4.8 for all, 26.0+/-16.5 for women; 
40.8+/-25.0 for men. 25(OH)D cut-off categories and 
% sample: women (<20: 40%; <10:13.5%) and men 
(<20: 20%; <10: 5.9%). 25(OH)D quintiles and 
ranges: women (Q1: <13; Q2: 13-20; Q3: 20-27; Q4: 
27-37; Q5: >37) and men (Q1: <21; Q2: 21-32; Q3: 
32-41; Q4: 41-57; Q5: >57ng/ml. Adjusted models, 
Difference in MMSE between quintiles: significant in 
women (p trend = 0.006) and men (p trend =0.007). 
Difference in gait velocity between quintiles: 
significant in women and men (both p trend p<0.001)  
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Table 4 continued.  
 Author, 
Year, Study 
Design 
Study Population Outcomes Conclusions  
7 Houston et 
al. (2013)44 
Cross-
sectional 
2099 adults (70-79 
years) from Health ABC 
study in United States 
Mean  +/-  SD age: 
74.6+/-2.9 years.  
25(OH)D (ng/ml) 
Gait velocity: 
calculated from time 
(s) used to calculate 
gait velocity, m/s. 
Cognitive tests: 3MS 
Significant findings: Lower 25(OH)D, slower gait 
velocity and lower MMSE scores. 25(OH)D cut off 
categories and % sample: <20: 28.9%; 50-30: 36.1%; 
>30: 35%. Difference in gait velocity between groups: 
significant (p <0.001). Difference in MMSE between 
groups: Significant (p<0.001) 
8 Gschwind et 
al. (2014)45 
Cross-
sectional 
404 older adult 
attending memory clinic 
(>65 year old). Mean  
+/-  SD age: 77.6+/-5.8 
years.  
25(OH)D (ng/ml) 
Gait velocity 
GAITRite measured 
usual and fast walking 
velocity (no practice, 
one walk, cm/s) 
Cognitive tests: 
MMSE 
 
Significant findings: Those in highest quartile 
performed 9.4% better in usual (p=0.02) and 9.2% in 
fast (p=0.004) walking velocity. Lower 25(OH)D, 
lower MMSE. 25(OH)D cut off categories and % 
sample: <20: 41.3% and <30: 69.8%. 25(OH)D 
quartiles and range: (Q1 <15.6; Q2 15.6-21.6; Q3 22.0-
32.4; Q4 >32.4. Difference in usual gait velocity 
between quartiles: significant (p<0.001). Difference in 
fast gait velocity between quartiles: significant 
(p<0.001). Difference in MMSE between quartiles: 
significant (p<0.006) 
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DUAL TASK PHYSICAL PERFORMANCE TEST INSTRUCTIONS 
 
Participant ID: __________________________        Date:  ________/____/_______ 
          month/day/year 
 
Practice trials  (Same order for all participants, RECORD FOR SINGLE TASK 
GAIT) 
1 Single gait task 
 
Data collection trials (random order) PARTICIPANT RANDOM ORDER 
NUMBER ______________ 
1 Single gait task Single cognitive task Dual task 
2 Single gait task Dual task Single cognitive 
task 
3 Single cognitive task Single gait task Dual task 
4 Single cognitive task Dual task Single gait task 
5 Dual task Single cognitive task Single gait task 
6 Dual task Single gait task Single cognitive 
task 
If the participant brings heeled-shoes, have them remove it. NOTE: ______________ 
Enter the participant ID, height, weight and leg length. Leg length: ________ 
Press start 
Read Instructions before each trial.  
Practice single gait task:  This is the walkway that we will use for some walking tests. 
For each walk, you must start behind the line in front of you and continue walking until 
you pass the line at the other end of the walkway. To familiarize yourself with walkway, 
start at this line and walk across the mat at the pace you prefer during daily activities. Do 
not run. Continue walking until you reach the line at the other side. You can start when 
you are ready. 
Este es el camino que vamos a utilizar para algunas pruebas de marcha. Por cada 
caminata, debe comenzar detrás de la línea en frente de usted y seguir caminando hasta 
pasar la línea en el otro extremo del camino. Para familiarizarse con el camino, comience 
en esta línea y camine por la alfombra al ritmo que usualmente camina durante las 
actividades diarias. No corra. Continúe caminando hasta llegar a la línea en el otro lado. 
Puede empezar cuando esté listo. 
Single cognitive task: Have participant stand in the starting line. While you are 
standing, count backwards out loud from 50 by 1 starting. Count all the way down to 1. If 
you make a mistake, don’t stop and continue counting.  
Haga que el participante se pare en la línea de inicio. Mientras que usted está de pie, 
cuente hacia atrás en voz alta de SDe 50 por 1. Cuente hasta llegar a 1. Si comete un 
error, no se detenga y siga contando. 
Single gait task: Have participant stand in the starting line. Starting at this line, walk 
across the mat at a pace you prefer during daily activities. Do not run. Continue walking 
until you reach the line at the other side. You can start whenever you are ready. 
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Haga que el participante se pare en la línea de inicio .A partir de esta línea, camine por 
la alfombra al ritmo que usualmente camina durante las actividades diarias. No corra. 
Continúe caminando hasta llegar a la línea en el otro lado. Puede empezar cuando esté 
listo. 
Dual task: Have participant stand in the starting line. For the following test, you will 
walk across the mat at a pace you prefer during daily activities, while you simultaneously 
count backwards out loud from 50 by 1. Do not run. If you make mistakes during 
counting keep on going. Continue walking without prioritizing either of the tasks until 
you reach the line at the other side. You can start when you are ready. 
Haga que el participante se pare en la línea de inicio. Para la siguiente prueba, usted 
caminará a través de la alfombra al ritmo que usualmente camina durante las actividades 
diarias, mientras cuenta al mismo tiempo hacia atrás en voz alta de SDe 50 por 1. No 
corra. Si se cometen errores durante el conteo siga contando. Continúe caminando sin dar 
prioridad a ninguna de las tareas hasta llegar a la línea en el otro lado. Puede empezar 
cuando esté listo. 
  
DUAL TASK PHYSICAL PERFORMANCE RANDOM ORDER TABLE 
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Figure 1: The GAITRite Walkay for the Assessment of Gait. Images taken from 
GAITRITE manual and software. 
Legend: The GAITRite is a 6 m long walkway. The start and finish lines were placed 2 
meters before and after to account for acceleration and deceleration (above). The 
participants were asked to walk on GAITRite during single walking and dual tasking 
(middle). The mat is connected to a computer software that calculates spation-temporal 
variables from the information gathered by the sensors (below).   
  
 241 
ELECTRO SENSOR COMPLEX INSTRUCTIONS 
 
1. Clean foot plates and oximeter 
2. Turn on computer: password: 12345 
3. Open program using the “CMS” shortcut on desktop. 
a. Write participant ID: last 2 numbers of year of birthday, 2 last numbers of 
phone number, space, 4 first letters of last name.  
b. Gender, DOB 
c. Ht, Wt, daily activity 
4. Ask them to: 
a. Seat 
b. take of shoes and socks 
c. place feet on metal foot plates 
d. Make sure they are not wearing nail polish or acrylic nails. Right 
index finger in oximeter – push white button until power on, allow 30s to 
stabilize. 
e. BP cuff on left arm, cord above arm and the hand resting on the table in 
front.   
f. Arms must be placed in an extended but relaxed and comfortable position.  
g. Remain perfectly still.  If move, retake.  
5. Move screen out of their site if possible.  
6. When it starts, ask them to relax, no talking  
7.  Valsalva: 
a. Remove feet from the plates 
b. Now you are going to clamp your nose with your left hand and try to 
breathe out your nose while plugging it for 15 seconds, and keeping your 
mouth closed like you were trying to pop your ears. I will tell you when to 
start and when you can breathe normally.  
c. Ahora se va a apretar la nariz con la mano izquierda y va a tratar de 
respirar por la nariz mientras la tapona durante 15 segundos y 
manteniendo la boca cerrada como si estuviera tratando de destapar los 
oídos. Le diré cuándo comenzar y cuándo puede respirar normalmente. 
8. Deep Breathing 30sec: 
a. Now you are going to inhale for 5 seconds and exhale for 5 seconds. I will 
direct you when to inhale and exhale. 
b. Ahora usted va a inhalar durante 5 segundos y exhalar durante 5 
segundos. Le indicare cuando inhalar y cuando exhalar. 
9. Stand up 
a. Finally, when I say go, I want you to stand up and remain standing up 
until the machine finishes measuring your blood pressure.  
b. Finalmente, cuando le indique, quiero que se levante de la silla y 
permanezca de pie hasta que el equipo termine de tomar su presión 
arterial. 
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Figure 2: The Electro Sensor Complex Device and Procedure. Images taken from 
company website and computer software.46,47  
Legend: The Electro Sensor Complex combines three devices into computer software 
(above). After placing the blood pressure cuff on the participant’s arm, feet on the metal 
plates and index right finger on the pulse oximeter, the software calibrates and measures 
baseline data. Then the participant is asked to perform the valsava maneuver, deep 
breathing and standing up cardiac autonomic reflex tests (middle). Once it finishes, the 
software provides a result scoreboard (below).
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Figure 3: Heart Rate Variability Time and Frequency Domains. Images taken from 
company website and computer software.46,47 
Legend: Example of plethysmograph used to measure heart rate variability (time from R 
to R intervals) in time domain (above), application of Fourier transform to the 
plethysmograph to convert from time domain into frequency domains (middle) and the 
three frequencies of heart rate variability (below). 
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Table 1: Description of ESC software variables used to calculate CMRS 
Name (Acronym) Normal 
values 
Representation 
ANS activity markers <2  
Standard deviation of the 
normal wave ( SDNN) 
40-80ms HRV time domain. Variation between each successive heartbeat. Reflects 
overall cyclic components of HRV. Marker of SNS PNS. Decreased  SDNN is 
associated to reduced left ventricular function. 
Square root of the mean  
squared differences of 
successive normal to normal 
R-R intervals (RMS SD) 
35-65ms HRV time domain. Indicator of PNS. Reflects the electrical stability of the 
heart. 
Total power (PTGTP) >=780ms2 HRV frequency domain. Total power of the FFT (Fast Fourier transform) 
performed on oximeter waveform. It is the sum of the areas under the curve 
covered by the 3-frequency domains. Main indicator of ANS activity used to 
define HRV score. It is usually decreased in those with chronic stress or with 
disease. 
ANS balance markers <2  
Low frequency (PTGLF) <220ms2 HRV frequency domain. Indicator of both PNS and SNS. It is controversial 
since it may also represent contribution influenced by RAAS and baroreceptor 
activity generating vagal outflow. 
High frequency (PTGHF) >=220ms2 HRV frequency domain. Indicator of PNS. Associated with R-R interval 
changes related to breathing, which is under PNS control. 
LF/HF 0.5-2.0 HRV frequency domain. Overall estimate of relative ANS balance within the 
entire cardiac ANS. >2% mean s SNS predominance <0.5% indicates PNS 
predominance 
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Table 1 continued. 
Name (Acronym) Normal 
values 
Representation 
Lipid biomarkers <2  
Fat mass 25-31% Energy storage of the body 
Body mas index 
(BMI) 
18.5-24.9 Body mass index (kg/m2) 
Arterial stiffness 
PTG (AIPTG) 
<0.45% Systematic arterial stiffness marker derived from the ascending aortic pressure waveform. 
Marker of lipid levels, related to atherosclerosis. 
Blood pressure 
markers 
<2  
Systolic blood 
pressure (SBP) 
110-140 
mmHg 
SBP average performed during measurement. Refers to the pressure of blood in the artery 
when the heart contracts. 
Diastolic blood 
pressure (DBP) 
78-90 
mmHg 
DBP average performed during measurement. Refers to the pressure of blood in the artery 
when the heart relaxes. 
Systemic Vascular 
Resistance (SVR) 
<1500 dyn-
s-cm2 
Indicator of peripheral resistance to flow that must be overcome to push blood through the 
circulatory system. 
Insulin resistance / 
IGT markers 
<2  
Total power index 
(PTGTPi) 
<377ms2 HRV frequency domain. PTGTP adjusted for fat mass. Significant marker of insulin 
resistance. Comparing PTGTPi marker versus the euglycemic clamp, it has a sensitivity of 
90% and specificity of 90% to detect insulin resistance.  
Very low frequency 
(PTGVLF) 
 HRV frequency domain. Associated with thermoregulation and sweating that results in 
oscillation in vasomotor tone controlled by SNS and/or RAAS.  
Very low frequency 
index (PTGVLFi) 
<33ms2 PTGVLF adjusted by ESRNO. Marker of IGT 
Stress index 
(Stress_I) 
<=180% Marker of SNS activity. Correlated with C-Reactive protein level. 
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Table 1 continued. 
Name (Acronym) Normal 
values 
Representation 
Sympatethic skin response 
markers using Sudo Test (used to 
calculate Sudomotor Response 
Score (SMRS)) 
<2 Cholinergic SNS function. Earliest detectable neurophysiologic abnormalities 
in distal small fiber neuropathy, often associated with higher risk of kidney 
nephropathy and retinopathy. SMRS has a sensitivity of 91.4% and specificity 
of 79.1% to detect peripheral neuropathy in diabetic patients.  
Electric Skin Respond to Nitric 
Oxide (ESRNO) 
>=50 μ Si Marker of SNS function and microcirculation. The peak of the 
electrochemical reaction on the bulk of the electrode reflects skin blood flow. 
It has a sensitivity of 68.4% and specificity of 84.4% as a marker of 
microcirculation disorder in diabetic patients.  
Electric Skin Response to the 
Chloride Ion (ESRCI) 
>= 53 μ Si Electrochemical reaction on the bulk of the electrode. Peak reflects sweat 
gland nerve density.  
Sweat Peak (Sweat_P) >=90 μ Si Reflects sweat gland function (sweat output) in respond to the electrical 
stimulation 
SNS tests (used to calculate 
Sympathetic Test Response 
Score (STRS)) 
<2 Adrenergic SNS function. Sympathetic response failure could increase 
cardiovascular events, and it is an indicator of CAN.  
SBP response to Valsalva 
maneuver in phase 2 (SPRV2) 
-20- -
40mmHg 
Correlated with norepinephrine response (adrenergic). 
SBP response to Valsalva 
maneuver in phase 4 (SPRV4) 
10-20 
mmHg 
Correlated with epinephrine response. 
Blood pressure response to 
standing (BPRS) 
<10 
mmHg 
Reflects SNS adrenergic response to standing.  
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Table 1 continued. 
Name (Acronym) Normal 
values 
Representation 
PNS tests (used to calculate 
Parasympathetic Test Response Score 
(PTRS)) 
<2 It is based on the analysis of the beat to beat heart rate changes during the 
Valsalva maneuver, deep breathing, and postural change. PNS response 
failure could increase cardiovascular events, and it is an indicator of CAN. 
Associated with symptoms of dizziness or orthostatic hypotension. 
Valsalva Ratio (Vals_R) >1.18% Ratio of SPRV4 and SPVR2. Reflects PNS response. Uses heart rate 
response to Valsalva Maneuver.  
Heart Rate Change to Standing 
position (K30/15 Ratio) 
>1.10% Evaluates the change in heart rate during the standing position. Heart rate 
increases during the first 15 seconds and decreases until it stabilizes at 30 
seconds. It reflects PNS response to the change of posture and orthostatic 
hypotension.   
Expiration/Inhalation ratio (E/I Ratio) >1.18% The heart rate ratio between expiration and inhalation during deep 
breathing. Calculated by the longest RR interval divided by shorter RR 
interval. Reflects PNS and it’s a test of sinus arrhythmia. 
Systolic time index (used to calculate 
Systolic Time Interval Score (STIS)) 
<2 Reflects cardiac performance 
Left ventricle ejection time index 
(LVETi) 
370-
420ms 
Cardiac output adjusted with heart rate 
Pre-Ejection Period (Pep) 90-
110ms 
Systolic time interval inversely correlated with left ventricle contractility. 
Primarily controlled by SNS beta-adrenergic activity.   
Preejection Period Index / Left 
Ventricle Ejection Time Index Ratio. 
(PEPi/LVET Ratio) 
<0.35% Correlated to cardiac performance. 
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Table 1 continued. 
Name (Acronym) Name 
(Acronym) 
Name (Acronym) 
Endothelial Tests (used to calculate 
Endothelial function test Score 
(EndoTS)) 
<2 Earliest clinically detectable stage of cardiovascular disease. Marker of 
endothelial dysfunction. 
Reflection Index (RI) <45% Indicator of stiffness of the small and medium arteries.  
Photoplethysmography Index 
(PTGi) 
>40 ms2 HRV frequency domain. The sum of the amplitudes of the 3 frequency 
domains.  
Plethysmography ratio  (PTGr) <2.1% HRV frequency domain. Ratio of the spectral analysis components 
Cardiometabolic risk score 
(CMRS) 
≤4 normal 
5-7 mild 
risk 
8-10 
Moderate 
Risks 
≥11 high 
risk 
Calculated from anthropometric data input in the system and the 10 
markers shown in grey. Each marker measured is scored as 
0=normal, 1=borderline or 2=abnormal and then used to calculate 
CMRS, which is normal if <=4, or represents mild risk (5-7), 
moderate risk (8-10) or high risk (>=11). The CMRS had a sensitivity 
of 92% and specificity of 83% (cut-off score > 4) to detect type 2 
diabetes.  
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ABBREVIATIONS AND ACRONYMS IN APPENDIX  A AND B TABLES  
25(OH)D  25- Hydroxyvitamin D 
AD   Alzheimer’s Disease 
BMI   Body Mass Index 
CAN   Cardiac Autonomic Neuropathy 
CE SDS  Center for Epidemiologic Studies Depression Scale 
CI   Confidence Interval 
cm   Centimeter 
cm/s   Centimeters per second  
DBP   Diastolic Blood Pressure 
F/U    Follow up 
ft   feet 
GDS   Geriatric Depression Scale  
HRV   Heart Rate Variability 
IGT   Impaired Glucose Tolerance  
m   Meters 
m/s   Meters per second 
MCI   Mild Cognitive Impairment 
min   Minutes 
OR   Odds Ratio 
PNS   Parasympathetic Nervous System 
PTH   Parathyroid Hormone 
s    Seconds 
SBP   Systolic Blood Pressure 
SNS   Sympathetic Nervous System 
SCI   Subjective Cognitive Impairment  
 SD   Standard Deviation 
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ABBREVIATIONS AND ACRONYMS OF STUDIES IN APPENDIX A AND B 
TABLES 
ADRC   Alzheimer’s Disease Research Center 
ARIC   Atherosclerosis Risk in Communities Study  
BFc80+  Befrail study >80 years old cohort.  
CLHLS  Chinese Longitudinal Healthy Longevity Survey 
EMAS   European Male Ageing Study 
EPIDOS  European Patient Information and Documentation Systems  
GAIT   Glucosamine/Chondroitin Arthritis Intervention Trial.  
Health ABC  The Health, Aging and Body Composition Study 
HSE 2000  Healthy Survey for England 2000 
InCHIANTI  Invecchiare in Chianti study 
ISAAC  Intelligent Systems for Assessment of Aging Changes Study 
LIFE-P  The Lifestyle Interventionot significant and Independence for 
Elders Pilot 
MrOS   Osteoporotic Fractures in Men Study 
NAME  Nutrition and Memory in Elders Study 
NHANES  National Health and Nutrition Examination Survey  
OPRA   Osteoporosis Prospective Risk Assessment 
Pro. V.A.  Progetto Veneto Anziani study 
SOF   Study of Osteoporotic Fractures.  
WHAS  Women’s Health and Aging Study 
WHI   Women’s Health Initiative 
ZENITH Zinc Effects in Nutrient Interactionot significant and Trends in 
Health and Ageing 
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ABBREVIATIONS, ACRONYMS AND DESCRIPTION OF COGNITIVE TESTS IN 
APPENDIX A AND B TABLES 
 
3MS   Modified Mini Mental State Examination: global cognition 
AMT    Abbreviated Mental Test: global cognition 
BD Block Design: visuospatial conot significanttruction 
CANTAB Cambridge Neuropsychological Testing Automated Battery: visual 
memory and executive function.  
CDR Clinical Dementia Rate 
CDT   Clock Drawing Test: global executive function 
CERAD WL  Consortium to Establish A Registry for Alzheimer’s Disease Word 
Recall: memory 
CERAD VFR  Consortium to Establish A Registry for Alzheimer’s Disease 
Visual Figures Recall: memory 
COT Crossing Off Test: processing velocity 
COWA Controlled Oral Word Association: verbal fluency 
CSI-D Community Screening Instrument for Dementia: global cognitive 
impairment. 
CTRM Camden Topographical Recognition Memory (CTRM) test: visual 
memory and recognition and episodic memory. 
DMS-IV  Diagnostic and Statistical Manual of Mental Disorders IV 
DSB Digit Span Backward: information updating and verbal working 
memory  
DSF Digit Span Forward: information updating and verbal working 
memory 
DSST Digit Symbol Substitution in the Wechsler Adult Intelligence 
Scale:  attention, concentration, processing velocity, working 
memory and executive function 
DVR  Delayed Visual Reproduction: working memory 
DWRT Delayed Word Recall Test: verbal learning and recent memory.  
EBMT East Boston Memory Test: episodic memory 
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FAB Frontal Assessment Battery: global executive function  
Go/No-Go  Go/No-Go score: motor inhibition.  
Language WRAT-R Wide Range Achievement Test – Reading: memory 
LM Logical Memory  
Lnot significant Letter-Number Sequencing: working memory 
MA Mental abbreviations 
MMSE  Mini Mental State Examination: global cognition 
MR Matrix Reasoning: visual construction and fluid reasoning 
N-back  N-back test: information updating.  
NAART  North American Adult Reading Test: verbal intelligence 
NINCDS-ADRDA  US. National Institute of Neurologic and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related Disorders 
Association.  
OMOT  Odd Man Out task: executive function 
PC Picture Completion: visuo-spatial construction 
ROCF Rey-Osterrieth Complex Figure test: visuo-constructional ability 
and episodic memory.  
RT Reaction Time: processing velocity 
SBT Short Blessed Test: memory, orientation and attention 
SPMSQ  Pfeiffer Short Portable Mental State Questionnaire: global 
cognition  
ST Stroop Tests- Stroop Color-Word Test for selective attention and 
susceptibility to behavioral interference and Stroop Interference 
Test for cognitive inhibition and executive function.  
SWM Spatial Working Memory, 4 parameters measured using the 
Cambridge Neuropsychological Testing Automated Battery 
TMT Trail Making Tests: visual attention, visuo-spatial scanning, task 
switching ability, sequential processing, motor velocity, attention, 
and executive function 
TMT-A Trail Making Test Part A: information processing 
TMT-B Trail Making Test Part B: mental shifting 
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VF Verbal Fluency: executive function 
WAIS-II BD Wechsler Adult Intelligence Scale Block Design: visuo-spatial 
construction.  
WDS Wechsler Digit Span: forward and backward test for attention and 
working memory for executive function.  
WLT World Learning Test: direct recall, decayed recall and recognition 
for episodic memory.  
WMS-III LM Wechsler Memory Scale III Logical Memory: episodic memory 
WMS-III WLL Wechsler Memory Scale III Word List Learning: episodic memor
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